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The patient with acute chest pain forms one of every day’s clinical challenges for the 
cardiologist. Early diagnosis and triage are of paramount importance to determine 
the corresponding treatment, especially in the case of a suspected acute coronary 
syndrome. This thesis focuses on one particular subset of patients, those with an ST-
elevation myocardial infarction. 
This diagnosis represents not merely an electrocardiographic difference from 
non ST-elevation acute coronary syndromes, but also implies pathophysiological 
differences which translate into a different prognosis, the use of additional 
antithrombotic treatment modalities, and a risk stratification based on (partly) other 
clinical and angiographic variables.
The general introduction will cover some of the basic background information on 
ST-elevation myocardial infarction and several specialistic clinical and angiographic 
items frequently used throughout this manuscript and not explained in detail in the 
different papers. The outline to the thesis will shortly highlight the study questions 
addressed in the respective chapters and will put these in both a clinical and 
scientific perspective. 
Acute coronary syndromes, pathophysiology
Acute or subacute coronary thrombosis on a ruptured atherosclerotic plaque forms 
the classical pathophysiological concept in the etiology of an acute coronary 
syndrome. After rupture of the plaque, subendothelial matrix such as collagen and a 
varying amount of lipid core is exposed, after which a cascade of reactions evolves. 
The resulting thrombusdeposition may cause a subtotal or total occlusion of the 
coronary artery, which impairs oxygen supply to the coronary bed (1). 
In the case of a non ST-elevation acute coronary syndrome some perfusion to the 
myocardium is still present in the majority of patients, whereas a total occlusion 
is most frequently the cause of an ST-elevation myocardial infarction. Inherent to 
these pathophysiological differences are the different approaches with respect to 
triage, treatment and the risk assessment in the long-term (Figures 1 and 2).
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ST-elevation myocardial infarction, treatment
The principal treatment difference as compared to patients with a non ST-elevation 
acute coronary syndrome is dictated by the absence of coronary perfusion in the 
case of ST-elevation myocardial infarction: Reperfusion should be achieved as 
quickly as possible to salvage the jeopardized myocardium (2).
Recanalization by primary percutaneous intervention, using a wire to cross the 
occlusion and an inflatable balloon for mechanical dilatation of the residual 
stenosis is one form of reperfusion therapy. Nowadays, stents are often used to 
prevent acute complications and restenosis. The majority of patients is still treated 
with pharmacological reperfusion therapy, known as thrombolytic therapy, or, more 
correctly referred to as fibrinolytic therapy. These agents target the fibrin network, 
the key determinant of a durable, strong clot.
Pooled analysis of randomized trials has demonstrated that the benefit of fibrinolysis 
in the first hour is exponentially related to the time from symptom onset (3), whereas 
after this first golden hour the number of lives saved decreases, and is near linearly 
related to the time to treatment (Figure 3). These observations fuel the interest in the 
concept of prehospital fibrinolysis programs, which are overall associated with a 
gain in time to treatment of about one hour (4). In the Nijmegen region here in the 
Netherlands, two thirds of patients is treated within 2 hours of symptom onset, and 
one quarter in the first golden hour (5).
Figure 3 Time to treatment and numbers of lives saved after fibrinolysis data from 
  randomized controlled trials with > 100 patients
THE LANCET
Regression functions were fitted in the tabulated data from the
separate trials. Data were weighted by the inverse of the variance
of the absolute benefit described.4 Goodness of fit was expressed
as the ratio of regression sum of squares and total sum of squares
(R2-value). Regression analyses were performed both with and
without USIM and ISIS-3 uncertain indication data.
Results
The 22 trials included a total of 50 246 patients, of whom
5762 (11%) were randomised within 2 h of symptom
onset and another 10 435 (21%) between 2 and 3 h.
Fibrinolytic therapy appeared to be beneficial up to at
least 12 h (figure 2). The absolute reduction in mortality
was greatest among patients who presented within 1 h of
symptom onset (average delay 0·75 h). Benefit in this
group was estimated at 65 (SD 14; 95% CI 38, 93) lives
saved per 1000 treated patients, which is higher than the
FTT estimation of benefit at nearly the same time point
(0·98 h) of 35 (11). Benefit was also higher in our analysis
than in the FTT analysis among patients randomised in
the second hour (37 [9]; 20, 55) per 1000 treated. The
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Figure 2: Mortality at 35 days among fibrinolytic-treated and
control patients, according to treatment delay
Figure 4: Absolute 35-day mortality reduction versus treatment
delay
Small closed dots: information from trials included in FTT analysis; open
dots: information from additional trials; small squares: data beyond
scale of x/y cross. The linear (34·7–1·6x) and non-linear
(19·4–0·6x+29·3x1) regression lines are fitted within these data,
weighted by inverse of the variance of the absolute benefit in each
datapoint.4 Black squares: average effects in six time-to-treatment
groups (areas of squares inversely proportional to variance of absolute
benefit described).
Figure 3: Proportional effect of fibrinolytic therapy on 35-day
mortality according to treatment delay
Odds ratios, plotted with 95% CI on a log scale, are significantly
different over the six groups (Breslow-Day test, p=0·001). Areas of
black squares proportional to amount of statistical information
benefit per 1000 treated in the subgroups presenting at
2–3 h, 3–6 h, 6–12 h, and 12–24 h was respectively
26 (6; 14, 37), 29 (5; 19, 40), 18 (6; 7, 29), and 9 (7; 5,
22).
Similarly, the proportional mortality reduction was
highest in the 1 h patients (48% [95% CI 31, 61]; figure
3), and significantly higher in patients treated within 2 h
than in those treated later (44% [32, 53] and 20% [15,
25], respectively). By contrast with the FTT report, odds
ratios differed significantly over the time-to-treatment
groups (p=0·001, figure 3).
The relation between absolute benefit of fibrinolytic
therapy and treatment delay can be described by a linear
function, similar to FTT, which shows a significant
reduction in benefit of approximately 1·6 (0·5) lives per
1000 patients per hour of treatment delay (H0: =0
rejected; p<0·01: R2=0·22). This linear model was not
significantly improved by addition of the term x2 (H0: =0
not rejected; p=0·29; R2=0·25). However, the component
x1 of the second non-linear model had a significant
contribution to the regression function (H0: =0 rejected;
p=0·03). In fact, this latter model fits best with the data
(R2=0·32), in particular with the early observations (figure
4). Inclusion of the USIM and ISIS-3 uncertain indication
data and exclusion of the intracoronary studies
(WWashICy26 and ICINy28) did not essentially change
these findings. Further analyses were performed including
all trials with at least 1000 (FTT dataset), 500 and 250
patients, respectively. In all cases, the second non-linear
model was significantly better than the linear model.
Discussion
In animals with a coronary circulation similar to that of
humans, the amount of myocardial tissue that is
salvageable directly depends on the duration of coronary
occlusion. This dependency is non-linear. Very early
reperfusion of the occluded coronary artery (within
30 min) may lead to full recovery of ischaemic tissue and
thus prevent necrosis. In experimental models most of the
irreversible damage to the myocardium occurs between
1 and 2 h, after the occlusion, and little or no salvage can
be achieved after 6 h of occlusion.
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As adjunctive to fibrinolytic therapy, antithrombotic agents are needed, both for 
the facilitation/optimization of reperfusion therapy and the prevention of recurrent 
ischemic events in the long-term. 
The additional antithrombotic agents used in the (sub)acute and chronic phase are:
1. Anti-platelet agents, inhibiting adhesion and/or aggregation of thrombocytes.
 The mechanism may vary from an effect on cyclo-oxygenase 1, 
 the ADP-receptor, or the glycoprotein IIb/IIIa receptor. Examples are aspirin, 
dipyridamole and clopidogrel, and abciximab.
2. Anticoagulants, with the following subclassification:
– Indirect thrombin inhibitors,
 such as unfractionated heparin and the low-molecular-weight heparins.
– Direct thrombin inhibitors,
 such as hirudin, hirulog (intravenous) and ximelagatran (oral).
– Vitamin K antagonists, often referred to as oral anticoagulants,
 such as warfarin and coumarin.
Most of the antithrombotic agents have been extensively tested for both types of acute 
coronary syndromes (6,7). As for the anti-platelet agents, the safety and efficacy of 
clopidogrel have not yet been established after fibrinolysis. Of the anticoagulants, 
the use of oral direct thrombin inhibitors can not yet be recommended in lack of 
sufficient trials.
Important angiographic and clinical characteristics
Whereas history, physical examination and the electrocardiogram provide important 
information for clinical risk stratification (8,9), the key correlates in the prediction 
of survival after ST-elevation myocardial infarction are early infarct artery patency 
and indicators of left ventricular function, the ejection fraction and systolic volume 
index in particular (10,11). 
TIMI flow in the infarct artery
In view of the importance of early realization of brisk, antegrade flow in the infarct 
artery in as many patients, as early as possible, this qualitative scoring system was 
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developed to validate comparisons between different fibrinolytic agents in their 
efficacy on this endpoint: The TIMI flow grading system (12).
This classification of the quality of epicardial flow has been proven to be one of 
the strongest prognostic indicators (11,13), with 30-day mortality rates varying 
from 8-10% in the case of failed reperfusion (TIMI flow grades 0-1) to 3-4% for 
patients with successful reperfusion (TIMI flow grade 3), as assessed 90 minutes 
after fibrinolysis.
With the increasing number of large scale angiographic trials initiated by study 
groups from the United States this scoring system has gained general acceptance 
over the past ten years. 
The classification proposed by the European Cooperative Study Group (14), which 
was used until the late 1980s and early 1990s, has lost its value for the evaluation in 
future trials. Yet, TIMI flow grade 0 represents the same as ECSG grade 5, and thus, 
data on this specific endpoint reflect the same and can be easily compared between 
different trials or used for pooled analyses. As can be deduced from Tables 1 and 2, 
ECSG grade 4 will merely represent TIMI grade 1 flow, but also some cases of TIMI 
grade 2 flow. 
In the APRICOT-trials all patients entered the study with good coronary flow. In 
APRICOT-1 inclusion occurred with ECSG grades 0-3, in APRICOT-2 in the case of 
TIMI grade 3 flow. In APRICOT-1 reocclusion was defined as ECSG grade 4 and 5 
(15). At follow-up angiography the infarct artery showed a culprit stenosis of more 
than 99% and did not, or not completely fill within 3 cardiac cycles. In APRICOT-
2, reocclusion was defined as TIMI grades 0-2 flow: total coronary occlusion, or 
filling distal to the obstruction at a rate perceptibly slower than proximal of the 
obstruction, or slower than in another coronary artery (16).
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Classifications of coronary artery patency
Table 1 European Cooperative Study Group classification
Stenosis grade
0 Normal
1 < 50% diameter stenosis
2 50% to 90% diameter stenosis
3 91% to 99% diameter stenosis, complete filling within 3 cycles
4 91% to 99% diameter stenosis, no complete filling within 3 cycles
5 Total occlusion with or without collateral filling
Table 2 TIMI flow grading system
TIMI 0 No perfusion: 
there is no antegrade flow beyond the point of occlusion
TIMI 1 Penetration without perfusion: 
The contrast material passes beyond the area of obstruction but “hangs” up 
and fails to opacify the entire coronary bed distal to the obstruction for the 
duration of the cineangiographic filming sequence
TIMI 2 Partial perfusion:
The contrast material passes across the obstruction and opacifies the 
coronary bed distal to the obstruction. However, the rate of entry of contrast 
material into the vessel distal to the obstruction or its rate of clearance from 
the distal bed (or both) are perceptibly slower than its entry into or clearance 
from comparable areas not perfused by the previously occluded vessel – e.g. 
the opposite coronary artery of the coronary bed proximal to the obstruction
TIMI 3 Complete perfusion:
Antegrade flow into the bed distal to the obstruction occurs as promptly 
as antegrade flow into the bed proximal to the obstruction, and clearance 
of contrast material from the involved bed is as rapid as clearance from an 
uninvolved bed in the same vessel or the opposite artery
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Reocclusion and reinfarction
A second angiographic parameter, which has only been studied by a few research 
groups over the world, is reocclusion. This is partly due to the required sequential 
angiographies, one showing an open infarct artery after reperfusion therapy, the 
second demonstrating subsequent occlusion. Methodologically even more correct, 
a third angiography would be required that shows an occluded infarct artery before 
fibrinolysis. Yet, now that the need for early restoration of coronary patency has 
been unequivocally demonstrated over the years, and intravenous fibrinolysis has 
replaced the initial intracoronary administration, this initial angiography can not be 
peformed anymore nowadays (17).
Of the clinical prognostic indicators during the index admission, reinfarction 
after fibrinolysis is associated with a twofold increased risk of mortality. Half 
of these reinfarctions occur within 48 hours after reperfusion therapy (18), and 
are often attributed to infarct artery reocclusion (17,19). Given their profound 
impact, reinfarction forms one of the main endpoints to compare antithrombotic 
regimens, despite the often cumbersome definition of this endpoint, especially 
early after fibrinolysis. Reocclusion has been shown to occur without clinical signs 
of reinfarction in about half of cases (19-22), and, even in the absence of clinical 
reinfarction, impaired recovery of left ventricular function has been demonstrated 
(23). Despite the potential prognostic consequences of these reocclusions, few 
studies have addressed this issue. 
The present thesis therefore primarily focuses on reocclusion, encompassing both 
reinfarction, and the ‘silent’ occlusions which interfere with left ventricular recovery 
after myocardial infarction.
Recurrent ischemia and revascularization
After fibrinolytic therapy, recurrent ischemia either at rest or during stress testing 
indicates an increased risk for unstable angina, reinfarction and mortality during 
follow-up (24). This forms the rationale for an ischemia-guided revascularization 
strategy. Both reinfarction and recurrent ischemia are often caused by recurrent 
(sub)total thrombosis. More potent antithrombotic regimens might therefore reduce 
these complications. 
Another approach that has been advocated is a more aggressive revascularization 
strategy. In that case patients after fibrinolysis undergo routine catheterization, 
irrespective of symptoms and/or recurrent ischemia, and subsequently, angioplasty 
 CHAPTER 1 19
will be performed or bypass surgery planned. As of to date, such a routine invasive 
strategy has not resulted in better outcome than an ischemia-guided approach. An 
increased risk of periprocedural infarctions has been postulated as the explanation 
for this lack of benefit (25).
Most of the evidence, however, reflects data from randomized trials performed in 
the late 1980s and early 1990s and is not representative for current interventional 
cardiology with the introduction of glycoprotein-receptor blockers and stents to 
reduce periprocedural events and restenosis, respectively.
Still, an angiographic follow-up study performed in the same era as the old trials 
suggested that a high grade stenosis does not predict reinfarction (19), which 
questions the need of a routine invasive approach. In fact, several observations 
have shown that reinfarction often occurs on previously less severe lesions (27). On 
the other hand, in most of the randomized trials to date angioplasty was restricted 
to the severe lesions, whereas incorporating dilatation of less severe lesions might 
be beneficial. 
Unfortunately, angiographic follow-up was not performed in the randomized studies 
on a routine invasive approach, and reocclusion was not addressed. The trials only 
focused on the clinical endpoint reinfarction. Several studies have demonstrated 
that stenosis severity does predict reocclusion, and thus, a potential benefit on this 
endpoint, and, for example, left ventricular function, may have gone undetected. 
Clinical events in these trials were followed for one year, which may have been too 
short to detect a benefit exerted through these mechanisms.
In view of the above, the APRICOT-trial having paired angiography in 87% of 
patients provides a unique opportunity to further unravel the relationship between 
reocclusion, reinfarction and stenosis severity, and may as such contribute to 
insights that may be valuable for the design and protocol of future randomized 
studies on the impact of a routine invasive strategy. Moreover, clinical follow-up 
information has been collected for more than ten years, which will provide insight 
into the prognostic impact of late reocclusion, with special interest in the clinically 
silent reocclusions. If indeed late reocclusion is associated with adverse long-term 
survival, the randomized trials on more aggressive revascularization regimens 
might incorporate reocclusion as one of the endpoints.
20 General introduction
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In Chapter 3 a general overview is presented regarding the evolutions in the 
treatment of ST-elevation myocardial infarction, varying from development of new 
fibrinolytics and combined pharmacological reperfusion regimens to the use of 
new adjunctive antithrombotic agents.
Chapter 4 addresses the impact of two different antithrombotic strategies: it 
concerns a randomized comparison of early prehospitally initiated fibrinolytic 
therapy with a strategy of in hospital initiated fibrinolysis, and is one of the few 
studies assessing the long-term outcome after these two reperfusion strategies. This 
study is known under the acronym MITI. In an additional analysis patients treated 
within the golden hour are compared to those treated later.
In Chapter 5 we performed the first long-term follow-up study in which patients 
with reocclusion were compared to those with sustained infarct artery patency in 
the 3 months after fibrinolytic therapy. In view of the detrimental impact on left 
ventricular contractile recovery, 3-year survival rates were compared between 
groups, as well as recurrent ischemic complications.
Chapter 6 describes the only randomized placebo-controlled angiographic follow-
up study to date addressing the impact of anti-platelet therapy on coronary artery 
disease progression in the non-infarct arteries. Although the effect of aspirin is most 
outspoken early after ST-elevation myocardial infarction, it has also been proven 
beneficial when started up to six months after the event, after which recurrent events 
are not as often related to the infarct artery as in the acute phase. It was therefore 
hypothesized that part of the long-term benefit of aspirin might be attributed through 
reduced progression of coronary artery disease in the non-infarct arteries. 
Given the adverse consequences of reocclusion and its incidence of about 25-
30% in the first year after myocardial infarction, better preventive strategies are 
warranted. Chapter 7 describes the randomized angiographic follow-up trial 
APRICOT-2, in which a prolonged, combined antithrombotic strategy of both 
anti-platelet and anticoagulation therapy is tested against a standard 48 hour 
anticoagulation regimen and the indefinite use of aspirin.
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Chapter 8 presents the collective evidence to date on the combination of 
oral anticoagulation therapy and aspirin. In addition to the moderately sized, 
mechanistic, angiographic follow-up studies, all clinical trials on this issue are 
reviewed, and important aspects for the implementation in daily clinical practice 
are discussed. 
The analysis in Chapter 9 aims to provide insight into an important issue with 
regard to the lack of benefit of a routine invasive strategy after fibrinolysis to 
improve outcome in terms of death and reinfarction. With stenosis severity being a 
strong predictor of reocclusion, reinfarction rates were expected to be reduced by 
a routine invasive strategy. Previously, a meta-analyses on the impact of a routine 
invasive strategy showed an increased risk of periprocedural events, and outcome 
was not better than after an ischemia guided revascularization strategy. However, an 
angiographic follow-up study performed in the same era as these trials, suggested 
that recurrent ischemic events were not associated with the residual stenosis severity. 
With APRICOT being conducted in that same period, we intend to further elucidate 
the relationship between the residual stenosis severity, reocclusion and reinfarction. 
Does the increased risk for reocclusion associated with a severe residual stenosis 
also translate into an increased risk for reinfarction, when compared to patients 
with a low-medium grade residual lesion?
 
In Chapter 10 a 10-year clinical follow-up study is presented on the patients that 
participated in the APRICOT-1 trial, investigating whether late coronary patency is 
associated with cardiac survival, independent of left ventricular function. Whereas 
the impact of early reinfarction and reocclusion are undisputed, conflicting data 
have been reported on the prognostic consequences of late coronary patency. This is 
the first angiographic follow-up observation describing the impact of late coronary 
patency after fibrinolysis in the setting of an ischemia guided revascularization 
strategy. 
Chapter 11 and 12 summarize the main outcomes of the presented analyses and 
provide implications both for daily clinical practice and for future (angiographic 
follow-up) trials after ST-elevation myocardial infarction.
 CHAPTER 2 27

PART 2 The thesis

 CHAPTER 3 31
CHAPTER 3
Adjunctive therapy in patients treated with 
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Introduction
Thrombotic occlusion of an epicardial coronary artery has been implicated as a 
potential mechanism involved in acute myocardial infarction in as early as 1910 
(W1), and became generally accepted after the landmark report by De Wood et al. 
in the early eighties. (W2)
In search of pharmacological means to dissolve thrombus so called ‘thrombolytics’ 
were developed. These agents target fibrin, the key element in clot-formation, 
and are therefore more accurately referred to as fibrinolytics. Large clinical trials 
confirmed the hypothesis that timely restoration of coronary patency had a marked 
impact on survival after ST-elevation myocardial infarction: ~20-30 lives saved per 
1000 patients treated (W3). With the improvements in techniques and experience, 
mechanical reperfusion therapy has been proven to be even more beneficial than 
in-hospital initiated fibrinolytic therapy (W4). Yet, pharmacological reperfusion 
therapy is more widely available, more easily applicable, and less dependent of 
institutional experience. 
Consequently, the majority of patients with ST-elevation myocardial infarction 
receives fibrinolytic therapy. Given the profound impact of early reperfusion (1), 
preferably within the first, “golden”, hour the initiation of prehospital fibrinolysis 
programs resulted in benefits in the same order as achieved by primary angioplasty: 
~18 lives saved per 1000 patients, when compared to in-hospital fibrinolysis (2). 
New pharmacological reperfusion strategies to achieve patency rates that could 
more favorably compare with those achieved by primary angioplasty constitute a 
second initiative. In addition to further optimization of antithrombotic treatment in 
the acute phase, the experience with anti-ischemic, plaque stabilizing strategies 
applied in the (sub)acute phase and in the long-term has evolved. The current 
review presents the latest pharmacological developments and their implications 
for daily clinical practice in patients with acute ST-elevation myocardial infarction 
(Figure 1). 
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Figure 1: Schematic representation of the currently recommended pharmacological 
 treatment strategy in acute myocardial infarction patients. 
Figure 2: Modified figure adapted from reference 5. 
 Thrombus formation and pharmacological interventions in the coagulation 
 cascade – Interaction of platelet aggregation (fibrinogen, GPIIb/IIIa) and 
 activation of the coagulation cascade results in the thrombin-induced formation 
 of a fibrin-rich clot. Fibrin cross-linking by factor XIII improves clot-strength. 
 Whereas oral anticoagulants interfere with the production of coagulation 
 factors, other agents inhibit the action of activated clotting factors. Fibrinolytics 
 target the degradation of fibrin, mediated through plasmin. 
 vWF = von Willebrand factor; PT = prothrombin (II);T = thrombin (IIa); 
 OAC = oral anticoagulants; UFH = unfractionated heparin; LMWH = 
 low-molecular-weight heparin; FDP’s = Fibrin degradation products
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Strategies to enhance coronary patency
- The acute and subacute phase –
From the very first randomized trials with fibrinolytic agents, angiographic 
(sub)studies demonstrated the concept of early restoration of coronary patency, 
better preservation of left ventricular function and improved survival (3). Secondly, 
the adverse consequences of reocclusion of the infarct artery were demonstrated in 
terms of impaired recovery of left ventricular function and higher rates of mortality 
and recurrent ischemic events (4). 
In order to optimize the efficacy of reperfusion therapy, concomitant thrombin and 
platelet inhibiton is required, not only aiming at enhanced early patency but also to 
reduce reocclusion and recurrent thrombotic events.
Pathophysiological rationale 
Acute thrombotic occlusion of an epicardial artery is often initiated by plaque 
rupture or erosion, after which subendothelial matrix is exposed to the blood. 
Following vasoconstriction, the initial response to vessel injury, a cascade of events 
evolves. Platelets adhere to the damaged vessel wall, secrete chemoattractive 
substances, that result in platelet recruitment and aggregation. Activation of tissue 
factor (factor VII) is one of the earliest involved responses, stimulating a prompt 
reaction of the extrinsic and intrinsic coagulation cascade. Thrombin constitutes 
one of the most important proteins. It has a potent effect on platelet aggregation, 
and promotes the formation of fibrin, the key element in the formation of a durable 
strong clot (5). Fibrinolytics induce activation of plasminogen into plasmin, resulting 
in degradation of fibrin (Figure 2). 
Reperfusion strategies
Despite many years of experience with fibrinolytic agents, some crucial aspects 
will be highlighted below. These concern relevant issues for the clinician’s choice 
of adjunctive treatment, and aspects regarding the rationale for the development of 
new strategies.
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Fibrinolytic therapy, efficacy, Table 1
With a varying survival benefit from ~20 per 1000 patients treated after 4-6 hours 
to ~50 per 1000 when starting within 1-2 hours of symptom onset, agents that 
can easily be used in the prehospital setting have always been of interest (1). After 
the initial success with streptokinase (6,W5), bolus treatment with anistreplase 
gained attention (W6,W7,W8). A second initiative has been the search for a more 
potent agent, realizing higher rates of early patency. A third goal constitutes the 
development of agents with less bleeding complications, which were thought to 
be related to the lack of fibrin specificity, i.e. the action on both fibrin-bound and 
circulating plasminogen, inducing systemic depletion of fibrinogen. “Second-
generation” agents like rt-PA were produced, but not until the introduction of an 
accelerated regimen a breakthrough was realized (W9). This regimen resulted in 
an early and sustained survival benefit as compared to streptokinase, and proved 
particularly effective in patients with anterior myocardial infarction (7,W10). The 
strongest predictor of survival was identified as the realization of early brisk, 
antegrade flow in the coronary artery, so called 90-minute-TIMI-3 flow, seen 
in 54% of patients on rt-PA versus 32% in those on streptokinase (3). Based on 
these insights the “third-generation” lytics were manufactured to further improve 
survival. Yet, despite promising patency data with the bolus agents reteplase and 
tenecteplase (W11,W12), no additional improvement in clinical outcome was 
observed (W13,W14). 
Fibrinolytic therapy, safety Table 2
The clinically most threatening complication is the risk of intracranial hemorrhage, 
which varies between trials from 0.4% to 1.1%, dependent on the agent, 
and the proportion of high risk patients included (7,8,W15,W16,W17). This 
constitutes a fatal complication in about half of patients, with another third being 
permanently disabled (7,8,W15). Unexpectedly, fibrin-specific agents increased 
this complication. Although patient factors are most important, the impact of 
the intensity of anticoagulation with unfractionated heparin can not be stressed 
enough. Each 10-second increase of the 12-hour APTT over 70 seconds has been 
shown to increase the absolute chance of intracranial hemorrhage with 0.07% (9). 
From past trials it has also been deducted that the dose of fibrinolytic therapy is of 
paramount importance (W18). This deserves renewed interest with the introduction 
of weight-adjusted bolus fibrinolytic therapy, given the potential impact of erroneous 
administration of a higher dose than indicated. 
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In light of the above, the decision to choose for fibrinolytic therapy, and the choice 
of agent, should be individually tailored, assessing the potential benefit and harm in 
the given situation. In lack of better agents, some institutions have primarily changed 
logistics by implementing prehospital fibrinolysis with a rather liberal rescue 
angioplasty policy, which resulted in comparable outcomes to primary angioplasty 
in the recent CAPTIM trial (10). Although the available randomized data support 
rescue angioplasty (11), a strategy of routine immediate angioplasty after non-
fibrin specific agents seems less favorable, which may in part be explained by the 
increased bleeding risk (W19). In individual cases with persisting pain, heart failure 
or cardiogenic shock rescue angioplasty should always be considered. The use of 
glycoprotein IIb/IIIa receptor blockers after streptokinase should be avoided (12), 
whereas the benefit of its periprocedural use following other fibrinolytics should be 
carefully weighed against the increased bleeding risk in each case individually. 
Half-dose lytic and GPIIb/IIIa-receptor blockade, rationale
The lack of additional clinical benefit from angiographically more potent fibrinolytic 
regimens questioned the somewhat limited focus on the TIMI-3 flow concept, and 
broadened the search towards improved strategies. Some postulated increased 
reocclusion rates as a result of enhanced platelet activation after more fibrin-specific 
therapy. A second suggestion was that improved epicardial patency per se may 
not translate into better outcome in the case perfusion at tissue-level is not (fully) 
restored (W20,W21). Part of this lack of endocardial perfusion might be caused by 
periferal embolization of platelet-rich clot debris. Importantly, fibrinolytic therapy 
not only results in fibrin degradation and thrombus dissolution, but also induces 
platelet aggregation by a thrombin and plasmin-mediated pathway. In ISIS-2 the 
addition of 35 days of aspirin resulted in improved outcome after streptokinase 
(6). Therefore, a combination of fibrinolytic therapy and stronger platelet-inhibition 
was hypothesized to confer additional benefit; not only by the potential to enhance 
early TIMI-3 flow, but also by the above mentioned mechanisms.
Half-dose lytic and GPIIb/IIIa-receptor blockade, efficacy, Table 3
The first results in angiographic pilot trials studying half dose rt-PA with full-dose 
abciximab were impressive, with TIMI-3 flow rates at 60 min. comparable to those 
at 90 minutes achieved with accelerated rt-PA alone (12). This promising regimen 
has never been tested in a large clinical trial, probably due to the introduction of 
TNK-tPA. The clinical ASSENT-3 trial evaluated the impact of a combined regimen 
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with TNK-tPA, which did not affect survival but reduced recurrent ischemia at the 
cost of higher bleeding rates (13). Data from the angiographic pilot study, published 
half a year after the clinical trial, showed no improvement in TIMI-3 flow (W22). 
The second large-scale clinical trial on this subject, GUSTO-V, did not demonstrate 
a survival benefit either (14). First, it should be realized that the regimen chosen was 
based on a subgroup-analysis from the angiographic pilot trial SPEED. Whereas the 
randomized treatment arms showed no clear benefit on TIMI-3 flow, the subgroup 
of patients on standard dose heparin did (W23). A second explanation results 
from the lessons learnt from GUSTO-1. To improve survival after pharmacological 
reperfusion with an absolute 1%, an absolute 20% improvement in TIMI-3 flow is 
necessary (3,W24). Neither of the discussed regimens, nor the strategies performed 
with other glycoprotein-blockers met this criterium (W24, W25,W26). 
Half-dose lytic and GPIIb/IIIa-receptor blockade, safety, Table 3
A combined regimen, using only half-dose lytic, was expected to reduce the most 
serious bleeding complication, i.e. intracranial hemorrhage. Yet, findings from 
GUSTO-V seemed dissapointing at first glance. More thorough analysis, however, 
showed that patients aged younger than 57 had a reduced risk of intracranial 
hemorrhage, whereas in those over 57 this risk was increased (W27). Older patients, 
especially those over 75 years, are a subgroup at particular high risk (14). Similar 
observations were made in ASSENT-3, with reduced recurrent ischemic events at 
the cost of higher bleeding, again specifically in the elderly (13).
Despite these somewhat disappointing findings, the combined regimen remains an 
attractive alternative to full- or half-dose fibrinolysis as pretreatment for facilitated 
angioplasty for acute myocardial infarction. As TIMI-3 flow before the procedure 
is a strong predictor of prognosis, the combined treatment strategy might confer 
benefit, with a door-to-balloon time often exceeding 2 hours (W28). Moreover, 
the concomitant administration of abciximab could positively impact procedural 
success at the microcirculatory level. The pending FINESSE and ADVANCE-MI 
trials address this question in over 8,500 patients with ST-elevation myocardial 
infarction. As of to date, the described combined regimen can not be recommended 
for general implementation in daily clinical practice.
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Table 1 Current fibrinolytic agents in the treatment of ST-elevation myocardial infarction
Streptokinase
Alteplase
rt-PA
Reteplase
r-PA
Tenecteplase
TNK-tPA
T1/2 (min.) 15-25 4-8 11-14 17-20
Allergenic Yes No No No
Fibrin specific - + + ++
PAI-1 resistent - - - +
Bolus No No Double Single
Dosing 1.5 MU 
over 30-60 min.
15 mg Bolus, 
followed by 
0.75 mg/kg 
– max. 50 mg –
over 30 min.
followed by 
0.5 mg/kg
 – max. 35 mg – 
over 1 hr.
10 U Bolus, 
twice, 30 min. apart
Weight-adjusted:
  < 60 kg: 30 mg
60-69 kg: 35 mg
70-79 kg: 40 mg
80-89 kg: 45 mg
  ≥ 90 kg: 50 mg
PAI = plasminogen activator inhibitor
Table 2 Risk factors for intracranial bleeding following fibrinolysis for ST-elevation 
 myocardial infarction
• Age > 75 years
• Body-weight < 67 kg
• Female gender
• Hypertension
• Previous TIA/CVA
• Inappropriate anticoagulation*
• Dose and type of fibrinolytic agent**
* Unfractionated heparin is the recommended anticoagulant, in the following regimen:
 An i.v. bolus of 60 U/kg (max. 4000 U ), followed by 
 a 48-72 hour infusion 12 U/kg/hr (max. 1000 U/kg/hr)
 a PTT monitoring at 3,6,12, 24 hrs after start of treatment (target aPTT: 50-70 sec)
**  Fibrin specific agents like rt-PA and TNK-tPA increase the risk of intracranial hemorrhage by a factor 
 1.5 to 2 when compared to streptokinase. In the case of TNK-tPA, careful attention should be paid 
 to the weight-adjusted dose.
CVA = cerebrovascular accident
TIA = transient ischaemic attack
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Adjunctive antithrombotic therapy
As stated before, the early and sustained success of fibrinolytic therapy is the result 
of the balance between forces stimulating lysis and those resulting in (re)occlusion. 
Adjunctive antithrombotic treatment should therefore be initiated as early as 
possible, and be continued indefinitely. 
Antiplatelet therapy efficacy and safety
–  Aspirin. Even in the absence of fibrinolytic treatment, the administration of 
aspirin has been shown to improve survival (6). A simple 35-day intervention 
with aspirin improved survival with 25 per 1000 treated patients: 10.7% vs. 
13.2%. This emphasizes the need to start aspirin in any patient with an acute 
coronary syndrome. Interestingly, the efficacy of aspirin seems independent of 
the duration of symptoms (6), in contrast to the benefits of fibrinolytic therapy 
(1). To induce an immediate effect, the starting dose should be 160 mg or higher, 
whereas for long-term administration 80-160 mg is sufficient. With regard to 
safety, quantitative review showed that the irreversible inhibition of cyclo-
oxygenase-1 does not result in significant gastro-intestinal bleeding, nor in an 
increase in intracranial hemorrhage (15).
–  Other antiplatelet agents. In those patients allergic or intolerant to aspirin, the 
ADP-receptor antagonist clopidogrel may be considered although only tested 
in the setting of non ST-elevation acute coronary syndromes (W29). The impact 
of the routine administration of clopidogrel on top of aspirin in patients treated 
with fibrinolytic therapy is evaluated in the currently running CLARITY/TIMI-28-
trial. 
Anticoagulant therapy, efficacy, Table 4
–  Unfractionated heparin. This agent exerts its effect through potentiation of anti-
thrombin III, so called “indirect thrombin inhibition”. In the pre-fibrinolytic 
era, its use has been proven to markedly improve prognosis (16). Yet, since the 
standardized combined use of aspirin and fibrinolysis few trials re-evaluated its 
magnitude of benefit (W30). 
 Based on pharmacological principles, the use of a bolus of heparin prior 
to, or concomitant with fibrinolytic therapy would counteract the liberated, 
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initially clot-entrapped thrombin, and facilitate early reperfusion. From the 
randomized trials on subcutaneous administration of unfractionated heparin, 
it was learnt that in-hospital outcome was modestly improved, a benefit that 
dissipated within three weeks after discontinuation of treatment (W7). For 
agents such as streptokinase, which results in prolonged fibrin depletion, 
48-72 hours of unfractionated heparin is not believed to be of benefit, but 
placebo-controlled evidence is lacking. The recent findings in the AMI-SK 
trial suggest that adjunctive anticoagulation is required (W31). As the most 
successful reperfusion regimen to date (7), the fibrin-specific accelerated rt-
PA, has never been tested without heparin, the regimen of newer fibrinolytics 
always included heparin. This is also based on the observation of a clustering of 
reinfarctions within the first 10 hours of discontinuation of intravenous heparin 
(9). This suggests an effect on rethrombosis cq. recurrent ischemic events after 
fibrinolysis, and forms the rationale of the 48-72 hour infusion. Intravenous 
heparinization constitutes several drawbacks varying from the use of an infusion 
pump, hampering mobilization, to the need of regular monitoring as a result of 
its rather unpredictable and varying plasma levels. 
–  Low-molecular-weight heparin. The introduction of agents like enoxaparin and 
dalteparin has overcome these problems. They have a better bioavailability, 
plasma levels are more stable, and monitoring is not necessary. Their impact 
is believed to be mostly achieved through inhibition of factor Xa and less 
by inhibition of thrombin activity, and results in similar early patency as 
unfractionated heparin (W32). The ease of subcutaneous administration also 
promotes prolonged treatment as performed in the old trials with subcutaneous 
unfractionated heparin. This reduced in-hospital reinfarction rates during 
treatment, with a catch-up phenomenon after discontinuation resulting in 
comparable outcome at 30-days (W33) to 1-year (W34). This supports the 
impact of continued anticoagulation therapy after fibrinolysis. Interestingly, 
the AMI-SK trial was the first to properly address the impact of an immediate, 
prolonged anticoagulation regimen in patients treated with streptokinase. In this 
placebo-controlled trial, early ST-resolution was significantly better in patients 
on enoxaparin, as was 5-7 day patency (W31).
–  Direct thrombin inhibitors. In contrast to heparins, this group of anticoagulants 
also affects thrombin bound to fibrin and fibrin degradation products. The impact 
of hirulog was evaluated as compared to unfractionated heparin in the over 
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17,000 patients HERO-2 trial, addressing ST-elevation myocardial infarction 
treated with streptokinase. Survival was not affected. In-hospital reinfarction, 
adjudicated in a blinded fashion, was significantly reduced from 3.6% to 2.8% 
(W35). 
–  Pentasaccharides. A pentasaccharide is a compound of unfractionated heparin, 
with the ability to strongly activate the anti-Xa activity of antithrombin-III, 
affecting the generation of thrombin without any direct effect on thrombin 
itself. This new agent resulted in similar 90-minute-patency after fibrinolysis as 
unfractionated heparin. In a secondary analysis, reocclusion was assessed in the 
subset of patients who did not undergo an intervention. A 5-7 day regimen of 
this new agent resulted in lower reocclusion rates, as compared to a 48-72 hour 
treatment with unfractionated heparin: 0.9% vs. 7.0%, respectively (p=0.065) 
(W36).
In summary, low-molecular-weight heparins are certainly more easily to administer 
and seem more effective than unfractionated heparin, which may in part be related 
to their prolonged administration. Whether these or other new agents should be 
implemented in daily clinical practice also depends on safety aspects.
Anticoagulation, safety, Table 4
–  Unfractionated heparin. Given the association between the level of 
anticoagulation and the risk of intracranial hemorrhage after fibrinolysis (9) 
downward dose-adjustments and more frequent assessment of the aPTT have 
been introduced (17). This has resulted in reduced rates of intracranial bleeding, 
without loss of efficacy (W37). The advantage of unfractionated heparin over the 
newer anticoagulants is the long-term experience in over hundred-thousands 
of patients. Given the modest impact on survival and reinfarction, safety is an 
important aspect.
–  Low-molecular-weight heparin. Whereas enoxaparin seemed an attractive 
alternative to unfractionated heparin, recent findings call for a more thorough 
evaluation of the safety of this agent as conjunctive to fibrinolysis. In the setting 
of non ST-elevation myocardial infarction, enoxaparin proved safe, and seemed 
to reduce recurrent ischemic events, be it with an administration until discharge 
as compared to 48-72 hours of unfractionated heparin (W38). The first trial 
using this enoxaparin regimen with in-hospital fibrinolysis showed increased 
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overall bleeding rates, but was too small to be conclusive on the risk of 
intracranial hemorrhage (13). The prehospital moderately sized ASSENT-3 PLUS 
trial, however, reported a significant increase in the incidence of intracranial 
hemorrhage in patients on enoxaparin: 2.0 vs 0.9% for unfractionated heparin 
(W39). The fact that this trial included a higher proportion of older, female 
patients with a low body-weight revealed this complication. Important other 
aspects are the lack of a weight-adjusted bolus and the almost doubled half-life 
of the subcutaneous dosis in elderly patients. The TIMI-25 EXTRACT trial will 
address the safety of subcutaneous enoxaparin with or without bolus, and in a 
weight-adjusted dose over the age of 75. In the pending CREATE trial, reviparin, 
a new low-molecular-weight heparin will be tested. 
–  Other anticoagulants. Given the limited experience with anti-Xa agents, and the 
higher bleeding rates with the rather expensive direct thrombin inhibitors, these 
agents are not to be recommended for general implementation. For patients with 
a heparin induced thrombocytopenia hirudin could serve as an alternative. 
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Table 4  A
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 0.07.
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Prevention of recurrent ischemic events
- The (sub)acute and chronic phase -
Irrespective of the initiation of reperfusion therapy, it is of the utmost importance 
to initiate interventions aimed at early hemodynamic stabilization, prevention of 
recurrent ischemia and malignant arrhythmias. Moreover, the unstable “hot” plaque 
should be “cooled off”, with agents affecting endothelial function and inflammation 
as additional treatment to antithrombotic agents (Figure 1). 
–  Nitrates. Due to its vasodilatation these agents are recommended for the first 
24-48 hours in patients with persistent ischemia, hypertension, heart failure and 
large anterior infarction (W40,W41).
–  Beta-blockers. Given the unfavorable prognostic impact of recurrent ischemia 
(W42), beta-blockers are a key intervention in the setting of myocardial infarction. 
In addition, its anti-hypertensive and, in particular, anti-arrhythmic properties 
are thought to form a major contribution to its beneficial effects on survival, as 
well as its beneficial effect on the incidence of cardiac rupture. Although the 
majority of evidence stems from the pre-fibrinolytic era (18,W43) this does not 
restrain its applicability in the current era of reperfusion therapy. Specifically in 
patients with restored patency the salvaged myocardium remains at renewed risk 
of ischemia, especially in the early phase, which was underscored in the TIMI-
IIb trial. Early initiation, i.e. within 2 hours, significantly reduced the combined 
(secondary) endpoint of reinfarction and recurrent ischemia in the first week as 
compared to patients in whom beta-blockers were initiated after this first week 
(W44). With respect to the choice of agent, cardioselective beta-blockers like 
atenolol and metoprolol are to be preferred over agents like propranolol, in 
order to avoid or reduce beta-2 related side effects. Importantly, randomized 
data on the use of cardioselective agents in patients with reactive airway 
disease only resulted in a limited decrease in FEV1 not associated with adverse 
respiratory effects (W45). Moreover, observational data in over 200,000 patients 
suggest that patients believed to have a relative contra-indication, i.e. diabetes, 
asthma etc., benefit from beta-blockers without clinically important side effects 
(W46). Thus, beta-blockers should be initiated as early as possible and deserve a 
central role in the (sub)acute phase and follow-up treatment of all patients with 
acute myocardial infarction, including those with left ventricular dysfunction, 
also in the era of reperfusion therapy (W47). Importantly, intolerable side effects 
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can be directly antagonized, in contrast to those of calcium channel blockers.
–  Calcium channel blockers. Short-acting agents from the dihydropyridine class 
like nifedipine are contra-indicated in the setting of myocardial infarction, 
given their negative effects as a result of reflex sympathetic stimulation, 
tachycardia and hypotension (19,W48). Long-acting agents, and the other 
calcium antagonists like diltiazem and verapamil have failed to improve survival 
(W49,W50,W51,W52,W53). For the latter agents, reduction of recurrent 
ischemic events has been demonstrated in a selected patient population, 
without left ventricular dysfunction (W49,W50). Therefore, its use should 
primarily be restricted to co-administration with a beta-blocker in the case of 
recurrent ischemia.
–  ACE-inhibitors. Patients with particular benefit are those with large infarcts, 
not only those with clinical signs of heart failure (W54,W55), but also in the 
asymptomatic patient with a reduced left ventricular function (W55,W56). As 
much of the survival advantage is realized in the first 48 hours, early initiation 
of oral treatment is indicated (20,W40,W41,W57,W58). With the emerging 
evidence that various subgroups of patients benefit from treatment, a six-week 
treatment period for all patients after infarction can certainly be considered (20). 
In the case of heart failure and reduced left ventricular function, angiotensin-
blockers can be used as an alternative, but also in addition to ACE-inhibitors to 
reduce cardiovascular, though not all-cause, mortality (W59).
-  Statins. The need for long-term use of statins is undisputed (W60,W61,W62). 
With respect to the additional impact of early initiation, no trials for ST-elevation 
myocardial infarction are available. Data from the MIRACL study suggest a 
reduced incidence of recurrent ischemic events with early treatment after a non 
ST-elevation acute coronary syndrome (W63). 
–  Additional antithrombotic treatment. Although a prolonged combined 
antithrombotic regimen of aspirin and (oral) anticoagulation has proven of 
additional benefit (5), the need of a good infrastructure of oral anticoagulation 
control has hampered implementation in daily care. With the successful initial 
data on the oral direct thrombin inhibitor ximelagatran on top of aspirin, 
this problem may be solved, which facilitates future comparisons with dual 
antiplatelet regimens (W64). The beneficial impact of the standard addition of 
clopidogrel has been proven in non ST-elevation acute coronary syndromes, and 
is currently under investigation in the large ST-elevation CCS2 trial. Therefore, 
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the majority of patients after ST-elevation myocardial infarction only receives 
treatment with aspirin at discharge, which should be used indefinitely.
Recommendations
In view of the fact that many patients with an ST-elevation myocardial infarction 
will not be treated by primary angioplasty in lack of a proper infrastructure, 
optimal pharmacological treatment is warranted. Importantly, time to initiation 
of treatment is a crucial element, a factor that can be positively influenced by 
early, preferably prehospital initiation of pharmacological reperfusion therapy. 
When primarily adopting a pharmacological approach to reperfusion therapy in 
ST-elevation myocardial infarction, an individually tailored approach with respect 
to the choice of a fibrin-specific or non-fibrin specific agent is a prerequisite, 
balancing the respective risks and benefits, which also holds true for the decision 
of rescue angioplasty. Aspirin, anticoagulation and early initiation of beta-blockade 
form the key triade of adjunctive treatment in the acute phase. The use of calcium 
channel blockers should be reserved to co-treatment with a beta-blocker, and only 
agents from the non-dihydropyridine class, like diltiazem, can be considered as an 
alternative to beta-blocker treatment in the case of clinically proven intolerance. In 
the subgroups of patients with a reduced left ventricular function, or clinical signs 
of heart failure ACE-inhibitors are indicated, and a six-week treatment period can 
be considered in all patients with an acute coronary syndrome. Finally, in order 
to prevent recurrent ischemic events and malignant arrhythmias and to stabilize 
the “hot” plaque, the continued use of aspirin and beta-blockers is recommended, 
complemented by long-term statin therapy.
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Abstract
Background: The Myocardial Infarction Triage and Intervention Trial of prehospital 
versus hospital administration of thromoblytic therapy markedly reduced hospital 
treatment times and the 2 groups had similar outcomes. However, patients treated 
< 70 minutes from symptom onset had better short-term outcomes. The purpose 
of this study was to determine the long-term influence of very early thrombolytic 
treatment for acute myocardial infarction.
Methods and Results: A total of 360 patients were followed for vital status and 
cardiac-related hospital admissions over a period of 34 ± 16 months. Patients enrolled 
in the trial had symptoms for < 6 hours, ST-segment elevation on the prehospital 
electrocardiogram, and no risk factors for serious bleeding. They received aspirin 
and recombinant tissue plasminogen activator either before or after hospital arrival. 
Primary end points in this study included long-term survival and survival free of 
readmission to the hospital for myocardial infarction, revascularization, angina, 
or congestive heart failure. Two-year survival was 89% for prehospital- en 91% 
for hospital-treated patients (p=0.46). Event-free survival at 2 years was 56% and 
64% for prehospital- and hospital-treated patients, respectively (p=0.42). In patients 
treated < 70 minutes from symptom onset, 2-year survival was 98%, and it was 88% 
for those treated later (p=0.12). Two-year event-free survival was 65% for patients 
treated early and 59% for patients treated later (p=0.80).
Conclusions: In this trial, poorer long-term survival was associated with advanced 
age, history of congestive heart failure, and coronary artery bypass surgery 
performed before the index hospitalization, but not with time to treatment.
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Introduction
Thrombolytic therapy has been proven to reduce early mortality and to improve 
1-year survival rates in patients with acute myocardial infarction. (1-7) The greatest 
mortality reduction is shown in patients who receive treatment within the first 1 to 
2 hours after symptom onset. (3,5,6,8) In several studies that have determined the 
components of treatment delay, patient decision time and hospital treatment times 
each could account for > 1 hour. Prehospital initiation of thrombolytic therapy 
might therefore provide the opportunity to treat a large proportion of patients within 
the first 2 hours of symptom onset.
Two trials of prehospital thrombolytic therapy demonstrated significant reductions 
in time to treatment, although mortality in the prehospital and hospital groups was 
not significantly different (12,13).
In the Myocardial Infarction Triage and Intervention (MITI) prehospital trial, time to 
treatment was reduced by 33 minutes in the prehospital group. In addition, patients 
treated < 70 minutes from symptom onset had lower mortality, smaller infarct size, 
and improved left ventricular function (13).
Over the years, several studies reporting the long-term influence of thrombolytic 
therapy have been published (14,15,16). The purpose of the current study was to 
determine whether the benefits of very early treatment were sustained in the years 
after discharge from the hospital.
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Methods
Patient population
All patients who called 911 and had chest pain were evaluated by the 15 paramedic 
units in the Seattle metropolitan area. Using a checklist with inclusion and exclusion 
criteria, paramedics gathered information on the patients’ clinical presentations. 
This information enabled hospital-based physicians to determine whether the 
patients were candidates for thrombolytic therapy. Patients were excluded from 
participating in the trial for the following reasons: (1) chest pain > 6 hours from 
symptom onset, (2) age > 75 years, or (3) the presence of complicating illnesses 
that were considered to be contraindications for prehospital thrombolytic therapy. 
Detailed information on the study protocol and criteria for patient selection have 
been published (11,13).
Briefly, a 12-lead prehospital electrocardiogram was obtained in the subset of 
patients who satisfied the criteria for enrollment. The final decision to randomize the 
patient was made by a physician in the emergency department of 1 of 6 paramedic 
base hospitals. Paramedics used a standard verbal consent to enrol patients into 
the study. After enrollment, patients were randomized to receive aspirin and 
recombinant tissue plasminogen activator either before or after hospital arrival. 
Intravenous sodium heparin was administered to both patient groups at the time 
of hospital arrival. After hospital discharge, 289 patients underwent radionuclide 
measurements of infarct size and left ventricular ejection fraction. 
Follow-up
To determine survival status and the need for readmission to the hospital for 
cardiac reasons, mail questionnaires were sent to patients annually. Patients were 
queried concerning hospital admissions for the following reasons: (1) angiography, 
(2) coronary angioplasty, (3) coronary artery bypass surgery, (4) congestive heart 
failure, (5) chest pain, or (6) subsequent myocardial infarction. In addition to the 
mail questionnaires, hospital admission logs were screened for cardiac-related 
admissions. Information about procedures and admission and discharge diagnoses 
was also recorded. Telephone contact with patients or surviving relatives often 
enabled us to complete missing information. Finally, the National Death Index was 
used to ascertain vital status for patients lost to follow-up. 
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Statistical methods
The primary end points of this study were survival and event-free survival, defined 
as survival free of myocardial infarction, or hospitalization for angina, congestive 
heart failure, or revascularization. Survival analyses included deaths from all causes. 
Survival curves for all groups were obtained according to the method of Kaplan and 
Meier (17). The log rank test was used to determine whether survival and event-free 
survival were different according to randomization group and time to treatment, 
dichotomized by a 70-minute cutpoint. Stepwise Cox regression analysis was used 
to identify factors related to long-term survival; variables were included in the 
model if the p value for inclusion was < 0.05. To compare the numbers of cardiac-
related hospital admissions, we calculated the average number of events per patient 
per follow-up year. Baseline characteristics and clinical outcomes were compared 
by the chi-square test for discrete variables and the t test for continuous variables.
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Results
Of all 360 patients, 175 were randomized to receive prehospital-initiated 
thrombolytic therapy, and the other 185 were allocated to thrombolytic treatment 
after hospital arrival. Baseline characteristics of these patients have been described 
(13). Cardiac histories and hemodynamic findings did not differ significantly 
between the groups, and baseline electrocardiographic findings were also 
similar: Anterior infarction occurred in 39% (p=0.99) and inferior infarction in 
58% (p=0.99) of both groups. Patients in the hospital group were slightly older 
than their counterparts (59 ± 10 years in the hospital group vs. 57 ± 10 years in 
the prehospital group; p = 0.04). Time from symptom onset to treatment differed 
significantly; the median time to treatment for the prehospital group was 77 minutes 
(56 and 101; 25th and 75th percentiles), and it was 110 minutes (85 and 140; 25th 
and 75th percentiles) for the hospital group (p < 0.0001). Overall, 336 patients 
received thrombolytic therapy in either the prehospital or the hospital setting; 24 
did not receive thrombolytic treatment for varying reasons (13). In nearly 25% (82 
of 336) of the patients receiving thrombolytic therapy, time from symptom onset 
to treatment was < 70 minutes. Most were treated later; 254 patients received 
thrombolytic therapy between 70 minutes and 3 hours of symptom onset.
The baseline characateristics of patients treated early (< 70 minutes) and of those 
treated later were similar. Patients in the early group were slightly younger, although 
this difference was not statistically significant (56 ± 10 years in the early-treated 
patients vs 58 ± 10 years in the later-treated patients; p = 0.051) Time to treatment 
showed a distinct difference: The median time to treatment was 55 minutes (49 and 
63; 25th and 75th percentiles) for the early-treated patients compared with 104.5 
minutes (85 and 141; 25th and 75th percentiles) for those who were treated later. 
Prehospital vs In-Hospital Thrombolysis
In the first year of follow-up, 31 patients died; information on cardiac-related events 
was available for 97% of patients. With the National Death Index and returned 
follow-up letters, it was possible to ascertain vital status for all patients. Figure 1 
shows cumulative survival curves for the prehospital and hospital groups. There 
was no significant difference in long-term survival between the two groups; 2-year 
survival was 89% for prehospital-treated patients and 91% for those treated in 
the hospital setting (p= 0.46). Event-free survival also did not differ according to 
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randomization group (Figure 2). Two years after enrolment, event-free survival was 
56% and 64% in the prehospital and hospital groups, respectively (p=0.42).
To determine whether patients differed in the number of cardiac-related events, we 
calculated event rates for both groups (Table 1). The prehospital group showed a 
slightly lower number of cardiac-related admissions (p=0.28). Overall, there was 
a difference of 68 cardiac-related events per 1,000 patients per year (Table 1). 
Hospital readmission rates at 1 and 2 years of follow-up were also determined. For 
the prehospital group, 31% and 36% of patients were rehospitalized at 1 and 2 
years, respectively. In the hospital group, 25% of patients were readmitted at 1 year 
and 31% at 2 years ( p=0.65).
Effect of time to treatment
During the first year of follow-up, 28 of 336 patients who received thrombolytic 
therapy died. Information on cardiac-related events was available for 96% of 
surviving patients. Figure 3 shows the long-term survival for the group that was 
treated very early versus the group that received thrombolytic agents > 70 minutes 
from symptom onset. Unadjusted survival in the early-treatment group appeared to 
be improved, but the difference was not statistically significant, because the survival 
curves crossed after 3 years. Two-year survival was 98% for the early-treated patients 
and 88% for those who received thrombolytics later (p=0.12). 
Figure 4 shows that there was no significant difference in event-free survival 
between the very early and the later-treated group. Event-free survival at 2 years 
was 65% for the early group and 59% for the later group (p=0.80). Event rates were 
similar in the 2 groups (Table 2). Readmission rates at 1 and 2 years of follow-up 
were 30% and 33%, respectively, for the early-treated patients and 27% and 33% 
for those treated later. These differences were not statistically significant (p=0.74).
To identify factors that were related to long-term survival, we performed Cox 
multivariate regression analysis in 329 patients with complete information. 
Advanced age, a history of heart failure, and bypass surgery performed before the 
index hospitalization were associated with decreased survival. After adjustment for 
these variables, treatment < 70 minutes from symptom onset was not associated 
with survival (p=0.30). In addition, time to treatment measured as a continuous 
variable was not predictive of long-term survival (p=0.84).
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Figure 1: Long-term survival for patients after prehospital and in-hospital thrombolysis
Figure 2: Long-term event-free survival for patients after prehospital and
 in-hospital thrombolysis
498 THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 78 SEPTEMBER 1, 1996
/ av1 2w0c 0001 Mp 498 Tuesday Aug 06 08:20 PM EL–AJC (v. 78, 5) 0001
FIGURE 1. Cumulative survival curves for the prehospital and hospital groups. No statistically significant difference was observed (p Å
0.46).
FIGURE 2. Event-free survival
analysis of 360 randomized
patients allocated to prehospi-
tal- or hospital-initiated throm-
bolytic therapy. There was no
statistically significant differ-
ence between the groups (p Å
0.42).
and criteria for patient selection have been pub-
lished.11,13
Briefly, a 12-lead prehospital electrocardiogram
was obtained in the subset of patients who satisfied
the criteria for enrollment. The final decision to ran-
domize the patient was made by a physician in the
emergency department of 1 of 6 paramedic base hos-
pitals. Paramedics used a standard verbal consent to
enroll patients into the study. After enrollment, pa-
tients were randomized to receive aspirin and recom-
binant tissue plasminogen activator either before or
after hospital arrival. Intravenous sodium heparin
was administered to both patient groups at the time
of hospital arrival. After hospital discharge, 289 pa-
tients underwent radionuclide measurements of in-
farct size and left ventricular ejection fraction.
Follow-up: To determine survival status and the
need for readmission to the hospital for cardiac rea-
sons, mail questionnaires were sent to patients an-
nually. Patients were queried concerning hospital ad-
missions for the following reasons: (1) angiography,
(2) coronary angioplasty, (3) coronary artery bypass
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Table 1 Observed cardiac-related events for both randomized groups 
                                                    Number of events/ 
      Number of Events              100 patients/year
Event
Prehospital
(n = 175)
Hospital
(n = 185)
Prehospital
(n = 175)
Hospital
(n = 185) p Value
Angiography 054 070 11.5 13.8 0.37
Angioplasty 034 043 07.0 08.5 0.45
Bypass Surgery 020 020 04.1 04.0 0.90
Congestive Heart Failure 012 013 02.6 02.5 0.94
Myocardial infarction 022 021 04.3 04.3 0.98
Recurrent ischemia 024 040 04.9 07.9 0.11
Total 166 207 34.2 41.0 0.28
Figure 3: Long-term survival for patients treated within and later than 70 minutes after 
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TABLE I Observed Cardiac-Related Events for Both Randomized Groups and the
Subgroups
Event
Number of Events
Prehospital
(n Å 175)
Hospital
(n Å 185)
Number of Events/100
Patients/Year
Prehospital
(n Å 175)
Hospital
(n Å 185) p Value
Angiography 54 70 11.5 13.8 0.37
Angioplasty 34 43 7.0 8.5 0.45
Bypass surgery 20 20 4.1 4.0 0.90
Congestive heart failure 12 13 2.6 2.5 0.94
Myocardial infarction 22 21 4.3 4.3 0.98
Recurrent ischemia 24 40 4.9 7.9 0.11
Total 166 207 34.2 41.0 0.28
FIGURE 3. Cumulative survival
curves for patients treated very
early (õ70 minutes) versus
those treated later (70 minutes
to 3 hours). The observed dif-
ference was not statistically
significant (p Å 0.12).
surgery, (4) congestive heart failure, (5) chest pain,
or (6) subsequent myocardial infarction. In addition
to the mail questionnaires, hospital admission logs
were screened for cardiac-relat d admissions. Infor-
mation about procedures and admission and dis-
charge diagnoses was also recorded. Telephone con-
tact with patients or surviving relatives often enabled
us to complete missing information. Finally, the Na-
tional Death Index was used to ascertain vital status
for patients who were lost to follow-up.
Statistical methods: The primary end points of this
study were survival and event-free survival, defined
as survival free of death, myocardial infarction, or
hospitalization for angina, congestive heart failure,
or revascularization. Survival analys s included
deaths from all causes. Survival curves for all groups
were obtained according to the method of Kaplan
and Meier.17 The log rank test was used to determine
whether survival and event-free survival were dif-
ferent according to randomization group and time to
treatment, dichotomized by a 70-
minute cutpoint. Stepwise Cox re-
gression analysis was used to iden-
tify factors related to long-term
survival; variables were included in
the model if the p value for inclu-
sion was õ0.05. To compare the
numbers of cardiac-related hospital
admissions, we calculated the aver-
age number of events per patient per
follow-up year. Baseline character-
istics and clinical outcomes were
compared by the chi-square test for
d crete var ables and he t test for
continuous variables.
RESULTS
Of all 360 patients, 175 were randomized to re-
ceive prehospital-initiated thrombolytic therapy, and
the other 185 were allocated t thrombolytic treat-
ment after hospital arrival. Baseline characteristics
of these patients have been described.13 Cardiac his-
tories and hemodynamic findings did not differ sig-
nificantly between the groups, and baseline electro-
cardiographic findings were also similar: Anterior
infarction occurred in 39% (p Å 0.99) and inferior
infarction in 58% (pÅ 0.99) of both groups. Patients
in the hospital group were slightly older than their
counterparts (59 { 10 years in the prehospital group
vs 57 { 10 years in the hospital group; p Å 0.04).
Time from symptom onset to treatment differed sig-
nificantly; the median time to treatment for the pre-
hospital group was 77 minutes (56 and 101; 5th
and 75th percentiles) , and it was 110 minutes (85
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Figure 4: Long-term event-free survival for patients treated within and later than 70 
 minutes after symptom onset
Table 2   Observed cardiac-related events for patients treated very early and those 
   treated later
                                                                           Number of events/ 
                                  Number of Events             100 patients/year
Event
< 70 min
(n = 82)
≥ 70 min
(n = 254)
< 70 min
(n = 82)
≥ 70 min
(n = 254) p Value
Angiography 27 089 11.0 13.1 0.45
Angioplasty 22 046 09.0 06.8 0.35
Bypass Surgery 09 029 03.7 04.3 0.69
Congestive Heart Failure 04 019 01.6 02.8 0.38
Myocardial infarction 08 035 03.3 05.1 0.18
Recurrent ischemia 11 049 04.5 07.2 0.18
Total 81 267 33.0 39.2 0.35
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FIGURE 4. Event-free survival
analysis for patients treated
very early (õ70 minutes) ver-
sus those treated later (70
minutes to 3 hours). The curves
were similar (p Å 0.80).
and 140; 25th and 75th ercentiles) for the hospital
group (p õ0.0001).
Overall, 336 patients received thrombolytic ther-
apy in either the prehospital or the hospital setting;
24 did not receive thrombolytic treatment for varying
reasons.13 In nearly 25% (82 of 336) of the patients
receiving thrombolytic therapy, time from symptom
onset to treatment was õ70 minutes. Most were
treated later; 254 patients received thrombolytic
therapy between 70 minutes and 3 hours of symptom
onset.
The baseline characteristics of patients treated
early (õ70 minutes) and of those treated later were
similar. Patients in the early group were slightly
younger, although this difference was not statisti-
cally significant (56 { 10 years in the early-treated
patients vs 58{ 10 years in the later-treated patients;
p Å 0.051). Time to treatment showed a distinct dif-
ference: The median time to treatment was 55
minutes (49 and 63; 25th and 75th percentiles) for
the early-treated patients compared with 104.5
minutes (85 and 141; 25th and 75th percentiles) for
those who were treated later.
In the first year of follow-up, 31 patients died;
information on cardiac-related events was available
for 97% of patients. With the National Death Index
and returned follow-up letters, it was possible to as-
certain vital status for all patients. Figure 1 shows
cumulative survival curves for the prehospital and
hospital groups. There was no significant difference
in long-term survival between the groups; 2-year sur-
vival was 89% for prehospital-treated patients and
91% for those treated in the hospital setting (p Å
0.46). Event-free survival also did not differ accord-
ing to randomization group (Figure 2). Two years
after enrollment, event-free survival was 56% and
64% in the prehospital and hospital groups, respec-
tively (p Å 0.42).
To determine whether patients differed in the
number of cardiac-related events, we calculated
event rat s for both groups (Table I ) . The prehos-
pital group showed a slightly lower number of car-
diac-related admissions (p Å 0.28) . Overall, there
was a difference of 68 cardiac-related events per
1,000 patients per year (Table I ) . Hospital read-
mission rates at 1 and 2 years of follow-up were
also determined. For the prehospital group, 31%
and 36% of patients were rehospitalized at 1 and 2
years, respectively. In the hospital group, 25% of
patients were readmitted at 1 year and 31% at 2
years (p Å 0.65) .
During the first year of follow-up, 28 of 336 pa-
tients who received thrombolytic therapy died. In-
formation on cardiac-related events was available for
96% of surviving patients. Figure 3 shows the long-
term survival for the group that was treated very
early versus the group that received thrombolytic
agents ¢70 minutes from symptom onset. Unad-
justed survival in the early-treatment group appeared
to be improved, but the difference was not statisti-
cally significant, because the survival curves crossed
after 3 years. Two-year survival was 98% for the
early-treated patients and 88% for those who re-
ceived thrombolytics later (p Å 0.12).
Figure 4 shows that there was no significant dif-
ference in event-free survival between the very early
and the later-treated group. Event-free survival at 2
years was 65% for the early group and 59% for the
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Discussion
Time to treatment is an important predictor of hospital mortality (3,8,13). The 
earlier thrombolytic treatment is initiated, the more myocardium is saved and the 
better the clinical outcome. According to this hypothesis, outcome would be best 
in patients treated very early. We conducted this follow-up study to assess the long-
term influence of very early initiation of thrombolytic therapy.
There was a trend toward improved long-term survival after very early thrombolysis. 
This benefit resulted primarily from a much more favorable in-hospital mortality 
rate for patients treated very early. Moreover, readmission rates and event-free 
survival were not influenced by a substantial reduction in time to treatment. 
Therefore, despite the major impact of early treatment on short-term mortality, the 
influence on long-term clinical outcome was less impressive. The benefits of very 
early treatment are immediate; with the passage of time, other factors, including 
age and gender, as well as the use of aspirin, beta blockers, risk factor reduction, or 
revascularization procedures, become pre-eminent for all patients.
Survival curves for the prehospital- and hospital-treated patients were similar. These 
findings may have been influenced by the unanticipated reduction of 40 minutes 
in hospital treatment times in this study (13). Consequently, prehospital initiation 
of thrombolytic therapy resulted in a reduction in time to treatment of only 33 
minutes, instead of the expected time of > 1 hour (13).
This, combined with the conservative selection criteria and the relatively low patient 
numbers, might have prevented the difference between treatment groups that was 
expected. In the analysis of early treatment, the earlier reported 30-day survival 
benefit for patients treated < 70 minutes from symptom onset resulted in markedly 
improved survival in this group. This gain was caused primarily by a lower number 
of in-hospital deaths for the early-treated patients. Considering the entire follow-
up period, the observed difference between curves was not statistically significant 
(p=0.12). In addition, results from Cox regression analysis indicated that early 
treatment was not associated with long-term survival. These findings do not suggest 
that very early treatment exerts an additional salutary effect that was realized in the 
first month after treatment.
Event-free survival was not influenced by a reduction in time to treatment. 
Readmission rates and the event rates also did not differ significantly. The slightly 
higher event-free percentages in the very early-treated group were caused by fewer 
 CHAPTER 4 71
deaths in this group and not by a difference in hospital admissions for cardiac 
events. These findings do not support the hypothesis that early treatment would 
result in improved overall cardiac status and thus fewer subsequent admissions. A 
Dutch study has suggested that freedom from reocclusion does result in improved 
long-term event-free survival (18).
Follow-up in the MITI prehospital thrombolysis trial demonstrated that short- and 
long-term clinical outcomes were similar for prehospital- and hospital-treated 
patients. Thirty-day survival was improved with very early thrombolytic therapy, but 
very early treatment did not decrease either subsequent survival or the number of 
cardiac events after hospital discharge.
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Abstract
Objectives: This study sought to assess the long-term clinical consequences of 
reocclusion after coronary thrombolysis. 
Background: After acute myocardial infarction successfully treated with 
thrombolysis, reocclusion occurs in ~30% of patients and leads to poorer in-
hospital outcome. However, the long-term effects of reocclusion are unknown.
Methods: Three hundred patients with no history of coronary surgery and with a 
patent infarct-related artery at coronary angiography within 48 h after thrombolysis 
were enrolled in the Antithrombotics in the Prevention of Reocclusion in COronary 
Thrombolysis (APRICOT) trial. At a mean (±SD) of 77 ± 23 days after thrombolysis, 
248 patients (87%) underwent follow-up angiography. Reocclusion was observed 
in 71 (29%) of 248 patients. To compare outcome between 71 patients with and 
177 without reocclusion an analysis of event-free survival, defined as a clinical 
course without death, reinfarction and revascularization, was performed. 
Results: Over a 3-year follow-up period, event-free survival was significantly better 
in patients without reocclusion: At 1 year it was 63% for patients with and 83% for 
those without reocclusion (p<0.001). In the first year, two or more cardiac-related 
events occurred in 24% of patients with and 6% of those without reocclusion 
(p<0.001). Patients with reocclusion had a markedly higher reinfarction and 
revascularization rate. At 1 year the reinfarction rate was 23% for patients with and 
5% for those without reocclusion (p<0.001).
Conclusions: This analysis shows the adverse influence of reocclusion on long-
term clinical outcome in relation to reinfarction and need for revascularization. 
To further optimize prognosis after thrombolysis, prevention of reocclusion should 
become a main priority. Future research should focus on the criteria and timing of 
elective revascularization procedures in the prevention of coronary reocclusion. 
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Introduction
In the past decade, thrombolytic therapy has become the cornerstone of treatment for 
acute transmural myocardial infarction. In 80% of all treated patients, recanalization 
of the infarct-related artery is eventually achieved. (1) However, several studies (2-8) 
have demonstrated that reocclusion occurs in 5% to 30% of patients after successful 
thrombolysis. Reocclusion has proved to be associated with an adverse short-term 
clinical outcome (3) and impaired residual left ventricular function (3,9), the most 
important prognostic factor after myocardial infarction after thrombolysis (10). The 
benefit of thrombolytic therapy – improvement of both short- and long-term survival 
– could therefore be optimized by the prevention of reocclusion. Routine invasive 
strategies after thrombolysis have not been shown to improve clinical outcome (11). 
There have been several studies (2-8) specifically addressing coronary reocclusion 
and the intermediate-term effects of oral antithrombotic therapy on reocclusion. 
These studies may provide insight into the long-term effects of reocclusion after 
coronary thrombolysis.
Several trials (12-14) have been conducted to determine long-term survival after 
thrombolytic therapy. To our knowledge, this report is the first follow-up study 
to assess the effects of reocclusion on long-term clinical outcome. The data are 
derived from the Antithrombotics in the Prevention of Reocclusion in COronary 
Thrombolysis (APRICOT) trial (2).
 CHAPTER 5 79
Methods
Study protocol
A detailed description of the APRICOT study protocol and criteria used to select 
patients has previously been published (2). In brief, 300 patients < 70 years old 
with no history of coronary surgery were enrolled between August 15, 1987 
and June 30, 1991. They presented with chest pain lasting > 30 min and < 4 h 
combined with a minimum of 0.2mV of ST segment elevation in two contiguous 
electrocardiographic (ECG) leads. They received thrombolytic therapy with either 
streptokinase or anistreplase followed by a fixed dose of intravenous heparin 
(20,000 U/24 h). Downward dose adjustments were made only when the activated 
partial thromboplastin time exceeded 2.5 times baseline values. Standard coronary 
care treatment was given (15). Within 48 h after the start of thrombolytic treatment, 
coronary angiography showed grade 1 to 3 stenosis of the infarct-related artery 
according to the criteria defined by the European Cooperative Study Group (16). 
European Cooperative Study Group grades 1 to 3 are identical to Thrombolysis in 
Myocardial Infarction (TIMI) grade 3 flow. Sixteen patients were retrospectively 
judged to have an occluded infarct-related artery and were not included in the 
study (Fig. 1).
All 284 patients with a patent infarct-related artery were randomized to treatment 
with 325 mg of aspirin daily, coumadin (international normalized ratio 2.8 to 4.0) 
or placebo. Infarct-related artery status at 3 months was the primary end point 
of the APRICOT trial. Revascularization was performed for clinical reasons only. 
Thirty-six patients did not undergo follow-up angiography because of refusal (n 
= 28), coronary bypass surgery (n = 6 ) or death (n = 2) (Fig. 1). Reocclusion was 
defined as a grade 4 to 5 stenosis (16) and corresponds to TIMI flow grades 0 to 2. 
The culprit lesions of patients undergoing angioplasty before the scheduled second 
angiography were analyzed in the catheterization laboratory immediately before 
the angioplasty procedure. On the basis of results of the second angiography, two 
groups of patients were defined: 
1. 71 patients with reocclusion; and 
2. 177 without reocclusion.
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Follow-up
Patients that participated in the APRICOT trial were screened for cardiac-related 
events over a 3-year follow-up period. Medical files were used to study hospital 
admissions for the following reasons: coronary angioplasty, coronary bypass surgery 
and reinfarction. In addition, survival status of all enrolled patients was assessed. 
Municipal registries and telephone contact with the patient, general practitioner or 
relatives enabled us to complete missing information. 
Clinical end points
Outcome between groups was compared according to vessel status at the second 
angiography, and clinical information since the day of randomization was used. 
The primary end point of the analysis was event-free survival. An event-free follow-
up was defined as a clinical course without death, reinfarction or readmission for 
coronary angioplasty or coronary bypass surgery. Criteria for recurrent myocardial 
infarction were chest pain accompanied by typical ECG changes combined with an 
increase in creatine kinase levels higher than twice the upper normal limit.
Statistics
Baseline characteristics are expressed as mean value ± SD and were compared 
by the Student’s t test. Whenever appropriate, the chi-square test was used for 
other comparisons between groups. Event-free survival curves were obtained as 
described by Kaplan and Meier (17). To determine the statistical significance of 
the difference between curves, the log-rank test was used. A p value < 0.05 was 
considered statistically significant. 
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Results
Follow-up
Of the 284 patients participating in the APRICOT trial, 248 (87%) had a second 
coronary angiography performed at a mean of 77 ± 23 days after thrombolysis (Fig. 
1). Patients without angiographic follow-up more often had a history of myocardial 
infarction (17% vs. 6%, p < 0.025), were slightly older (60 ± 7 vs. 56 ± 9 years, p 
< 0.01) and were more often female (31% vs. 17%, p < 0.05) (2). The 248 patients 
with both a first and a second angiography formed the present study group. Follow-
up data were collected for a median of 31 months (25th to 75th percentile, 19 to 46 
months) starting on the day of randomization. No patient was lost to follow-up. In 
the first follow-up year six patients died. Information on 238 (98%) of the surviving 
242 patients after > 1 year of follow-up was available. 
Table 1 shows the baseline characteristics of patients with and without reocclusion. 
No statistical differences were observed. 
Clinical outcome
Figure 2 shows event-free survival in patients with and without reocclusion over 
a 3-year follow-up period. In the reocclusion group, the majority of all events 
occurred in the first 3 months. In this short period of time, the event-free survival 
rate decreased to 68% for patients with reocclusion compared with 92% for those 
without reocclusion. There was a significant (p < 0.001) overall difference in the 
event-free survival curves, with most of the difference occurring within the first 
weeks. At 1 year these percentages were 63% and 83%, respectively (p < 0.001). 
Over the entire follow-up period, 19 patients (27%) with and 16 patients (9%) 
without reocclusion had a reinfarction. Reinfarction occurred in the same area as 
the index infarction, exept in one patient. Proportionally, the reocclusion group 
experienced three times as many reinfarctions (Table 2). Data are expressed as event 
counts rather than event rates because of the decreasing follow-up percentage after 
the first year of follow-up. 
In the first year of follow-up the incidence of cardiac-related events was 59% for 
patients with and 24% for those without reocclusion (p < 0.001). These rates were 
similar over 3 years: 75% for the former and 33% for the latter. Patients without 
reocclusion experienced 39 cardiac-related events in the first year of follow-up. 
Forty-four percent of events occurred within 3 months after randomization, in 
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contrast to 74% of all observed events in patients with reocclusion (p < 0.03). At 
1 year of follow-up, a clinical course with two or more cardiac-related events was 
seen in 24% of patients with, compared to 6% of patients without reocclusion (p < 
0.001). Over the entire follow-up period, multiple events occurred in 22 patients 
(31%) with and 15 (9%) without reocclusion. 
Figure 1: Reasons for not undergoing follow-up coronary angiography after 3 months. 
 IRA= infarct-related artery
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Table 1 Baseline characteristics in patients with and without reocclusion
No reocclusion
n = 177
Reocclusion
n = 71
Male (%) 81% 87%
Age (years) 56 ± 9 57 ± 9 
Angina pectoris
 < 4 wk
 ≥ 4 wk
52 (29%)
33 (19%)
25 (35%)
15 (21%)
Previous myocardial infarction 11 0(6%) 040 (6%)
Time of symptoms (thrombolysis) (h) 2.0 ± 1.0 2.0 ± 1.1
Peak creatine kinase (U/liter) 1,545 ± 1,509 1,567 ± 1,419
Study medication
 Aspirin
 Coumadin
 Placebo
70 (40%)
57 (32%)
50 (28%)
23 (23%)
24 (34%)
24 (34%)
Infarct-related artery: 
 LAD
 LCX
 RCA
071 (40%)
028 (16%)
078 (44%)
34 (48%)
11 (16%)
26 (37%)
One-vessel disease 106 (60%) 36 (51%)
Two-vessel disease 049 (28%) 24 (34%)
Three-vessel disease 022 (12%) 11 (16%)
Ejection fraction (%)
 No. of pts
51 ± 10
120
52 ± 13
52
End-systolic volume (ml)
 No. of pts
76 ± 29
97
73 ± 31
46
End-diastolic volume (ml)
 No. of pts
152 ± 43
97
152 ± 39
46
Unless otherwise indicated, data presented are mean value ± SD or number (%) of patients (pts). 
LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; 
RCA = right coronary artery. 
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Figure 2: Event-free survival (defined as a clinical course without death, reinfarction or  
 revascularization) in patients with and without reocclusion. The follow-up  
 period starts at first coronary angiography (within 48 hours after successful  
 thrombolysis)
Table 2    Clinical events over 3-year follow-up in patients with and without reocclusion
Before
2nd 
Angio
2nd 
Angio
to 1st yr 2nd yr 3rd yr Total
No. of patients with 
reocclusion at risk (n=71)  71  48  45  27 0071
 Death  2  1  2  1 0006 (9%)
 Reinfarction  5  1  2  1 0019 (27%)
 PTCA  12  6  3  0 0021 (30%)
 CABG  2  3  2  0 0007 (10%)
 Total  31  11  9  2 0053 (75%)
No. of patients without 
reocclusion (n=177)  177  163  147  94 00177
 Death  0  3  3  0 00006 (3%)
 Reinfarction  3  5  6  2 00016 (9%)
 PTCA   12  9  3  0 00024 (14%)
 CABG  3  4  4  1 00012  (7%)
 Total  18  21  16  3 00058 (33%)
Data presented are number or number (%) of patients (pts). Angio = Angiography; CABG = coronary 
artery bypass grafting; PTCA = percuteneous transluminal coronary angioplasty.
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Discussion
Reocclusion and event-free survival
To our knowledge, this is the first study to demonstrate the sustained adverse 
influence of reocclusion on clinical outcome. The first months after successful 
thrombolysis appear to be of major importance: ~60% of all cardiac-related events 
in the reocclusion group occurred within 3 months after thrombolytic therapy. 
Although the mortality rate was low, a result of the study design (2), there was a 
marked difference in event-free survival in favour of patients without reocclusion, 
due to the relatively high rate of reinfarction and angioplasty in patients with 
reocclusion.
Long-term survival after myocardial infarction is primarily predicted by the 
functional status of the left ventricle (18). Reocclusion is associated with impaired 
recovery of left ventricular function (3,9). These findings strongly suggest that 
mortality would have been higher if selection criteria had not been as strict as in 
the present study. The 1-year mortality rate for the study group was 2.4%. Even over 
a 3-year follow-up period, only 12 (5%) of 248 patients died. Three-year survival 
rates reported by long-term survival trials of thrombolysis vary from 84% to 87% 
(12,14). Because of the low mortality profile, the difference in event-free survival 
might even be slightly underestimated.
Reocclusion and reinfarction
Reinfarction occurs more frequently in patients with than without reocclusion. Our 
data are in accordance with earlier findings (3) showing that most recurrent ischemic 
events occur within the first days after thrombolytic therapy. The majority of the 
reocclusions (78%) are not associated with clinically apparent reinfarction. During 
this period and thereafter, reocclusion is likely to occur asymptomatically because 
of the development of collateral channels (19). Only two of the 15 reinfarctions 
observed in the first 3 months did not occur within 10 days. Overall, 84% of the 
reinfarctions in the reocclusion group occurred within 3 months after enrollment. In 
contrast, only 20% of the reinfarctions in patients without reocclusion occurred in 
the 3-month period. Therefore, in this group, 80% of the reinfarctions occurred later 
in the first year and in the second and third follow-up year. These reinfarctions are 
most likely to be related to the ongoing atherosclerotic process, whereas the early 
reinfarctions most likely result from rethrombosis after thrombolytic therapy (12). 
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Reocclusion and need for revascularization
Over the entire follow-up period, revascularizations represented the majority of 
cardiac-related events. It should be noted that these procedures were performed 
for clinical, not angiographic, reasons only. In the reocclusion group, ~50% of 
all angioplasty procedures were performed before the second angiography. The 
information obtained at angiographic follow-up may have caused the physician to 
perform more revascularizations than usual. However, the consequences for the 
pattern of the event-free survival curves are negligible because the period leading 
up to the second angiography is of greater clinical importance.
Reocclusion and multiple events
Reocclusion has proved to be associated with a higher incidence of cardiac-related 
events and hospital admissions. Only 15 (9%) of the 177 patients without reocclusion 
had two or more events compared with 22 (31%) of 71 with reocclusion. Therefore, 
nearly 33% of patients with reocclusion experienced multiple events. This finding, 
combined with the fact that 37 patients with reocclusion had no events, indicates 
that some patients with reocclusion have a higher risk for a complicated clinical 
course than others.
Effects of thrombolytic therapy on long-term improvement
The results of the present study emphasize the clinical importance of an initially 
and persistently patent infarct-related artery in comparison with an initially open 
but reoccluded artery. An earlier long-term analysis (20) of the prognostic effects 
of patency included only one angiographic observation performed 1 month after 
thrombolysis and also identified patency as an important prognostic factor, which 
proved to be independent of left ventricular function.
To optimize the results of thrombolytic therapy, a combination of two approaches 
might be successful:
1. The reocclusion rate should be reduced as much as possible. New antithrombotic 
drugs, such as hirudin and hirulog (6,21), may better prevent reocclusion. 
Identification of patients with a high risk for reocclusion would also be of major 
importance. So far, clinical variables have failed to determine predictors of 
reocclusion (22).
2. Patients with reocclusion might benefit from elective angioplasty within a 
few weeks after myocardial infarction, when coronary angioplasty can safely 
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be performed, especially if collateral supply is sufficient. Late recanalization 
may prevent ventricular dilation (23,24). This ventricular enlargement is a 
compensatory mechanism to restore stroke volume at the expense of an 
increased preload and afterload to the left ventricle, which may stimulate further 
dilatation (9,25). It has been demonstrated that ventricular enlargement occurs 
more frequently with an occluded than with a patent infarct-related artery 
(9,26,27) and that reperfusion can prevent dilation (28).
 One could argue whether all patients of the reocclusion group would have 
benefited from a recanalization procedure. More than 50% of patients 
with reocclusion had no events over a 3-year follow-up period; however, 
asymptomatic reocclusion might have occurred in some of them. An option 
would be to perform coronary angioplasty in a prespecified subgroup. Our data 
show that new cardiac-related events are most likely to occur in patients with an 
event in the first 3 months. Twenty-two new events occurred after angiographic 
follow-up: 11 occurred in patients who had already had 1 event.
In the APRICOT trial (2), a conservative strategy was intended: Revascularizations 
were performed only for reasons of recurrent ischemia not responsive to medical 
anti-ischemic treatment. The advantage of elective angioplasty would be that 
ventricular enlargement would be less extensive than with angioplasty performed 
at the time of symptoms. These options should be investigated further, because the 
optimal benefits of thrombolytic therapy have not yet been attained.
Study limitations
One limitation of the present study design is that only patients who survived the 
acute phase and, in addition, were fit enough to undergo catheterization within 
48 h, were eligible to enter the study. Furthermore, only patients who had a patent 
infarct-related artery at first angiography and underwent follow-up angiography 
were included in this analysis. This selection bias certainly contributed to the low 
mortality rate observed and may have influenced the number of observed events. 
Another restriction concerns the exclusion of patients with coronary bypass surgery 
before the second angiography. Finally, only patients < 70 years of age participated 
in the trial, which may also have contributed to an underestimation of the incidence 
of cardiac-related events after successful thrombolysis. Despite the aforementioned 
restrictions, the number of revascularizations might have been lower if a second 
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angiography had not been performed. Generally, symptoms of recurrent ischemia 
not responding to anti-ischemic treatment would be an indication to perform 
revascularization. In the present trial, the information obtained at follow-up 
angiography may have led the physician to follow a less conservative treatment 
strategy.
Conclusions
The results of the present study demonstrate that reocclusion after successful 
thrombolysis for acute myocardial infarction is associated with a less favorable 
long-term clinical course. Reocclusion results in a relatively high rate of reinfarction 
and angioplasty procedures during the first 3 months, drastically affecting event-
free survival. The observed effect on clinical outcome remains significant over a 
3-year follow-up period. These findings underscore that both the prevention, and, 
possibly, adequate treatment of reocclusion should become the main priorities of 
thrombolytic therapy for myocardial infarction. Future research might focus on the 
timing, criteria and results of elective revascularization procedures.
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Abstract
Objectives: To determine whether anti-platelet therapy influences coronary disease 
progression in non-infarct arteries. 
Background: After ST-elevation myocardial infarction (MI), anti-platelet therapy 
reduces subsequent cardiac events, which are often attributed to recurrent 
thrombosis and occlusion of the infarct-related artery. Little data is available 
regarding the impact on non-infarct artery coronary disease progression. 
Methods and Results: Quantitative coronary angiography (QCA) was undertaken 
on paired cine-angiograms of 154 patients from fibrinolytic trials who had a 
patent infarct-related artery at 3-4 weeks following ST-elevation MI and who were 
randomized to either continue the daily combination of 50-mg aspirin and 400-mg 
dipyridamole or to matching placebo. Follow-up angiography was scheduled at 
one year and data suitable for analysis was available on non-infarct arteries in 149 
patients. Progression was prespecified as an 0.40 mm change in MLD.
On a per patient basis, the change in MLD was 0.00 mm (95% confidence interval 
[CI]: -0.05 mm to 0.05 mm) in the aspirin/dipyridamole group (n=76) and was 0.01 
mm (95%CI: -0.04 mm to 0.06 mm) in the placebo group (n=73). The difference 
between these groups in the changes in MLD was not significant (-0.02 mm; 
95%CI: -0.09 – 0.05); neither were there significant differences in mean luminal 
diameter (0.02 mm; 95%CI: -0.06 – 0.11) and diameter stenosis (1.3%; 95%CI: 
-0.2 – 2.8). Per segment comparisons between aspirin/dipyridamole (n=732) and 
placebo (n=704) did not show a treatment effect on any of the QCA-parameters. The 
proportions of patients with progression were 68% and 64%, respectively (p=0.7). 
Progression did not independently predict clinical outcome (median follow-up 99 
months). 
Conclusion: In this randomized placebo-controlled follow-up trial after ST-elevation 
myocardial infarction, the combination of aspirin and dipyridamole did not affect 
non-infarct artery disease progression over 1 year. Progression occurred in two 
thirds of patients, but did not predict long-term outcome. 
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Introduction
Anti-platelet therapy has been shown to reduce early and late mortality and 
reinfarction after ST-elevation myocardial infarction [MI] (1). Half of these 
reinfarctions occur within 48 hours of fibrinolysis for ST-elevation MI and are often 
associated with reocclusion of the infarct-related artery [IRA] (2,3). Aspirin has been 
associated with a 50% reduction in in-hospital reocclusion of the IRA after MI (4). 
However, in patients who survive the acute phase, anti-platelet therapy has not 
been shown to reduce late reocclusion up to one year (5,6).
Nevertheless, a large meta-analysis demonstrated that aspirin still confers clinical 
benefit when initiated a month or more after an acute coronary syndrome, albeit 
with a less pronounced relative risk reduction (1). This suggests that aspirin may 
have an effect on thrombotic occlusions on plaques related to the non-infarct 
arteries, as the likelihood of infarct artery related events decreases over time. The 
mechanism of benefit of long-term aspirin therapy shown in the Anti-Thrombotic 
Trialists’ Collaboration (1) may in part be due to an influence on the occurrence of 
thrombosis in non-infarct arteries.
The clinical manifestations of coronary thrombosis may only represent the “tip of 
the iceberg” of all thrombotic processes in the coronary arteries. In the absence 
of clinical ischemic events, serial angiographic studies have demonstrated that 
progression is a phasic rather than a linear process (7,8). It is postulated that clinically 
silent repeated plaque rupture and fissuring with mural thrombus formation and 
subsequent reorganization may lead to progression of coronary artery disease (9). 
Moreover, at the time of an acute event, non-occlusive thrombus formation has also 
been demonstrated in non-infarct arteries in up to 20% of patients (10). Given the 
inhibitory effect on platelet aggregation, aspirin might influence this more subtle, 
often subclinical process of coronary artery disease progression. To examine the 
influence of aspirin, in combination with dipyridamole, on progression in non-
infarct arteries in the year after ST-elevation MI, we assessed changes in paired non-
culprit coronary artery segments by quantitative coronary angiography (QCA) .
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Methods
Study patients
The study group comprised consecutive consenting patients with ST-elevation 
MI, who presented within 4 hours of the onset of ischaemic chest pain who were 
enrolled in two trials of fibrinolytic therapies from 1984-1988 (11,12), and who had 
thrombolysis in myocardial infarction (TIMI) grade 2 or 3 flow in the IRA at 3 to 4 
weeks. These patients were then randomized to continue an oral combination of 
50-mg aspirin and 400-mg dipyridamole daily (Asasantin, Boehringer Ingelheim) or 
to receive matching placebo until follow-up angiography, which was scheduled at 
one year (6). A conservative approach to revascularization was adopted (6) and over 
the year only 5% of patients underwent coronary artery bypass grafting or coronary 
angioplasty. 
Coronary angiography
Sublingual nitroglycerin was given prior to coronary angiography, which 
was performed in the standard manner by the femoral approach with hand 
injection. Cine-angiography was recorded at 25 frames per second (6,13). Left 
ventriculography and calculation of end-systolic volume index were performed 
as previously described (14). Blood flow in the IRA was assessed as previously 
described; patency was defined as TIMI flow grade 2 or 3 (6). The culprit stenosis 
in the IRA was defined as the stenosis, with angiographic thrombus, or the one that 
best correlated with the regional wall and/or electrocardiographic abnormalities 
(13). Coronary artery stenoses, the number of diseased vessels and the coronary 
segments were determined according to the Coronary Artery Surgery Study (CASS) 
criteria (15). 
Quantitative Coronary Angiography 
Quantitative coronary angiography (QCA) analysis was performed on 154 paired 
cine-angiograms with identical coronary artery views. Suitable coronary segments 
were assessed irrespective of stenosis severity by an experienced QCA angiographer 
(BJW) at our angiographic laboratory. The analysis of each pair of angiograms was 
performed in one session to avoid time-related changes, and was undertaken 
blinded to treatment allocation and the order of films. Analysis of cine-frames was 
performed in end diastole, free of superimposed structures and foreshortening. QCA 
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analyses were done using the Cardiovascular Measurement System (CMS-MEDIS 
Medical Imaging Systems) and the 1-cm grid was used for calibration, although in 
some patients a non-tapering portion of an angiographic catheter was used. QCA 
analysis included the minimal luminal diameter (MLD; mm), mean luminal diameter 
(mm), diameter stenosis (%) and reference diameter (mm) for each segment. The 
reproducibility of the QCA analysis in our laboratory has previously been reported 
(16). For MLD the standard deviation for repeat measurement was 0.17 mm from 
pairs of angiograms at an interval of 2 months. We prospectively defined a change 
of ≥ 0.40 mm in MLD as progression of a coronary lesion over a one-year period for 
consistency with previous reports (17). 
Angiographic endpoint
The angiographic endpoints were the one-year changes in MLD, mean luminal 
diameter and diameter stenosis on a per patient basis in non-IRA segments. The 
changes in these QCA-measures between angiograms (angiogram 2 - angiogram 1) 
were compared between the aspirin/dipyridamole and placebo groups. To calculate 
the average changes on a per patient basis, the differences in the respective QCA-
parameters observed in the paired coronary segments were added for each patient 
individually, and subsequently divided by the number of contributing segments. 
Patients with a new occlusion or at least one lesion worsening ≥ 0.40 mm in 
MLD in the non-infarct artery segments were defined as showing progression 
(progressors) and all other patients were defined as non-progressors. Patients with 
new lesion formation had at least one segment with a diameter stenosis ≤ 20% at 
baseline, worsening ≥ 0.40 mm in MLD to a ≥ 20% diameter stenosis at follow-
up angiography. Semi-quantitative analysis defining the proportion of progressors 
and non-progressors was also used to compare randomized treatment allocations. 
To assess the aspirin/dipyridamole therapy at the level of individual coronary 
segments, analyses on a per segment basis were performed. 
Progression and long-term clinical follow-up
Late follow-up was performed by recording hospitalizations, recall to the outpatient 
clinic, by the family doctor, by telephone or by mail. Reinfarction was defined as 
an admission for prolonged ischaemic chest pain and a creatine kinase level > 2 
times the upper limit of the reference range and/or development of new Q-waves. 
All events were verified by source documents.  
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The long-term clinical impact of progression was studied using the semi-quantitative 
dichotomous definition. Additionally, the long-term clinical impact of progression 
was assessed with progression 1) as a continuous variable and 2) divided in quartiles 
of the 1-year changes in minimal luminal diameter.
Statistical analyses
Normally distributed continuous variables are expressed as means and standard 
deviations and these were compared using a paired T-test or an independent 
T-test for within group differences and between group differences, respectively. 
Continuous variables not normally distributed are expressed as medians and 
interquartile ranges (IQR). These were compared using non-parametric tests. 
Proportions were compared by chi-square and Fisher’s exact tests. Survival curves 
were constructed using the Kaplan-Meier method and compared using the log-
rank test. Multivariable predictors of clinical outcome were identified using the 
Cox proportional-hazards regression model, using forward and backward logistic 
regression analysis. Included were variables that significantly differed, or tended to 
differ between progressors and non-progressors (p < 0.10), and variables associated 
with clinical outcome (p < 0.10). Irrespective of their corresponding p-values in 
univariate analyses, age, previous myocardial infarction and end-systolic volume 
index (18) were chosen to be included. A two-sided p < 0.05 for all hypothesis tests 
was considered to be significant. 
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Results
Study population
Of 215 patients with TIMI grade 2 or 3 flow (patency) in the IRA at a median of 25 
days (IQR: 21 - 32), ten patients died and 51 patients did not undergo follow-up 
angiography because of refusal (Figure 1). There were no differences in baseline 
characteristics and clinical outcomes between the 51 patients with a single 
angiogram and the 154 patients with paired angiograms. Clinical and angiographic 
baseline characteristics of the treatment and placebo group are shown in Table 
1. Thirteen patients had a non-fatal reinfarction before the planned follow-up 
angiogram, seven patients in the aspirin/dipyridamole group and six patients in the 
placebo group. Nine revascularizations were performed between angiograms, five 
in the treatment group (3 CABG and 2 PCI) and four in the placebo group (1 CABG 
and 3 PCI). 
Angiographic changes over 1 year: impact of anti-platelet therapy
Per patient analysis. Data suitable for analysis on non-infarct arteries was available 
in 149 patients (Figure 1). The QCA values according to treatment on a per patient 
basis are shown in Table 2 and Figure 2. 
Patients in the aspirin/dipyridamole group did not have a significantly different 
change in QCA-parameters over one year as compared to the placebo group. The 
respective differences in the 1-year changes were: 1) MLD -0.02 mm (95%CI: -0.09 
– 0.05); 2) mean luminal diameter 0.02 mm (95%CI: -0.06 – 0.11); 3) diameter 
stenosis 1.3% (95%CI: -0.2 – 2.8) 
Semi-quantitative analysis. No treatment effect could be demonstrated on semi-
quantitative analysis: 68% of patients allocated to aspirin/dipyridamole therapy and 
64% in the placebo group were progressors (p = 0.7). Two patients, one in each 
group, had a silent occlusion of an initially patent non-infarct artery at follow-up 
angiography, both patients had reocclusion of the IRA as well. New lesion formation 
was present in 17% of the patients in the aspirin/dipyridamole group and 22% of 
the patients in the placebo group (p = 0.5). 
Per segment analysis. A total of 1436 paired non-IRA coronary segments were 
available for analysis, 732 in the aspirin/dipyridamole group and 704 in the placebo 
group; baseline characteristics on a per segment basis were similar between the 
treatment groups. QCA analysis by treatment allocation on a per segment basis 
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showed no differences between the aspirin/dipyridamole and placebo group in any 
QCA parameter (Table 3). However, there were significant within group differences 
over 1 year in the mean luminal diameter, diameter stenosis and the reference 
diameter in the aspirin/dipyridamole group (all with p < 0.01). In the placebo 
group, the within group differences were significant for mean luminal diameter and 
reference diameter (both p < 0.05). 
In segments with a baseline stenosis of ≥ 50%, both groups (aspirin/dypiridamole 
and placebo) showed a significant increase in MLD at one year, but no treatment 
effect was observed (0.18 mm vs. 0.20 mm; p = 0.7, respectively). Analysis of 
various other angiographic subgroups for changes in MLD (LAD vs. non-LAD, 
proximal vs. mid vs. distal segments) did not show a treatment effect either.
Late prognostic significance of progression
There were 99 patients with angiographic progression and 50 patients without 
progression. The clinical and demographic baseline characteristics did not differ. At 
first angiography significantly wider baseline minimal and mean luminal diameters 
were found for progressors as compared to non-progressors (2.03 mm ± 0.34 vs. 
1.77 mm ± 0.33 and 2.72 mm ± 0.39 vs. 2.44 mm ± 0.35, respectively). 
The 149 patients were followed for a median of 99 months (IQR, 86 - 113) after 
follow-up angiography. Cardiac death occurred in 20 patients (13%), cardiac death 
and myocardial infarction occurred in 31 patients (20%). 
The long-term survival free from the combined endpoint of cardiac death and 
myocardial infarction in progressors compared to non-progressors is shown in 
Figure 3. Progressors had a survival rate free from cardiac death and reinfarction of 
79% as compared to 71% for non-progressors (p = 0.3). 
In the case progression was assessed based on changes in all coronary arteries, 
including the IRA, progression was seen in 87% of patients (aspirin/dipyridamole 
84% vs. placebo 89%, p = 0.4). Event-free survival did not differ either between 
progressors and non-progressors (76% vs. 77%, respectively, p = 0.9). 
A multivariable model with the following variables was used to assess a potential 
independent association between progression and clinical outcome (see Methods): 
age, previous myocardial infarction, end-systolic volume index, vessel disease and 
the average minimal luminal diameter and mean luminal diameter per patient 
at baseline angiography. Cox regression identified one independent predictor of 
long-term cardiac mortality and reinfarction: end-systolic volume index, Hazard 
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Ratio (HR): 1.02 (95%CI: 1.00 - 1.05, p = 0.04). Multivessel disease tended to be 
an independent predictor, HR: 1.96 (95%CI: 0.94 - 4.06, p = 0.07). Progression as 
a dichotomous variable was not independently associated with long-term cardiac 
mortality nor with the combined endpoint cardiac death and reinfarction. When 
entered as a continuous variable, or in quartiles, the 1-year changes in minimal 
luminal diameter were not associated with long-term outcome either. 
Figure 1: Flow chart showing the number of patients and segments suitable for 
 QCA-analysis. 
 IRA = infarct-related artery; MI = myocardial infarction; IQR = Interquartile 
 range.
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Table 1  Clinical and Angiographic baseline Characteristics: 
 Aspirin/Dipyridamole versus Placebo
Aspirin/Dipyridamole
n = 79
Placebo
n = 75
Age (years) 55 ± 9 56 ± 8
Male 82% 76%
Smoking 48% 48%
Diabetes 10% 05%
hypertension 30% 25%
Total Cholesterol (mmol/l) 6.3 ± 1.3 6.3 ± 1.3
History of MI 06% 08%
CTFC (of IRA)
     (IQR)
26 
(18 – 41)
31 
(20 – 48)
CK-max  (U/l)
     (IQR)
2300 
(1033 – 3258)
2196 
(1700 – 3525)
Infarct-related artery :
  LAD 33% 43%
  RCA 56% 43%
  LCX 11% 14%
Vessel disease (CASS) :
  0 vessel 27% 32%
  1 vessel 48% 45%
  2 vessels 14% 12%
  3 vessels 11% 11%
Data are presented as a percentage for discrete variables (%), as mean ± SD for continuous variables 
and as median (interquartile range) for continuous data not normally distributed. MI = myocardial 
infarction; CTFC = corrected TIMI frame count; IRA = infarct-related artery; CK = creatine kinase; LAD 
= left anterior descending artery; RCA = right coronary artery; LCX = left circumflex coronary artery; 
CASS = coronary artery surgery study.
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Figure 2: Mean changes with 95% CIs in quantitative coronary angiographic parameters 
 of non-infarct artery segments at one-year follow-up angiography on a per 
 patient basis: aspirin/dipyridamole versus placebo. 
 black = Aspirin/Dipyridamole
 white = Placebo
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Table 2 Quantitative coronary angiography measurements: 
 Per patient analysis of non-infarct arteries
Aspirin/
Dipyridamole
n = 76
Placebo
n = 73 p Value
Minimal Luminal Diameter, mm
Baseline 1.92 (1.85 – 1.99) 1.97 (1.88 – 2.06) 0.4
Follow–up 1.91 (1.84 – 1.98) 1.98 (1.89 – 2.07) 0.2
Change -0.00 (-0.05 – 0.05) 0.01 (-0.04 – 0.06) 0.6
Mean Luminal Diameter, mm
Baseline 2.60 (2.51 – 2.69) 2.65 (2.55 – 2.75) 0.4
Follow–up 2.65 (2.57 – 2.73) 2.67 (2.57 – 2.77) 0.7
Change 0.05 (-0.01 – 0.11) 0.02 (-0.04 – 0.08) 0.5
Diameter Stenosis, %
Baseline 33.7 (32.3 – 35.1) 33.5 (32.0 – 35.0) 0.8
Follow–up 35.2 (33.7 – 36.7) 33.7 (32.0 – 35.4) 0.2
Change 1.5 (0.5 – 2.5) 0.2 (-0.9 – 1.3) 0.08
Reference Diameter, mm
Baseline 2.81 (2.72 – 2.90) 2.87 (2.75 – 2.99) 0.4
Follow–up 2.86 (2.77 – 2.95) 2.89 (2.78 – 3.00) 0.6
Change 0.05 (0.00 – 0.10) 0.02 (-0.04 – 0.08) 0.6
Progression 68% 64% 0.7
New lesion 17% 22% 0.5
Data are presented as the per patient mean of QCA parameters of non-infarct artery segments, between 
brackets the 95% Confidence Interval.
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Figure 3:  Long-term survival free from cardiac death and non-fatal myocardial infarction: 
 progressors versus non-progressors in non-infarct related arteries. 
 ReMI = recurrent myocardial infarction
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Table 3  Quantitative coronary angiography measurements: 
 Per segment analysis of non-infarct arteries
Aspirin/
Dipyridamole
n = 732
Placebo
n = 704 p Value
Minimal Luminal Diameter, mm
Baseline 1.90 (1.83 – 1.97) 1.94 (1.86 – 2.02) 0.5
Follow-up 1.92 (1.85 – 1.99) 1.97 (1.89 – 2.05) 0.4
Change 0.02 (-0.01 – 0.05) 0.03 (-0.01 – 0.07) 0.6
Mean Luminal Diameter, mm
Baseline 2.58 (2.51 – 2.65) 2.62 (2.54 – 2.70) 0.5
Follow-up 2.64 (2.57 – 2.71) 2.65 (2.57– 2.73) 0.8
Change 0.06 (0.03 – 0.09) 0.03 (0.00 – 0.06) 0.2
Diameter Stenosis, %
Baseline 33.5 (32.5 – 34.5) 33.3 (32.2 – 34.4) 0.8
Follow-up 34.7 (33.7 – 35.7) 33.6 (32.5 – 34.7) 0.1
Change 1.2 (0.4 – 1.8) 0.2 (-0.7 – 1.1) 0.1
Reference Diameter, mm
Baseline 2.78 (2.70 – 2.86) 2.83 (2.75 – 2.91) 0.4
Follow-up 2.83 (2.75 – 2.91) 2.87 (2.79 – 2.95) 0.6
Change 0.06 (0.03 – 0.09) 0.04 (0.00 – 0.08) 0.5
Data are presented as the average QCA parameters of non-infarct artery segments, between brackets 
the 95% Confidence Interval. A/D = aspirin/dipyridamole; P = placebo.
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Discussion
To our knowledge, this is the first randomized placebo-controlled angiographic 
follow-up study to examine the influence of anti-platelet therapy on the progression 
of coronary artery disease as assessed by QCA in non-infarct artery segments in the 
first year after ST-elevation MI. Progression of coronary artery disease, observed in 
two thirds of our patients, was not significantly affected by a combined anti-platelet 
regimen of aspirin and dipyridamole. Neither QCA analysis on a per segment basis, 
nor a semi-quantitative analysis demonstrated a significant treatment effect. New 
lesion formation was less common in patients randomized to anti-platelet therapy, 
17% vs. 22%, but this difference was not significant. The increase in the diameter 
stenosis in patients allocated to combined anti-platelet therapy was unexpected, 
and may be related to vasodilatation caused by dipyridamole, or neurohumoral 
effects on coronary arteries after myocardial infarction (19).
Effect of anti-platelet therapy on clinical and angiographic outcomes
The clinical benefit of aspirin after myocardial infarction is undisputed (1). 
Most early reinfarctions are attributed to infarct artery reocclusion and the 50% 
reduction in in-hospital reocclusion seems a likely explanation for at least part of 
the mechanism of early benefit with aspirin therapy (4). However, despite its proven 
long-term clinical efficacy, anti-platelet therapy initiated 24 hours to 3 weeks after 
acute myocardial infarction has no statistically significant effect on reocclusion at 
3-months and 1-year respectively (5,6). The initiation of aspirin approximately 2-6 
months after an acute event confers a clinical benefit (1), albeit less pronounced 
than when therapy is initiated immediately. This suggests the possibility that aspirin 
may have an effect on thrombotic events not associated with plaque rupture in the 
IRA, as the likelihood of infarct artery related events decreases over time. 
In our analysis of angiographic progression of coronary artery disease in non-infarct 
arteries, no treatment effect of aspirin/dipyridamole could be demonstrated. In spite 
of the relatively short follow-up duration, the small changes in QCA measurements 
in our study were of the same order of magnitude as those shown in trials of lipid 
modifying therapies, referring to patients with stable coronary artery disease and 
with longer time intervals between angiograms (17). Moreover, our analysis of 
post-MI patients showed higher rates of patients with at least one progressing 
lesion compared to the studies of clinically stable patients. The observed rates of 
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progression in the present analysis were comparable to the single angiographic trial 
of lipid lowering therapy after MI (20). Thus, in spite of a high-risk population for 
progression no treatment effect of aspirin/dipyridamole could be substantiated. The 
data for the current analysis stem from the time period 1984-1988 and although 
dietary advice was routinely given, statins and other lipid modifying drugs were not 
commonly used in this time period. Confouding of our results by lipid modifying 
drugs is therefore unlikely.
Lack of angiographic benefit of anti-platelet therapy
There are several potential explanations for the lack of a demonstrable effect of 
anti-platelet therapy on coronary artery disease progression in our study. Firstly, 
coronary angiography may not be sensitive enough to discern subtle changes 
in coronary atheroma progression/regression. Intravascular ultrasound (IVUS) is 
currently the method more frequently used to assess disease progression, because 
in addition to the coronary lumen, the arterial wall with different structural entities 
can be visualized. Serial IVUS analysis has demonstrated that improvement of the 
lipid profile is associated with a reduction of atheroma volume expansion, probably 
due to growth retardation of the lipid core (21). 
With respect to anti-platelet therapy, IVUS studies on coronary disease progression 
are lacking. As of to date, one other angiographic follow-up study has been reported, 
in preliminary form (22). The available clinical, angiographic and animal studies 
have suggested that the mechanism of benefit of aspirin therapy mainly concerns an 
anti-thrombotic effect: it reduces the incidence of (sub) acute recurrent thrombotic 
events and has been shown to prevent (sub) total coronary (re) thrombosis in 
experimental and angiographic models. With respect to the usually sub-clinical, 
non-occlusive process of mural thrombosis, animal studies suggest an incomplete 
inhibitory effect of aspirin in this milieu (23) and it has been postulated that to 
decrease the superficial deposition of platelets, anti-thrombin therapy is required to 
counteract the strong thrombin effect of aggregates of platelets (23). 
These observations of an incomplete anti-platelet effect on mural platelet 
aggregation, provide mechanistic support for the lack of a demonstrable effect on 
the process of coronary progression. Occlusions in non-infarct arteries were too 
infrequent to address a potential anti-thrombotic effect. It is uncertain whether 
aspirin has effects on plaques other than inhibition of platelet aggregation. It 
is possible that the anti-inflammatory properties of aspirin could have a role in 
110 Anti-platelet Therapy and Progression of Coronary Artery Disease
plaque stability, albeit at a higher and more frequent dosage as the lowest effective 
antithrombotic dose regulary used in daily clinical practice.
Although the combination of aspirin 50-mg and dipyridamole 400-mg which we 
used in this study has not been investigated extensively, a recent meta-analysis 
showed no dose-related difference in the risk reduction conferred by aspirin (1). 
Moreover, a combined anti-platelet regimen was found to result in risk reductions 
in clinical endpoints at least as large as those occurring with aspirin alone (1). In 
the CABADAS trial, a subgroup of patients with saphenous vein grafts and small 
calibre distal arteries randomized to the same combined anti-platelet regimen as 
in the current study had a lower 1-year occlusion rate as compared to patients 
randomized to aspirin alone (24). 
Correlation of angiographic observations and clinical outcome
Angiographic progression has been reported as a predictor of future cardiac events 
(25). However there is no uniformity in the definition of progression, with one 
study that correlated per patient average decrease in MLD as a continuous variable 
with outcome (26), whereas another described progression in a semi-quantitative 
manner (25), with a dichotomous comparison. In this study we used both definitions 
of progression, including a prespecified absolute change in MLD of 0.40 mm to 
assess this endpoint. Although progression occurred in the majority of our patients 
we did not find that progression was a predictor of future ischemic events. In lack 
of a generally accepted definition of progression, of which the clinical impact has 
proved reproducible, caution should be taken to make inferences from angiographic 
trials to the potential impact in daily clinical practice. 
This statement is supported by the fact that clinical trials of ACE-inhibitors and 
poly-unsaturated fatty acids have unequivocally demonstrated a reduction in MI in 
patients with stable angina (27) and of sudden death after myocardial infarction (28), 
whereas in angiographic follow-up trials these agents did not modify progression of 
atherosclerosis (29,30). 
Another example concerns hormone replacement therapy which did not affect 
coronary disease progression, but proved prothrombotic in large scale clinical trials 
(31,32). Part of this problem may be related to the fact that the timing of the second 
angiography influences the chances of detecting clinical recurrent thrombosis, 
the most outspoken form of coronary artery disease progression. If in the case 
of recurrent ischemic events immediate follow-up angiography would have been 
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performed, progression due to coronary thrombosis might have been detected more 
easily.
Limitations
Angiography only yields information about the coronary lumen, and vessel 
tortuosity, overlap of structures and effects of lumen shape may confound the 
assessment of progression. In the present analysis, a conservative revascularization 
strategy was adopted and a systematic elective follow-up angiography was 
performed at one year. Consequently, a clinically mandated, earlier performed 
angiography in the setting of a readmission for a recurrent acute coronary syndrome 
was not frequently performed and not used as angiographic follow-up endpoint. 
With 1-year angiography representing a snapshot in time, progression may not have 
been detected in patients with intercurrent clinical thrombosis before the scheduled 
repeat angiography.
Conclusion
In this randomized placebo-controlled angiographic follow-up trial in patients with 
a patent IRA 3-4 weeks after ST-elevation myocardial infarction, the combination of 
aspirin and dipyridamole did not affect one-year coronary artery disease progression 
in non-culprit artery segments as assessed by quantitative angiography. Progression, 
though present in two thirds of patients, was not validated as a surrogate endpoint 
for long-term clinical events. 
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Abstract
Background: Despite the use of aspirin, reocclusion of the infarct-related artery 
occurs in ~ 30% of patients within the first year after successful fibrinolysis, with 
impaired clinical outcome. This study sought to assess the impact of a prolonged 
anticoagulation regimen as adjunctive to aspirin in the prevention of reocclusion 
and recurrent ischemic events after fibrinolysis for ST-elevation myocardial 
infarction.
Methods and Results: At coronary angiography < 48 hours after fibrinolytic therapy, 
308 patients on aspirin and intravenous heparin had a patent infarct-related artery 
(Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow). They were randomly 
assigned to standard heparinization and continuation of aspirin alone or to a 
3-month combination of aspirin with moderate-intensity coumarin, including 
continued heparinization until a target international normalized ratio (INR) of 2.0 
to 3.0. Angiographic and clinical follow-up were assessed at 3 months.
Median INR was 2.6 (25
th
 to 75
th
 percentiles 2.1 to 3.1). Reocclusion (TIMI grade 2 
flow) was observed in 15% of patients on aspirin and coumarin compared with 28% 
in those receiving aspirin alone (relative risk [RR], 0.55; 95% CI 0.33 to 0.90; p < 
0.02). TIMI grade 0 to 1 flow rates were 9% and 20%, respectively (RR 0.46; 95%CI 
0.24-0.89; p < 0.02). Survival rates free from reinfarction and revascularization 
were 86% and 66%, respectively (p < 0.01). Bleeding (TIMI major and minor) was 
infrequent: 5% versus 3% (p = ns).
Conclusion: As adjunctive to aspirin, a 3-month-regimen of moderate-intensity 
coumarin, including heparinization until the target INR is reached, markedly 
reduces reocclusion and recurrent events after successful fibrinolysis. This 
conceptual study provides a mechanistic rationale to further investigate the role of 
prolonged anticoagulation after fibrinolytic therapy. 
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Introduction
With the introduction of fibrinolytic therapy, survival after ST-elevation myocardial 
infarction has been shown to largely depend on early restoration of coronary 
patency (1).
Recurrent ischemic events are often attributed to reocclusion of the infarct-related 
artery (2,3). Reocclusion is a time-dependent phenomenon (4), which is seen in ~ 
10% of patients at the time of discharge (5), with an incidence of up to ~ 30% in 
the first year, despite the use of aspirin (6,7). Previous studies have demonstrated 
a 2-fold increased risk of mortality in the case of early reocclusion after successful 
thrombolysis (2) and a higher risk of reinfarction and recurrent ischemic events in 
both the short term and the long term (3). Even in the absence of clinical reinfarction, 
reocclusion has been shown to preclude recovery of left ventricular function (8), the 
most important determinant of prognosis after myocardial infarction. Prevention of 
reocclusion is therefore warranted.
Although aspirin has become the standard antithrombotic therapy, oral 
anticoagulation has also been shown markedly effective in coronary artery disease 
(9). In patients with non ST-elevation acute coronary syndromes (9-11), a combined 
regimen of anti-platelet and anticoagulation therapy seemed promising.
It was therefore hypothesized that outcome after ST-elevation myocardial infarction 
could be improved by a prolonged adjunctive anticoagulation regimen of 3 months 
moderate-intensity coumarin, including intravenous heparinization until an 
international normalized ratio (INR) of 2.0 to 3.0, when compared with standard 
anticoagulation as adjunctive to fibrinolysis and aspirin. The Antithrombotics in 
the Prevention of Reocclusion In COronary Thrombolysis (APRICOT)-2 trial sought 
to assess the efficacy of this prolonged combined antithrombotic regimen in the 
prevention of reocclusion and recurrent ischemic events in patients with a patent 
infarct artery after fibrinolytic therapy for suspected acute myocardial infarction. 
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Methods
Study Protocol
The APRICOT-2 trial was an investigator-initiated, open-label, randomized 
angiographic and clinical follow-up study performed in 7 centers in The Netherlands 
between 1994 and 2000 (Figure 1). Patients with chest pain 30 minutes and < 6 
hours, refractory to nitrates, were treated with fibrinolytic therapy in the case of 
ST-elevation 0.2mV in 2 contiguous precordial leads, or 0.1mV in 2 limb leads. 
The agents used were anistreplase (30 U in 5 minutes), streptokinase (1.5 million 
units in 30 to 60 minutes), reteplase (2 bolus doses of 10 U, 30 minutes apart), 
or accelerated recombinant tissue-type plasminogen activator (r-tPA) (1). Patients 
received a starting dose of 160 mg aspirin, followed by 80 mg once daily. Adjunctive 
intravenous unfractionated heparin (UFH) was given for 48 hours. An intravenous 
bolus of 5000 U was followed by an infusion of 24000 U/24 hours, with a target 
activated partial thromboplastin time of twice the control. After fibrinolytic therapy, 
patients with clinical and/or ECG signs of reperfusion who were clinically stable 
were asked for informed consent. In the case of participation, coronary angiography 
had to be performed within 48 hours after the start of fibrinolytic therapy. 
Patients were eligible to enter the study if the local investigator assessed the flow 
in the infarct-related artery as Thrombolysis In Myocardial Infarction (TIMI) grade 
3 flow (12). By telephone service, patients were allocated to one of two treatments 
by block randomization, stratified per center. In one arm the patient continued the 
daily use of 80 mg of aspirin, and heparin was discontinued at 48 hours. In the 
other arm coumarin was started in addition to 80 mg of aspirin, and heparin was 
continued until moderate-intensity anticoagulation was achieved, with a target INR 
between 2.0 and 3.0. 
Follow-up angiography was scheduled at 3 months. Clinical follow-up, including 
bleeding complications, was collected until the second angiography. By protocol, 
an ischemia-guided revascularization strategy was followed (6). If angioplasty was 
performed before the scheduled follow-up angiography, the patency status of the 
infarct-related artery before dilation was considered the angiographic follow-up 
end point. The study was approved by the ethics review boards of the participating 
hospitals. 
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Exclusion Criteria 
Patients older than 75 years, those with a contraindication to antithrombotic 
therapy, and those with a bypass graft as the infarct-related vessel were not eligible. 
Patients with a culprit stenosis that had previously been dilated, with left main stem 
stenosis or an unidentifiable culprit lesion patients were not included.
Coronary Angiography
The infarct-related artery was identified by correlating the coronary anatomy with 
the distribution of wall motion abnormality on the 30° right anterior oblique and 
60° left anterior oblique ventriculograms. This information was combined with the 
distribution of ST-elevation on the admission ECG. If applicable, lead V4R was used 
for discrimination between the circumflex artery and the right coronary artery as the 
infarct-related artery (6).
TIMI flow grading (12) and quantitative coronary angiographic assessment were 
performed at a core laboratory (Heartcore Leiden B.V., Leiden, the Netherlands), 
each by a different reader, blinded to the assigned strategy. The optimal single-plane 
projection was selected that identified the culprit stenosis in its greatest severity, 
with minimal foreshortening or overlapping of branches, and end-diastolic frames 
were chosen for quantitative angiographic analysis. 
Study End Points
The primary end point was reocclusion of the infarct-related artery at angiographic 
follow-up, defined as TIMI grade 2 flow or less: TIMI grades 0 and 1 flow 
representing anatomic reocclusion and TIMI grade 2 flow functional reocclusion, 
as patients were included with good antegrade flow (TIMI grade 3 flow). 
The secondary end point was event-free survival: a clinical course without death, 
reinfarction or revascularization. Mortality refers to death of all causes. Reinfarction 
was defined with use of the Global Utilization of Streptokinase and Tpa for 
Occluded coronary arteries (GUSTO)-1 trial criteria. At least 3 of the 4 criteria were 
required to qualify for reinfarction (13). As a safety end point, TIMI major and minor 
bleeding is reported (14).
Statistical Analysis
Sample Size In the APRICOT-1 trial, reocclusion occurred in 25% of patients 
allocated to aspirin, according to the European Cooperative Study Group criteria 
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(ECSG; grading 4 and 5) (7). For the present study, we anticipated a similar rate 
of TIMI 0-1 flow (ECSG-grade 5) as in the APRICOT-1 aspirin arm (20%). Based 
on differences in definition, the incidence of TIMI grade 2 flow was expected to 
be higher than the observed 5% of ECSG grade 4 in APRICOT-1. The estimated 
incidence of reocclusion for APRICOT-2 was therefore set at 30%. The trial was 
designed to have 80% power to demonstrate a relative reduction of 50% in the 
incidence of reocclusion, with a 2-sided of 5%. This would require 266 patients 
with angiographic follow-up. In the APRICOT-1 study, 87% of patients underwent 
both angiographies (7). Therefore, the target for this study was set at 305 patients. 
Stopping rules were not formally prespecified. Death, reinfarction, and major 
hemorrhage were reported to the principal investigator (FWAV) at 100 and 200 
randomly assigned patients. At his discretion the trial could be prematurely 
discontinued.
Analysis Continuous variables were compared by the Student’s t test or the Mann-
Whitney U test, whenever appropriate. For comparisons between discrete variables 
the χ2 test and Fisher’s exact probability test were used. Analyses were performed 
according to the intention-to-treat principle.
Figure 1: Design of the study
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Results
In total, 308 patients were randomly assigned, of whom 34 (11%) were excluded 
from analysis because flow in the infarct artery was not considered TIMI grade 3 
flow by the core laboratory. Follow-up angiograms of the patients with TIMI grade 2 
flow at inclusion angiography were not routinely analyzed. 
Clinical and angiographic baseline characteristics of the remaining 274 patients 
were similar to those of the 308 patients. Clinical follow-up was complete for 
all patients with adjudicated TIMI grade 3 flow after fibrinolysis. Fibrin-specific 
agents (reteplase, r-tPA) were used in 44% of patients allocated to the prolonged, 
combined antithrombotic regimen (59 of 135) and in 36% of those on the standard 
antithrombotic regimen (50 of 139; p=ns).
Angiographic follow-up was available in 251 of the 274 patients (92%). After 
initial consent, 19 patients (7%) refused to undergo the second angiography. 
Other reasons for not undergoing follow-up angiography are given in Figure 2. 
Baseline characteristics of patients with and without a second angiogram were not 
different. 
Table 1 shows the baseline characteristics at the time of study entry. The treatment 
groups were well balanced.
Antithrombotic Medication
After the start of coumarin, heparin was continued until the target INR (2.0 to 
3.0) was reached. Consequently, heparinization lasted 66 hours longer in patients 
allocated to the combined antithrombotic regimen, when compared with patients 
randomly assigned to standard heparinization and the use of aspirin alone: 110 
versus 44 hours (p < 0.01). In 9 of 135 patients (7%) the target INR was not reached 
during hospitalization. Overall, heparin was discontinued in 16 patients (12%), 
although adequate oral anticoagulation had not (yet) been achieved. The median 
INR during follow-up was 2.6 (25
th
 to 75
th
 percentiles 2.1 to 3.1).
Sixteen patients (12%) randomly assigned to aspirin and coumarin did not receive 
the assigned antithrombotic medication (Figure 3). Three of these refused follow-
up angiography, in the other 13 patients 3 reocclusions (23%) were observed. 
Six patients (4%) allocated to aspirin alone received additional coumarin during 
follow-up (Figure 3). Two of these refused angiographic follow-up, the others 
had TIMI grade 3 flow at the second coronary angiography. None of the patients 
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allocated to the standard antithrombotic regimen discontinued aspirin before 
follow-up angiography.
Reocclusion
Figure 4 shows the primary outcome as assessed by the core laboratory. In patients 
allocated to aspirin and coumarin, reocclusion was observed in 19 of 123 patients 
(15%), compared with 36 of 128 (28%) in patients receiving aspirin alone (relative 
risk [RR] 0.55; 95% CI 0.33 to 0.90, p < 0.02). This difference is mainly caused 
by a reduction in the incidence of TIMI grade 0 to 1 flow: 11 of 123 (9%) versus 
25 of 128 (20%) (RR, 0.46; 95% CI 0.24 to 0.89; p < 0.02). Reocclusion rate for 
the fibrin-specific lytics was 17%, for the non-fibrin specific agents it was 24% (p 
= ns). No interaction between the fibrin specificity of the lytic and the allocated 
antithrombotic regimen was observed (p = 0.56). 
Clinical outcome
Table 2 shows the secondary end points. Event-free survival was significantly higher 
in patients allocated to aspirin and coumarin compared to those in the aspirin alone 
arm.
Patients on the combined antithrombotic regimen had a significantly lower 
reinfarction rate. Of interest, in the aspirin alone group 6 of the 11 reinfarctions 
occurred after discharge, against 1 of the 3 reinfarctions on the combined 
regimen. Both in-hospital reinfarctions in the combination group occurred during 
continued heparinization while the target INR had not yet been reached. Of the 5 
in-hospital reinfarctions in the aspirin alone group, 4 occurred within 24 hours of 
discontinuation of intravenous heparin.
The lower number of patients with a revascularization in the combination group 
was primarily caused before discharge: 5 of 135 (4%) versus 27 of 139 (19%) (p < 
0.01). One patient in the aspirin alone arm underwent CABG after an unsuccessful 
urgent angioplasty. Procedure-related infarctions were seen in 3 patients allocated 
to the standard antithrombotic regimen and in none of those allocated to the 
combined regimen. From the time of random assignment, patients allocated to 
aspirin alone were discharged after 8 days, those receiving the combined regimen 
after 9 days (p = ns).
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Bleeding
Bleeding complications according to the TIMI criteria occurred in 7 patients (5%) in 
the combination treatment group (2 major, 5 minor) and 4 (3%) in the aspirin alone 
group (2 major, 2 minor; p = ns). No cerebral bleeding was reported in either group. 
In each group 1 patient (1%) underwent blood transfusion. 
Figure 2: Flow chart showing the number of patients excluded, and the number 
 remaining per treatment group with clinical and angiographic follow-up 
 ASA = aspirin; OAC = oral anticoagulation; CABG = coronary artery bypass 
 grafting
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Figure 3: Changes in the assigned antithrombotic medication after random assignment
 ASA = aspirin; OAC = oral anticoagulation; GI = gastro-intestinal 
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Table 1 Clinical and angiographic characteristics at study entry
Aspirin and Coumadin
n = 135
Aspirin
n = 139
Men 111 (82%) 112 (81%)
Age (years) 57 ± 11 58 ± 10 
Previous MI 15 (11%) 17 (12%)
Current smoker 82 (61%) 77 (55%)
Diabetes 8 (6%) 9 (6%)
Hypertension 31 (23%) 43 (31%)
Cholesterol ≥ 5.0 mmol/l 79 (59%) 86 (62%)
Time to thrombolysis (hours) 2.3 ± 1.3 2.4 ± 1.4
Median peak CK
       (IQR)
1034 
(388-2202)
861 
(496-1825)
Thrombolysis to first angio (hours) 30 ± 14 31 ± 15
Infarct-related artery:
  LAD 59 (44%) 52 (38%)
  LCX 14 (10%) 27 (19%)
  RCA 62 (46%) 60 (43%)
Single vessel disease 75 (56%) 75 (54%)
Culprit stenosis severity, QCA (%) 57 ± 15 59 ± 13
Data are presented as the number (%) of subjects for discrete variables, and as mean ± SD for 
continuous variables, except for the peak CK value.
MI = myocardial infarction; IQR = interquartile range; CK = creatine kinase; LAD = left anterior 
descending artery; LCX = left circumflex coronary artery; RCA = right coronary artery; 
QCA = quantitative coronary angiography 
Figure 4: The incidence of reocclusion at follow-up angiography 
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Table 2  Clinical outcome until 3-month follow-up angiography
Aspirin and Coumarin
n = 135
   Aspirin
   n = 139
Death  1   0
Reinfarction          3 (2%)           11 (8%) †
  In-hospital  2   5
  After discharge  1   6
Revascularization          17 (13%)              43 (31%) ‡
  In-hospital PTCA  5  25
 CABG  0    3
  After discharge PTCA 11  14
 CABG   1    2
Eventfree survival         116 (86%)               92 (66%) *
Data are presented as number of subjects and the proportion (%) per treatment group
Patients may have had events in more than one category
Reinfarctions presented are not procedure related (see text)
PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass grafting
* p < 0.01;  † p < 0.05; ‡ p < 0.01
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Discussion
APRICOT-2 is the largest randomized study to date with both clinical and 
angiographic follow-up addressing the efficacy of a continuous, combined 
antithrombotic regimen up to 3 months after ST-elevation myocardial infarction. 
The current findings in patients with an open infarct-related artery after fibrinolytic 
therapy are in concordance with a smaller angiographic study in a more 
heterogeneous population (10). In the present study, an antithrombotic regimen of 
aspirin, prolonged heparinization and 3 months of moderate-intensity coumarin 
conferred a 45% relative reduction in reocclusion as compared to standard 
heparinization and the use of aspirin alone.
Heparin and aspirin in acute myocardial infarction
The introduction of aspirin has markedly improved clinical and angiographic 
outcome after fibrinolytic therapy (5,15). With it, the routine use of subcutaneous 
UFH only conferred a modest additional clinical benefit, which was lost early after 
discharge (16,17). The limited data regarding adjunctive intravenous UFH do not 
suggest an important clinical benefit (17,18), despite a suggested beneficial effect 
on patency and reocclusion in different settings.
With conventional administration of 3 to 6 hours of r-tPA, adjunctive intravenous 
UFH did not result in higher 90-minute patency (19), yet an effect on 7- to 120-
hour patency has been demonstrated (20,21). With regard to streptokinase, the 
GUSTO-1 angiographic trial did not demonstrate an effect of intravenous UFH on 
90-minute patency; the impact on 24-hour patency remains unknown in lack of a 
placebo-controlled comparison. The best 5- to 7-day angiographic outcome after 
streptokinase was observed with adjunctive intravenous UFH, with comparable 
patency and reocclusion rates to r-tPA and intravenous UFH (1).
In view of the above, the APRICOT-2 protocol mandated that all patients received 
adjunctive intravenous UFH, irrespective of the fibrinolytic agent; this was 
to exclude selection-bias through a potential effect on patency at the time of 
inclusion angiography. For patients allocated to receive coumarin, heparin was 
continued until the target INR (2.0 to 3.0) was reached. Consequently, patients in 
the coumarin arm received intravenous heparin for an additional 21/2 days when 
compared to patients in the aspirin alone arm. This design ensured a continuous, 
combined antithrombotic regimen. How much prolonged heparinization in itself 
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has contributed to the observed effect on reocclusion and reinfarction, is beyond 
the scope of this trial and can not be determined in this design. 
Adjunctive intravenous UFH carries the potential risk of a rebound after its 
discontinuation, which continuous, prolonged anticoagulation with coumarin 
might prevent. Interestingly, the majority of in-hospital reinfarctions in the aspirin 
alone group were seen within 24 hours after discontinuation of intravenous heparin, 
suggesting a rebound phenomenon, as observed in the GUSTO-1 trial (22). In 
previous trials, anticoagulation until discharge with either subcutaneous UFH (16) 
or the low-molecular-weight-heparin (LMWH) dalteparin (23) showed a promising 
in-hospital clinical benefit, which dissipated within 1 month after discontinuation. 
These observations, and the fact that in the present study at least half of the 
observed difference in reinfarction was realized after discharge support a beneficial 
effect of prolonged anticoagulation with coumarin (Table 2). As stated before, 
reocclusion is a time-dependent phenomenon with TIMI flow grade 0 to 1 rates of 
~ 10% at discharge (4) and 20% at 3 months in patients using aspirin (6). Even after 
demonstrated patency at 4 weeks, reocclusion occurs in ~ 25% of patients within 1 
year (7). Although longer heparinization may account for part of the early benefit, 
the continued use of oral anticoagulation after discharge seems pivotal to prevent a 
rebound in recurrent ischemic events and additional reocclusions. 
Coumarin and aspirin in acute myocardial infarction
Dose-adjusted, frequently monitored, and individually tailored therapy is a 
prerequisite for optimal anticoagulation therapy, with both safety and efficacy 
depending on the intensity of treatment (9,24). Compliance is another important 
aspect, which has recently been shown to vary per country and hospital, markedly 
affecting efficacy (11). The large trials studying the addition of lower-intensity 
anticoagulation to aspirin like CARS (25) (fixed dose warfarin 1 or 3 mg/day, 
mean INR’s 1.1 and 1.6) and CHAMP (26) (dose-adjusted, mean INR 1.8) reported 
more bleeding, but did not demonstrate a clinical benefit. However, the smaller 
APRICOT-2 and Antithrombotics in the Secondary Prevention of Events in Coronary 
Thrombosis (ASPECT)-2 trials (27) with mean INR’s well above 2.0 showed improved 
clinical outcome. Moreover, compliance in the present study was high, with 88% 
of patients assigned to the combined antithrombotic regimen treated according to 
the protocol.
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As far as inferences to daily clinical practice are concerned, this trial does not 
represent the general population with myocardial infarction: eligible when clinically 
stable, younger than 75 years, and TIMI grade 3 flow as inclusion criteria. A similar 
consideration holds true for the low bleeding rates in this study (24), in combination 
with the rather stringent TIMI bleeding criteria (14). However, the larger ASPECT-2 
(mean INR 2.4) (27) and Warfarin-Aspirin ReInfarction Study (WARIS)-2 (mean INR 
2.2) (24) trials, which refer to a broader population, also reported benefit from the 
addition of oral anticoagulation with acceptable safety. A second Scandinavian trial 
is Low Dose Anticoagulation and ASA Study (LOWASA) (aspirin versus aspirin plus 
oral anticoagulation, INR 1.0 to 1.5) which is still running and designed to include 
5000 patients. In aggregate, these trials will provide a more reliable risk-benefit 
estimation, although the available evidence to date seems promising (24). 
Implications
With the continuing search toward earlier reperfusion in a higher proportion of 
patients, prevention of subsequent reocclusion has inherently become an even 
more important issue (28). In view of the interindividual and intraindividual 
variability in anticoagulation with both heparin and coumarin, other agents might 
prove more efficacious, be it through a more predictable effect, more profound 
impact on the coagulation cascade, or simply better compliance. Two large 
angiographic trials, the Heparin-Aspirin Reperfusion Trial (HART)-2 (29) and Acute 
Myocardial Infarction –Streptokinase (AMI-SK) (24), showed promising findings 
using LMWHs after fibrinolysis. Of note, in the trials suggesting that LMWHs 
(Assessment of the Safety and Efficacy of a New Thrombolytic [ASSENT]-PLUS (23), 
ASSENT-3 (29a)) or direct Xa-inhibition (synthetic PENTasaccharide as an Adjunct 
to FibrinoLYsis in ST-elevation acute myocardial infarction [PENTALYSE] (29b)) 
are superior to intravenous UFH, administration of the new agents was continued 
for several days after discontinuation of intravenous heparin in the anchor arm. 
This in contrast to the Hirulog Early Reperfusion or Occlusion (HERO)-2 trial, in 
which bivalirudin administered for a similar duration as intravenous UFH resulted 
in lower reinfarction rates after streptokinase (30). Whereas coumarin requires 
regular monitoring, these agents do not, and oral direct thrombin inhibitors have 
recently seen the light. In anticipation of follow-up studies with the aforementioned 
agents, the implementation of long-term therapy with coumarin could be facilitated 
through self-assessed dose-adjusted anticoagulation (24). 
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Whether a routine invasive strategy in this study population could positively 
influence reocclusion and associated events remains to be determined. The available 
evidence to date does not support such an aggressive approach (31). This explains 
the symptom-driven, ischemia-guided revascularization strategy in this trial, 
irrespective of the presence of a severe stenosis at baseline angiography. Although 
the 3-month TIMI grade 0 to 1 flow rate of 9% on the combined antithrombotic 
regimen seems to compare favorably with the rates observed after primary PTCA 
with or without stenting (32), it should be realized that the current study group is 
much more selected. With the improved techniques and use of glycoprotein IIb/IIIa 
receptor blockers re-evaluation of the impact of a routine invasive strategy following 
successful thrombolysis seems warranted.
Limitations
As this trial was investigator-initiated and performed in an era of various consecutive 
large, sponsored reperfusion trials, inclusion took 6 years, which also accounts 
for the different types of lytics that have been used over the years. Although the 
observed clinical benefit seems promising, the present study is limited by its open 
design, sample-size and selected population. The trial was designed and powered 
as an angiographic study, with blind assessment of the primary end point. With 
clinical outcome as secondary end point, it should be considered a conceptual 
study, which provides insight into the mechanism underlying a potential clinical 
benefit. 
Conclusions
The APRICOT-2 findings strongly suggest that a continuous, prolonged anti-
thrombotic regimen of both anti-platelet and anticoagulation therapy has additional 
impact after fibrinolytic therapy. This was achieved with an acceptable safety in a 
high compliance setting. With respect to the implications for daily clinical practice, 
the results of larger trials on this and other combined antithrombotic regimens will 
have to be awaited.
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Table 1 Established indications for oral anticoagulant therapy and recommended 
 therapeutic range
Indications Target INR
Prophylaxis of venous thrombosis
Treatment of venous thrombosis
Treatment of pulmonary embolism
Prevention of systemic emoblism
• Atrial fibrillation
• Tissue heart valves
• Valvular heart disease
• Acute myocardial infarction*
Mechanical prosthetic valves (high risk)
Bileaflet mechanical valve in aortic position
INR 2.0-3.0
INR 2.5-3.5
INR 2.0-3.0
* = as demonstrated in case A
Modified table, source (15)
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The following two case presentations illustrate the range of considerations 
when formulating plans for oral anticoagulation in patients with acute coronary 
syndromes.
Case A
A 59-year old patient with a 5-hour-old transmural anterior myocardial infarction was 
treated with accelerated alteplase, adjunctive heparin, aspirin and a beta-blocker. Maximum 
CK-MB was over ten times the upper limit of normal. At day 4 echocardiography revealed 
a mass suggestive of a mural left ventricular thrombus, and important apical wall motion 
abnormalities. ACE-inhibition was initiated. To reduce the risk of systemic embolization, 
heparinization with a target APTT to 1.5-2.0 times control was started, followed by 6 months 
of dose-adjusted warfarin, target INR 2.5-3.5 (Table 1).
Case B
A 66-year old diabetic, using aspirin for a prior TIA, presented with chest pain at rest and 
dynamic ST-depression > 1mm. He recovered from the acute phase after treatment with low-
molecular-weight heparin, nitroglycerin, aspirin and beta-blocker therapy. Cardiac markers 
remained negative. During the convalescence period no recurrent chest pain occurred, and 
exercise testing was negative with respect to symptoms and electrocardiographic signs of 
ischemia. Before discharge dose-adjusted medium intensity oral anticoagulation therapy 
(target INR 2-3) was started on top of aspirin (80 mg daily) as secondary prevention strategy 
for death, infarction and stroke (current update).
Background
Notwithstanding the improvements in the secondary prevention of acute coronary 
syndromes, death and (re)infarction still occur in ≈ 10 to 15% of patients in the 4 
to 6 weeks after presentation, despite the use of aspirin. Interestingly, increased 
activity of the coagulation system has been reported up to six months after the index 
event (1). In addition, raised concentrations of factor VII are associated with both 
initial and recurrent ischemic events (2).
These observations stimulated renewed interest in the potential benefit of oral 
anticoagulants. The INR has replaced the nonstandardized prothrombin time and 
quick tests (3) and INR monitoring by patients is now a new feature in clinical 
practice (4,5). Several trials have evaluated a combined regimen of aspirin with 
dose-adjusted coumarins (6,7,8,9,10), 2 of which also addressed the direct 
comparison of both agents alone (9,10).
In view of these developments, the present report forms an update on the role of 
oral anticoagulation therapy in acute coronary syndromes with the emphasis on 
secondary prevention and its additional effect in combination with aspirin.
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Pathophysiological Rationale
The process of coronary thrombosis can be divided into 3 major steps:
1. vascular injury with exposure of the thrombogenic subendothelial surface;
2. adhesion and aggregation of platelets; and
3. formation of a fibrin-rich clot
Exposure of subendothelial collagen not only activates platelets, but also the 
coagulation system (Figure 1). As a result, prothrombin is cleaved into thrombin by 
prothrombinase (factor Xa, Va and phosopholipids). Thrombin is a potent platelet 
activator, a process not inhibited by aspirin or clopidogrel. In addition, thrombin 
activates important cofactors (V and VIII) for coagulation and is the key factor in the 
process of fibrin clot formation. Not only does it cleave fibrinogen into fibrin, it also 
activates factor XIII, which results in improved clot strength with more resistance to 
endogenous and exogenous fibrinolysis. 
In view of the above, an antithrombotic regimen of both anti-platelet and 
antithrombin therapy could potentially have an additional impact when compared 
to a regimen of anti-platelet therapy alone (Figure 1). This favors the combination 
of aspirin with either unfractionated heparin, low-molecular-weight heparin or a 
direct antithrombin in the initial hospital treatment phase in patients with acute 
coronary syndromes (11,12,13). After hospital discharge, recurrent ischemic events 
are not infrequent, and in light of the demonstrated persistent increased coagulant 
activity, prolonged oral anticoagulation after hospitalization might be beneficial.
Pharmacology
Oral anticoagulants such as warfarin act through interference with the vitamin K- 
dependent production of coagulation factors II, VII, IX, and X, which are produced 
by the liver (Figure 2). In addition, protein C and S, regulatory anticoagulants, are 
also produced in a biologically less active form after warfarin treatment. Based on 
their half-lives, concentrations of protein C and factor VII are the first to drop, within 
24 hours of initiation of therapy, whereas levels of factors II, IX, and X fall after ≈ 
4 days. This underscores the possibility of a procoagulant effect developing in a 
patient early after initiation or termination of oral anticoagulant therapy. Absorption 
of warfarin from the gastrointestinal tract is rapid, with a high bioavailability. The 
drug circulates bound to plasma proteins with subsequent accumulation and 
metabolization in the liver. Accordingly, dietary aspects related to increased or 
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decreased intake of the fat-soluble vitamin K, gastrointestinal malabsorption and 
hepatic dysfunction are some of the factors that can interfere with the response 
to oral anticoagulation therapy. Various drugs can cause interactions or affect 
the metabolic clearance of warfarin. A common interaction is with antibiotics, 
some potentiating (trimethoprim, metronidazol), others inhibiting (rifampicin) 
anticoagulant efficacy. Important for in-hospital and outpatient care in cardiology 
is amiodarone, which potentiates anticoagulant activity (14,15). Nonsteroidal anti-
inflammatory drugs (14,15), and high doses of aspirin (> 1g/day) plus high-intensity 
warfarin have been associated with an increased bleeding risk (16).
Given the extent of drug interactions and range of genetic factors impacting 
drug disposition, interindividual and intraindividual variability in anticoagulant 
efficacy and safety is not surprising. However, monitoring was standardized with 
the introduction of the INR and results became internationally exchangeable and 
comparable (3). Both efficacy and safety were found to depend on the intensity 
of anticoagulation (14,15,17), and the maximum time spent in the target range 
(15). This, in turn, relates to the frequency of monitoring (15), which emphasizes 
the future potential of self-monitoring (4,5). In view of these developments and 
the lower daily doses of aspirin presently prescribed, new studies in the primary 
and secondary prevention of acute coronary syndromes were initiated, not 
only addressing the efficacy of a combined regimen with different intensities of 
anticoagulation but also the direct comparison of warfarin versus aspirin alone.
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Figure 1 Thrombus formation and pharmacological interventions in the coagulation 
 cascade - Tissue injury not only induces subendothelial adhesion (vWF, GP 
 1b, GP Ia/IIa) and aggregation of platelets (fibrinogen, GPIIb/IIIa), but also 
 activates the coagulation cascade. Activation of the extrinsic and intrinsic 
 coagulation pathways results in the thrombin-induced formation of a fibrin-
 rich clot. Fibrin cross-linking by factor XIII improves clot-strength. Whereas 
 oral anticoagulants interfere with the production of coagulation factors, other 
 agents inhibit the action of activated clotting factors.
 vWF = von Willebrand factor; PT = prothrombin (II);T = thrombin (IIa); 
 OAC = oral anticoagulants; UFH = unfractionated heparin; LMWH = low-
 molecular-weight heparin
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Figure 2 Oral anticoagulants – Mechanism of action 
 Coumarins inhibit the conversion of vitamin K epoxide (Vit.KO) to its reduced 
 form (Vit. KH2) through interference with two reductases: KO-reductase and 
 K-reductase. Subsequent insufficient gamma-carboxylation results in 
 coagulation factors with impaired biological function. Most of the impact is 
 exerted through inhibition of the coumarin-sensitive KO-reductase. As 
 K-reductase is relatively coumarin resistant, dietary aspects and administration 
 of vitamin K (Vit.K1) are interfering factors. (modified figure, source (15) )
Clinical Efficacy
Primary Prevention
Dose-adjusted low intensity warfarin (target INR 1.3 to 1.8) has been shown to 
reduce the risk of ischemic heart disease to an extent similar to 75 mg of aspirin. 
Interestingly, warfarin (mean INR, 1.5) primarily reduced fatal events and aspirin 
nonfatal myocardial infarction. The combination of warfarin and aspirin had 
additional beneficial impact, but increased fatal strokes and minor bleeding. 
The use of either agent alone was associated only with more minor bleeding 
(18). Similar to primary prevention studies with aspirin (19), the benefit of oral 
anticoagulant therapy in primary prevention is confined to high-risk men, with little 
data available for women. 
Secondary Prevention
Monotherapy versus control. Oral anticoagulation is one of the oldest strategies 
of secondary prevention of ischemic heart disease. After a large number of 
controlled trials in the 1960s, 2 large double-blind placebo-controlled randomized 
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trials in the early 1990s unequivocally demonstrated the efficacy of full-intensity 
anticoagulation (INR, 2.8 to 4.2), at the cost of a 4-fold increased risk of major 
bleeding (17,20,21).
Monotherapy versus aspirin. Given its ease of administration and favorable safety 
profile, aspirin has become the initial antithrombotic agent of choice in acute 
coronary syndromes. Meta-analysis on the few small trials comparing moderate-
to-high intensity anticoagulation versus aspirin did not demonstrate a difference 
in efficacy, whereas bleeding was lower on aspirin (17). Interestingly, the recently 
presented ASPECT-2 (target INR, 3.0 to 4.0) and WARIS-2 (target INR, 2.8 to 4.2) 
trials both reported that full-intensity anticoagulation as monotherapy was superior 
to aspirin alone in the secondary prevention of death, (re)infarction, and stroke 
(9,10). Thus, high-intensity oral anticoagulation seems an effective alternative for 
aspirin in the setting of well-organized frequent INR monitoring. 
Combination therapy versus aspirin alone. Oral anticoagulation therapy at 
medium-high and low intensity combined with aspirin has been tested (Table 
2). A combination of medium-high intensity oral anticoagulation plus aspirin 
seems promising (17), whereas fixed-dose, low intensity does not improve clinical 
outcome (22). Since the start of the new millennium, 4 trials with a target INR > 2 
have been completed, 3 involving patients with myocardial infarction (8,9,10), and 
1 that primarily included patients with unstable angina (6). APRICOT-2 and ASPECT-
2 were performed in the Netherlands (8,9) and WARIS-2 in Norway (10), countries 
that are known for the high quality of their anticoagulation clinics. ASPECT-2 
was unfortunately prematurely discontinued due to slow recruitment. Although 
underpowered, a significant clinical benefit for the combined antithrombotic 
regimen (reached INR, 2.4) was observed when compared to aspirin alone (9). In 
APRICOT-2, designed and powered as angiographic follow-up trial, the combined 
antithrombotic regimen (reached INR, 2.6) produced a 40% reduction in 3-month 
reocclusion after successful fibrinolytic therapy. Similar findings were observed in 
a smaller, more heterogeneous group of patients after acute coronary syndromes. 
Clinical outcome, the secondary end point, was also significantly improved (8,23). 
The large WARIS-2 trial (INR, 2.2) confirmed these observations over a 4-year 
follow-up period, with a reduction in the combined end point of death, reinfarction 
and stroke from 20% to 15% (10). OASIS-2 was performed worldwide, and showed 
a non-significant 10% reduction for the combined strategy (6). When OASIS-2 
was reanalyzed, stratified by countries with good compliance to anticoagulation 
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therapy a marked clinical benefit was apparent (Table 2). The largest worldwide trial 
after myocardial infarction to date, CHAMP, was aimed at a target INR of 1.5 to 2.5, 
and was neutral. In this trial, with a mean INR of 1.8, most patients had an INR near 
the lowest target intensity (7).
In aggregate, the available data suggest that in a setting of good compliance and 
well-organized INR monitoring, addition of oral anticoagulation (INR, > 2.0) to 
aspirin seems beneficial. More insight into the efficacy and safety of a regimen with 
a target of 1.5 to 2.5 will be provided by the LOWASA study, which is enrolling > 
5000 patients in Sweden.
Clinically observed mechanism of benefit
The controlled trials of warfarin as a single agent showed marked reductions in 
death, (re)infarction and stroke, respectively (17). As for the direct comparison with 
aspirin, or a specification of the efficacy of the combined regimen, an updated 
meta-analysis including final data of the unpublished trials is warranted. The fact 
that oral anticoagulants take 2 to 4 days to become therapeutically effective is an 
important clinical consideration. Timing of initiation of oral anticoagulation and the 
antithrombotic regimen administered during the acute phase therefore must take 
into account such pharmacological factors. 
Adverse Events 
In patients taking oral anticoagulants, the initiation or withdrawal of concurrent 
medications must be reviewed by a health care professional, preferably a member 
of a dedicated anticoagulation service committed to close communication with the 
patient. The most frequent complication is bleeding, which is related to the intensity 
of anticoagulation (14,15,17) and is more frequent when oral anticoagulation is used 
in patients with cerebrovascular or peripheral disease (24). High-risk subgroups are 
those with a history of gastro-intestinal bleeding, stroke, hypertension, impaired 
renal function and anemia. Whether increased age is an independent risk factor, 
or whether bleeding is primarily a result of comorbid factors remains an issue of 
controversy. Irrespective of age, bleeding episodes should trigger a search for a 
possible underlying occult lesion, which may be malignant (14,15). With respect to 
the safety of a combined regimen of aspirin and dose-adjusted oral anticoagulation 
therapy, the different studies report a 2- to 3-fold increased risk of minor and major 
bleeding, without an increased risk of intracerebral hemorrhage (6,7,8,9,10).
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A less frequently observed side effect is skin necrosis attributable to thrombosis of 
the venules and capillaries within the subcutaneous fat. An abrupt drop in protein C 
levels or a preexisting deficiency is held responsible for the procoagulant response 
seen in the first 3 to 8 days after initiation of therapy (14,15).
It should be noted that oral anticoagulants are associated with an increased risk of 
fetal central nervous system and bone abnormalities, bleeding and fetal death. For 
most pregnant women requiring anticoagulant therapy, unfractionated heparin and 
subcutaneous low-molecular-weight heparin are safe alternatives (14,15). 
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Recommendations
Irrespective of the indication, dose-adjusted, frequently monitored and individually 
tailored therapy is a prerequisite for optimal oral anticoagulation. Primary preven-
tion can be considered in high-risk patients with difficult or nonmodifiable risk 
factors, aiming at a target INR of 1.5 (18). In patients with an acute coronary 
syndrome oral anticoagulation should be prescribed for established indications (eg, 
case A, (15), Table 1) in the absence of contraindications. Secondary prevention 
of coronary events attributable to recurrent thrombosis is a major component of 
management of patients after presentation with an acute coronary syndrome. Given 
its ease of administration, predictable safety, and proven efficacy, aspirin should be 
the preferred agent for this indication (19).
In clinical settings with a good infrastructure, full-intensity oral anticoagulation 
(target INR, 2.8 to 4.2) is an effective alternative, with ample evidence-based support 
(9,10,17). If aspirin is contraindicated, oral anticoagulation is the only effective 
alternative long-term antithrombotic regimen so far tested in patients after ST-
elevation myocardial infarction. Although both low-molecular-weight heparin and 
clopidogrel in addition to aspirin have been proven safe in the long-term treatment 
after a non ST-elevation acute coronary syndrome (25,26), only clopidogrel proved 
to be of additional benefit. In cases of aspirin intolerance, 75 mg of clopidogrel 
once daily seems a practical long-term alternative. With respect to the long-term 
benefits of clopidogrel (27), direct comparisons with oral anticoagulation, both 
as single agents and in addition to aspirin, have not been performed to date. We 
believe this is an important area for future trials.
Data on the combination of moderate intensity anticoagulation (target INR, 2 
to 3) with aspirin seem promising (6,8-10,17), but routine implementation can 
not (yet) be recommended in uncomplicated patients (eg, Case B). Combination 
therapy can certainly be considered in individual (high-risk) cases; in that case, 
the recommended aspirin dose is 80 mg daily (7-10,22) to be taken along with 
moderate-intensity oral anticoagulation. Definition of the optimal duration of 
therapy and identification of subsets of patients with the optimal risk-benefit profile 
are relevant clinical issues. A practical aspect of concern is the fact that even in 
countries with an established good quality anticoagulation service infrastructure 
and high short-term compliance, ≈ 20 to 25% of patients discontinue therapy 
within 6 months, and only a minority do so as a result of bleeding (6,9).
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Conceptually, the observed benefits of anticoagulant therapy in addition to an anti-
platelet regimen call for the search of a less cumbersome long-term alternative, that 
is at least as effective as warfarin, but with less intraindividual and interindividual 
variability. For patients after ST-elevation myocardial infarction, data on low-
molecular-weight heparin seem promising in hospital (28) and consideration 
should be given to trials of long-term therapy in that patient subset. For the entire 
spectrum of patients recovering from an acute coronary syndrome, agents without 
the need for hematologic monitoring, such as Xa inhibitors (29,30) and oral direct 
thrombin inhibitors, seem appealing candidates for additional study. 
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Abstract
Background: After successful thrombolysis a high-grade stenosis at 24-hour 
angiography strongly predicts reocclusion, and is often believed to result in 
high reinfarction rates. However, routine angioplasty did not reduce death or 
reinfarction in past trials. Importantly, systematic angiographic follow-up shows 
that reocclusion often occurs without clinical reinfarction. This study investigates 
whether the increased risk for reocclusion associated with a high-grade lesion 
translates into impaired clinical outcome.
Methods: In the ischemia-guided APRICOT-1 trial 240 ST-elevation MI patients with 
an open infarct artery 24 hours after thrombolysis had 3-month repeat angiography 
to assess reocclusion with clinical follow-up at 3 months and 3 years. 
Results: Based on the optimal discriminative stenosis severity, reocclusion was 
40% (47/118) in patients with a high-grade residual stenosis and 16% (20/122) in 
those with a low-medium-grade lesion (RR 2.43, 95% CI 1.54-3.84, p<0.01). Three-
month death and reinfarction did not differ: 6% (7/118) versus 9% (11/122) (RR 
0.66, 95% CI 0.26-1.64, p=ns). Systematic angiographic follow-up revealed that 
reocclusion of a high-grade lesion occurred in the absence of clinical reinfarction 
in 85% (40/47) as compared to 45% (9/20) in patients with a low-medium-grade 
stenosis (RR 1.89, 95% CI 1.15-3.12, p<0.01). Despite an independent association 
with reocclusion, a high-grade stenosis predicted neither short- nor long-term death 
and reinfarction.
Conclusions: Following an ischemia-guided strategy after successful thrombolysis, 
patients with a high-grade stenosis experience similar death/reinfarction rates as 
patients with a low-medium-grade lesion. This, despite a two- to threefold higher 
risk for reocclusion. The finding that reocclusion of a high-grade lesion often occurs 
without clinical reinfarction, explains the absence of a relationship between a 
severe stenosis and death/reinfarction. Appreciation of these observations may 
contribute to an optimal design of a future randomized trial to re-evaluate the 
impact of a routine invasive strategy.
156 High-grade infarct related stenosis after successful thrombolysis
Introduction
Despite the undisputed benefits on early infarct artery patency and clinical outcome 
(1), the initial success of thrombolytic therapy is often partly offset by reocclusion. 
Reocclusion occurs in ~30% of patients within the first year after acute myocardial 
infarction (2-4) and portends adverse short- and long-term outcome (5-7).
Past observations suggested a relationship between a high-grade residual stenosis and 
reocclusion after successful thrombolysis (8-11). It was assumed that reocclusion of 
a high-grade stenosis leads to a high incidence of death, reinfarction and recurrent 
ischemia (8-12). Unexpectedly, a meta-analysis on routine angioplasty did not 
show reduced death and reinfarction rates as compared to an ischemia-guided 
revascularization strategy, which was attributed to high peri-procedural event rates 
(13). Unfortunately, angiographic reocclusion was not addressed in those trials. 
Later studies demonstrated that reocclusion occurs asymptomatically in up to two-
thirds of patients, that is without death or clinical reinfarction (3,5,6); collateral 
supply to the infarct area has been suggested as a potential mechanism (14). 
Given the absence of a 1:1 relationship between reocclusion and these events, 
the attainable benefit from angioplasty to reduce death or reinfarction depends 
on the proportion of symptomatic reocclusions occurring in patients with a severe 
stenosis. 
The Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis 
(APRICOT)-1 trial (2) was performed in the same era as the trials in the meta-
analysis. In this angiographic and clinical follow-up trial an ischemia-guided 
revascularization strategy was followed, irrespective of the presence of a high-grade 
stenosis. In this setting, we previously demonstrated that stenosis severity 24 hours 
after successful thrombolysis was the only independent predictor of reocclusion 
(15). 
In the current analysis we dichotomized our study population according to the 
optimal quantitative stenosis severity cut-point to predict reocclusion. Subsequently, 
we sought to assess whether the increased risk for reocclusion in patients with a 
high-grade stenosis at 24-hour angiography translates in impaired clinical outcome 
in both the short- and the long-term. 
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Methods
Protocol
The APRICOT-1 study protocol has been reported in detail previously (2). In brief, 
300 patients < 71 years old with chest pain lasting > 30 minutes and < 4 hours, and 
0.2 mV ST-segment elevation in at least 2 contiguous leads on the electrocardiogram 
(ECG), received thrombolysis for suspected myocardial infarction followed by 20,000 
U of intravenous heparin/24h. In the case of clinical and/or electrocardiographic 
signs of reperfusion, clinically stable patients were asked informed consent to 
undergo coronary angiography within 48 hours after thrombolysis. The infarct-
related artery was identified using previously described methods (2) and in the case 
of a patent artery, grade 1 to 3 stenosis according to the European Cooperative Study 
Group (ECSG) criteria (Table I), patients were eligible for the study. Sixteen patients 
were retrospectively excluded for not having a patent infarct artery at baseline 
angiography according to the blinded angiography committee.
The 284 patients with a patent infarct artery were randomly allocated to one of 
three arms: blinded treatment with either 325 mg of aspirin or placebo, or open-
label coumadin including continued heparinization until the target INR (2.8-4.0) 
was reached. By protocol revascularization was only to be performed for recurrent 
ischemia refractory to maximal anti-ischemic medication. To assess reocclusion 
follow-up angiography was scheduled at three months. If coronary angioplasty 
(PTCA) was performed before the planned repeat angiography, the patency status of 
the infarct artery before dilatation was scored as follow-up endpoint.
At baseline angiography quantitative coronary angiography (QCA) of the culprit lesion 
was performed, providing a precise estimation of the diameter stenosis with low intra- 
and interobserver variability (16). For this analysis the optimal single projection with 
the most severe measured stenosis was used. Morphology of the culprit lesion was 
scored according to Ambrose et al. (17). Collateral filling of the infarct artery was 
assessed at both angiograms according to the Rentrop grading system (18). 
Three-month clinical follow-up data included survival, reinfarctions, revascula-
rizations and recurrent ischemia. Follow-up on survival and reinfarction was 
extended over a 3-year period. Information was derived from medical charts, 
municipal registries, or by telephone contact with the patient, relatives or the 
general practitioner.
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Definition of patient groups and endpoints 
Based on the optimal stenosis severity cut-point to predict reocclusion the study 
population was dichotomized in patients with a high-grade or a low-medium-grade 
stenosis. Patients were followed for death and reinfarction until the day of 3-month 
repeat angiography. A patient with a reoccluded infarct artery at urgent repeat 
angiography performed for clinical reinfarction was considered to have a so called 
“symptomatic” reocclusion. 
The definition of reocclusion was ECSG grade 4 or 5 (2). Clinical reinfarction was 
defined as recurrent ischemic symptoms lasting > 30 minutes accompanied by 
transmural ischemia in the same ECG area as the index infarction with elevated 
creatine kinase levels. At follow-up visits a careful patient history was taken and the 
ECG was screened for new Q-waves in order to detect possible silent reinfarctions.
In addition to death and reinfarction, revascularizations were scored as well as the 
incidence of recurrent ischemia until the day of follow-up angiography. Recurrent 
ischemia was defined as recurrent chest pain during stress testing or at rest, 
accompanied by electrocardiographic signs of ischemia. 
To study the prognostic impact of stenosis severity in the long-term, infarct-free 
survival at 3-year follow-up was assessed.
Statistics
Statistical analysis was performed with SPSS 9.0 (SPSS Inc. 1999, Chicago, USA). 
Receiver operating characteristics (ROC) analysis was performed on QCA stenosis 
as a predictor of reocclusion. The optimal cut-point level for stenosis severity was 
obtained with Fisher’s linear discriminant analysis.
To test differences between groups the Student’s t test, Mann-Whitney-U-test or 
χ2-test were used whenever appropriate. Statistical significance was defined as a 
two-sided p-value < 0.05. 
Multivariable logistic regression analysis was used to determine the association 
between a high-grade stenosis and 1) reocclusion; 2) short-term death and 
reinfarction. Variables included in the multivariable model were those causing 
imbalances in baseline characteristics (see results) combined with 1) univariate 
predictors of reocclusion (15) and 2) TIMI-risk score variables associated with 
clinical outcome (19). Long-term event-free survival analysis was performed 
according to Kaplan and Meier, using the log-rank test for comparison between 
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groups. Cox-regression analysis was used to assess a possible independent 
relationship between stenosis severity and long-term infarct-free survival. 
Table 1 European Cooperative Study Group classification
Stenosis grade
0 Normal
1 < 50% diameter stenosis
2 50% to 90% diameter stenosis
3 91% to 99% diameter stenosis, complete filling within 3 cycles
4 91% to 99% diameter stenosis, no complete filling within 3 cycles
5 Total occlusion with or without collateral filling
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Results
Out of the 284 patients participating in the APRICOT-1 trial the current study group 
consists of the 240 patients with two angiograms and complete QCA-analysis. 
Thirty-six patients did not undergo follow-up angiography for reasons of refusal 
(n=28), coronary bypass surgery (n=6) or death (n=2). In 8 patients QCA-analysis 
was technically not possible. These 44 patients did not differ from the study group 
except for a tendency towards older age (59 + 9 versus 56 + 9 years, p=0.06). 
Figure 1 shows the distribution of the quantitatively assessed severity of infarct 
related stenoses. Baseline angiography was performed at a mean of 24 + 14 hours. 
Stenosis severity was not related to the timing of the first angiogram. Follow-up 
angiography was performed after a mean of 75 + 31 days.
Optimal diameter stenosis cut-point level for reocclusion
ROC analysis to determine the optimal QCA stenosis severity to predict reocclusion 
is shown in Figure 2. Diagnostic accuracy of QCA stenosis to predict reocclusion 
was moderate. Fisher’s linear discriminant analysis identified a 62.7% residual 
diameter stenosis at baseline as the optimal cut-point level for reocclusion. 
Sensitivity was 70%, with a negative predictive value of 84%. 
This cut-point level dichotomized the study population in two groups:
– a group of 118 patients with a high-grade stenosis (QCA ≥ 62.7%) at high risk for 
reocclusion (40%; 47/118), and 
– a group of 122 patients with a low-medium-grade stenosis (QCA < 62.7%) at 
lower risk for reocclusion (16%; 20/122)
This difference (40% vs. 16%) represents an unadjusted relative risk for reocclusion 
of 2.43 (95% CI 1.54-3.84, p<0.01) for patients with a high-grade stenosis at 
baseline.  
Baseline characteristics are shown in Table 2. Smoking (70%), hypercholesterolemia 
(57%), diabetes (6%) and hypertension (26%) did not differ between groups. In 
patients with a high-grade stenosis a higher occurrence of smooth culprit lesions 
and a tendency towards more previous angina were observed. 
High-grade stenosis and death/reinfarction
Figure 3 shows the incidence of reocclusion and the incidence of death or 
reinfarction. Interestingly, despite the two- to threefold increased risk for reocclusion 
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in patients with a high-grade stenosis, the incidence of death or reinfarction did not 
differ from patients with a low-medium-grade lesion: 6% (7/118) and 9% (11/122), 
respectively (RR 0.66, 95% CI 0.26-1.64, p=ns). 
Systematic angiographic follow-up revealed that overall 73% (49/67) of reocclusions 
occurred in the absence of clinical reinfarction. Proportionally, reocclusion occurred 
more often without clinical reinfarction in patients with a high-grade stenosis than 
in patients with a low-medium-grade lesion: 85% (40/47) versus 45% (9/20), 
respectively (RR 1.89, 95% CI 1.15-3.12, p<0.01).
Recurrent ischemia and revascularization
Recurrent ischemia was seen in 32% (38/118) of patients with a high-grade stenosis 
and 27% (33/122) of patients with a low-medium-grade lesion (RR 1.19, 95% CI 
0.80-1.76, p=ns). In aggregate, revascularization rate was 11% (26/240): 14% (16/
118) in patients with a high-grade stenosis and 8% (10/122) in patients with a low-
medium-grade lesion (RR 1.65, 95% CI 0.78-3.50, p=ns). 
Of all patients who were conservatively managed for recurrent ischemia, only one 
patient suffered a reinfarction, that occurred after hospital discharge. This patient 
had a < 50% stenosis at 24-hour angiography. 
Collaterals
Out of the 67 patients with reocclusion, the presence and quality of the collateral 
filling of the infarct artery could be assessed in 63 (94%). At baseline angiography 
none of these patients had good collaterals. 
At follow-up angiography good collaterals were seen in 61% (27/44) of patients 
with a high-grade baseline stenosis and 42% (8/19) of patients with a low-medium-
grade baseline lesion: RR 1.46, 95% CI 0.82-2.60, p=0.15.
Multivariable analysis
Multivariable analysis identified a high-grade QCA-stenosis as an independent 
predictor of reocclusion: OR 3.36, 95% CI 1.81-6.26, p<0.01. During the time 
period from baseline angiography until the day of repeat catheterization a high-
grade stenosis was not a predictor of death or reinfarction: OR 0.61, 95% CI 0.22-
1.67, p=ns. Morphology of the culprit lesion predicted neither reocclusion, nor 
clinical outcome.
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Long-term follow-up
Median long-term clinical follow-up from the time of randomization was 858 days 
(25th-75th percentiles: 565-1293). At 3-year follow-up survival free from reinfarction 
was 81% in patients with a high-grade stenosis as compared to 82% in patients with 
a low-medium-grade stenosis (Figure 4, p=ns). A high-grade stenosis at baseline 
was not a predictor of long-term death and reinfarction: HR 0.99 , 95% CI 0.53-
1.85 (Cox-regression, p=ns). 
Figure 1: Distribution of the quantitatively assessed severity of the infarct related 
 stenoses at 24-hour angiography
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Figure 2: ROC analysis for QCA stenosis as predictor of reocclusion 
 (area under the curve 0.680, 95% CI 0.605-0.754, p < 0.01)
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Table 2 Baseline characteristics
High-grade 
stenosis
n = 118
Low-medium-
grade stenosis
n = 122
Men (%) 99 (84%) 100 (82%)
Age (years) 56 ± 9 56 ± 9
Previous angina  
 < 4 weeks
 ≥ 4 weeks
41 (35%)
25 (21%)
 31 (25%)†
23 (19%)
Previous myocardial infarction 7 (6%) 8 (7%)
Time symptoms – thrombolysis (hr) 2.1 ± 1.0 2.0 ± 1.0
Thrombolytic
 Streptokinase
 Anistreplase
101 (86%)
117 (14%)
109 (89%)
113 (11%)
Peak creatine kinase (units/L)* 
               (IQR) 
1086 
(454-1941)
1100 
(624-2211)
Time thrombolysis – first angiography (hr)*
               (IQR) 
22 
(13-31)
22 
(14-33)
Anterior infarction
Single vessel disease
% stenosis QCA
44 (37%)
62 (53%)
70.5 ± 5.5
55 (45%)
73 (60%)
52.3 ± 9.1‡
Lesion type
 Smooth
 Complex
74 (63%)
44 (37%)
 61 (50%)§
61 (50%)
Antithrombotic regimen
 Coumadin
 Aspirin
 Placebo
37 (31%)
49 (42%)
32 (27%)
42 (34%)
41 (34%)
39 (32%)
Data are presented as the number (%) of subjects for discrete variables, and as mean + standard 
deviation for continuous variables unless indicated otherwise.
* median; IQR = Interquartile range; † p = 0.07 for previous angina versus no previous angina, 
‡ p < 0.01, § p < 0.05
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Figure 3: Incidence of reocclusion in patients with a high-grade stenosis (n=118) 
 and a low-medium-grade stenosis (n=122) 
 Death and reinfarction rates dashed.
Figure 4: Event-free survival, defined as a clinical course without death or reinfarction 
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Discussion
This analysis on 240 patients with successful thrombolysis, in whom an ischemia-
guided revascularization strategy was followed, is the largest observation to date 
on the relationship between residual stenosis severity, reocclusion, death and 
reinfarction. In contrast to what is generally believed, patients with a high-grade 
residual stenosis – optimized to predict reocclusion – did not experience adverse 
clinical outcome when compared to patients with a low-medium-grade lesion; 
this, despite a two- to threefold higher risk of reocclusion. Although the absence of 
an association between stenosis severity and clinical outcome has been reported 
before (20), the current data provide insight into a potential underlying mechanism. 
Moreover, an additional explanation is postulated for the lack of benefit observed 
in past trials on routine angioplasty after successful thrombolysis.
Rationale of past angioplasty trials
The current observations are in contrast to the hypothesis that formed the basis of 
previous trials studying routine angioplasty after successful thrombolysis. These 
trials were based on 2 premises: 1) a suggested relationship between a high-grade 
residual stenosis and reocclusion, and 2) the assumption that, with this increased risk 
for reocclusion, the subset of patients with a high-grade lesion could be identified as 
a high-risk group for death and reinfarction (8-12). Consequently, reduction of the 
residual lumen narrowing was thought to reduce the incidence of reocclusion and 
subsequently to lead to improved clinical outcome (8,9). However, meta-analysis of 
the randomized trials did not show a benefit on death and reinfarction for routine 
angioplasty after successful thrombolysis when compared to an ischemia-guided 
strategy (13). This was attributed to high peri-procedural event rates. 
The premises on which these trials were based have never been questioned, 
although at the time of initiation they were derived from small observational studies 
involving selected patients (8-12). Later reports from large angiographic trials 
consistently showed an association between stenosis severity and reocclusion, 
although an independent relationship has only been demonstrated in patients 
undergoing delayed angiography, having survived the first 24-48 hours or more 
(5,15,21-23). 
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Stenosis severity, reocclusion and recurrent events
It has also been demonstrated that reocclusion is associated with adverse clinical 
outcome (5-7,24). Given the markedly increased risk for reocclusion in patients 
with a high-grade stenosis, it is temptative to consider these patients at higher risk 
for death or reinfarction than patients with a low-medium-grade lesion. Trials on 
routine angioplasty after successful thrombolysis were already ongoing, when it 
was shown that reocclusion occurs without without death or clinical reinfarction 
in up to two-thirds of patients (3,5,6). Inherently, the degree of clinical benefit 
attainable with routine angioplasty largely depends on how often reocclusion of a 
high-grade stenosis occurs with these events. The unique design of the APRICOT-1 
trial allowed us to study this question. Clinical and angiographic follow-up were 
assessed simultaneously at the day of repeat angiography and the analysis included 
patients undergoing early angiography for recurrent ischemia. Importantly, the 
rather conservative revascularization strategy in this trial (overall revascularization 
rate 11%) offers unique insight into the “natural clinical course” following 
successful thrombolysis. 
It was found that, despite a two- to threefold increased risk for reocclusion, patients 
with a high-grade residual stenosis experienced similar short- and long-term clinical 
outcome when compared to patients with a low-medium grade stenosis (Figure 3,4). 
At first glance, this may seem unexpected: yet, while only one out of six patients 
with a reocclusion on a high-grade stenosis presented with clinical reinfarction, this 
was the case in about one out of every two patients with a reocclusion on a low-
medium-grade lesion. 
The clinical presentation of reocclusion may also be affected by the presence 
and quality of collateral supply to the reoccluded infarct artery, and factors as the 
viability of the myocardium distal to the culprit and the presence of diabetes (less 
pain perception).
Our finding that stenosis severity after successful thrombolysis is not related to 
short-term clinical outcome not only complements observations from a previous 
study with 90-minute angiography (20), but also extends into the long-term. 
The fact that patients with a high-grade stenosis were somewhat more likely to 
undergo revascularization in case of recurrent ischemia does not seem to have 
affected death and reinfarction rates: of all patients with recurrent ischemia who 
were not revascularized, only one patient (stenosis < 50% at baseline) suffered a 
reinfarction. 
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Thus, even in the setting of a rather conservative, ischemia-guided strategy a high-
grade stenosis did not predict clinical reinfarction, despite the associated high-risk 
for reocclusion. Also with stenosis severity as continuous variable, ROC-analysis 
was unable to detect a predictive cut-off level for clinical reinfarction (data not 
shown). 
Implications
Although the current observations should be considered as hypothesis generating, 
they may carry important considerations for a future prospective re-evaluation of a 
routine invasive strategy following successful thrombolysis. 
The technical developments in interventional cardiology in the past decade and the 
use of glycoprotein IIB/IIIA receptor blockers will certainly contribute to a reduction 
in procedure-related events (25). After balloon angioplasty following successful 
thrombolysis, reocclusion is still frequent (~17%) (24), with an incorporated risk 
for reinfarction. This underscores the need for stenting. The use of intravascular 
ultrasound may further improve procedural outcome and provide more detailed 
information for identification and characterization of the culprit lesion (26). 
Although this was not confirmed in our study, previous angiographic studies 
showed an association between complex morphology of the culprit lesion and 
impaired outcome in patients with unstable angina (27). 
Furthermore, our findings suggest that the routine invasive arm of a future trial 
should not prescribe a certain cutpoint for severity of the culprit lesion to perform 
angioplasty. Many of the past randomized trials used a visually assessed stenosis 
severity of 60% or 70% as cutpoint (13). Our observations suggest that reocclusion 
of a lower grade lesion, proportionally, more often occurs symptomatically than 
reocclusion of a more severe lesion. 
After several non-randomized reports suggesting favorable outcome with routine 
angioplasty after thrombolysis (28,29), the randomized GRACIA-trial recently 
showed that in the current era routine revascularization following thrombolysis 
is safe and feasible (30). Low event rates precluded conclusions with respect to 
clinical outcome. Importantly, with the benefit of a routine invasive approach being 
uncertain as of to date, an active approach of viability and ischemia detection is 
mandatory. 
Given the favorable outcome after successful thrombolysis large patient numbers 
and long-term follow-up are required for a clinical efficacy study. However, in the 
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case of stunned or hibernating myocardium improving and/or maintaining infarct 
artery patency could result in left ventricular contractile recovery (31). A primary 
angiographic endpoint could therefore also be considered, i.e. the incidence of 
reocclusion or improvement in left ventricular ejection fraction. 
Study limitations
Our findings refer to a rather selected studypopulation of clinically stable patients 
younger than 71 years, who received thrombolysis within 4 hours of symptom-
onset and showed clinical and/or electrocardiographic signs of reperfusion with 
angiographically proven patency at 24-hour angiography. This may explain the 
low event rates in our study. However, the substantial reocclusion rates confidently 
allow comparison of the proportion of asymptomatic reocclusions between patients 
with a high-grade and a low-medium-grade residual stenosis.
Despite careful identification of the culprit lesions by the angiographic committee, 
we can not exclude that misinterpretations may have occurred, especially in 
patients with multi-vessel disease and multiple lesions.
Although patients were screened regarding history and ECG for silent reinfarction, it 
cannot be excluded that patients with a high-grade lesion experienced more silent 
reinfarctions.
Whereas to date use of the TIMI criteria (22) is standard in angiographic studies, 
the APRICOT-1 trial used the ECSG criteria (2). If only anatomical reocclusions 
– ECSG grade 5 stenoses (2) - were considered, the outcome of this analysis would 
not change.
Conclusion
Even though our observations should be considered as hypothesis generating, 
they challenge the generally believed association between a high-grade stenosis 
and reinfarction in patients with an open infarct artery after thrombolytic therapy. 
This was observed in the setting of a rather conservative, ischemia-guided 
revascularization strategy. In addition to peri-procedural events, the fact that past 
trials on routine angioplasty mainly focused on severe lesions may also explain 
their lack of clinical benefit. Our findings indicate that reocclusion of a lower grade 
lesion is more likely to result in clinical reinfarction. 
Based on these findings, a future randomized re-evaluation of a routine invasive 
strategy should target all amenable lesions, using glycoprotein IIb/IIIa blockers and 
stents to reduce peri-procedural events and reocclusion. 
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Abstract
Background: Reocclusion is seen in about 25-30% of patients within the first year 
after successful fibrinolysis, and often occurs in the absence of clinical reinfarction. 
Most reinfarctions occur early after fibrinolysis and carry a twofold increased risk of 
mortality. Notably, even in the absence of clinical reinfarction, reocclusion has been 
shown to impair left ventricular contractile recovery. The prognostic consequence 
of late reocclusion has not been thoroughly addressed. We therefore assessed the 
impact of 3-month coronary patency on 10-year cardiac survival, and if an effect 
independent of left ventricular function could be demonstrated.
Methods and Results: In the ischemia-guided APRICOT-1 trial 248 ST-elevation 
MI patients with an open infarct artery 24 hours after fibrinolysis had 3-month 
repeat angiography to assess reocclusion. In 99.6% of surviving patients > 10 years 
of clinical follow-up was available. Reocclusion was observed in 71 of the 248 
patients (29%). Cardiac survival at 10 years was 88% for patients with sustained 
patency and 73% in patients with a reoccluded infarct artery (p < 0.01), a difference 
also present in patients without ischemic symptoms between angiograms (85% 
versus 73%; p < 0.03). Multivariable analysis identified sustained patency at 3-
month angiography as independent predictor of 10-year cardiac survival (HR 2.10; 
95%CI 1.10 - 4.02) together with left ventricular ejection fraction.
Conclusions: Sustained infarct artery patency in the 3 months after fibrinolysis is a 
strong predictor of 10-year cardiac survival, independent of left ventricular function. 
Given the detrimental impact of both symptomatic and asymptomatic reocclusion, 
future preventive strategies should also focus on ‘clinically silent’ reocclusions. 
Studies on better antithrombotic regimens and their combination with a routine 
invasive strategy at some time point after fibrinolysis are warranted.
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Introduction
Despite a gradual increase in the use of primary percutaneous coronary interventions 
for ST-elevation myocardial infarction, the majority of patients is still treated with 
fibrinolytic therapy. Unfortunately, part of the initial success of pharmacological 
reperfusion is offset by reinfarction, recurrent ischemia and reocclusion (1). The 
incidence of 30-day reinfarction is about 5%, half of which occurs within 48 
hours after fibrinolysis (2), often attributable to infarct artery reocclusion. These 
early symptomatic reocclusions are associated with a twofold increase in mortality 
(1,2,3).
Reocclusion rates increase from 5 to 10% before discharge (1,4,5) to about 20 
to 30% in the 3-12 months after fibrinolysis (6,7,8). Systematic angiographic 
follow-up has revealed that about half of reocclusions occurs without overt 
ischemic symptoms (9,10). Interestingly, even when reocclusion occurs in the 
absence of clinical reinfarction, impaired left ventricular contractile recovery 
has been demonstrated (11). In contrast, patients with sustained patency showed 
improvement in left ventricular ejection fraction, a key correlate of both short- and 
long-term outcome (12). 
To date only one study after fibrinolysis demonstrated the adverse prognostic 
consequences of late reocclusion over a 6-year follow-up period, independent 
of left ventricular function. Reocclusion was assessed 6 months after routine 
angioplasty, performed 10 days after fibrinolysis (10). Other studies on the impact 
of an open artery reported contradicting findings, and included a heterogeneous 
population of patients with persistently occluded and reoccluded infarct arteries, 
both with and without prior reperfusion therapy (13). 
In light of the renewed interest in the concept of late coronary patency (13), we 
studied the impact of 3-month coronary patency on 10-year cardiac survival, 
adjusted for left ventricular ejection fraction, in a well defined population of 
myocardial infarction patients with a patent infarct artery 24 hours after fibrinolysis, 
in whom an ischemia-guided revascularization strategy was followed.
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Methods
Protocol
The APRICOT-1 study protocol has been reported in detail previously (6). In brief, 
300 patients < 71 years old with chest pain lasting > 30 minutes and < 4 hours, and 
0.2 mV ST-segment elevation in at least 2 contiguous leads on the electrocardiogram 
(ECG), received fibrinolysis for suspected myocardial infarction followed by 20,000 
U of intravenous heparin/24h. In the case of clinical and/or electrocardiographic 
signs of reperfusion, clinically stable patients were asked informed consent to 
undergo coronary angiography within 48 hours after fibrinolysis. Patients with a 
patent infarct artery, defined as grade 1 to 3 stenosis according to the European 
Cooperative Study Group (ECSG) criteria (Table I), were eligible for the study. 
Sixteen patients were retrospectively excluded for not having a patent infarct artery 
at baseline angiography according to the blinded angiography committee.
The 284 patients with a patent infarct artery were randomly allocated to one of three 
arms: blinded treatment with either 325 mg of aspirin or placebo, or open-label 
coumadin including continued heparinization until the target INR (2.8-4.0) was 
reached. Symptom-limited bicycle stress testing according to the local hospitals’ 
protocol was performed at discharge or before the first out patient visit, planned at 
4-6 weeks after admission. By protocol, revascularization was only to be performed 
for recurrent ischemia refractory to maximal anti-ischemic medication. 
Cardiac catheterization
Follow-up angiography was scheduled at three months to assess reocclusion, 
defined as a grade 4 or 5 stenosis. If coronary angioplasty was performed before the 
planned repeat angiography, the patency status of the infarct artery before dilatation 
was scored as follow-up endpoint. 
Left ventricular ejection fraction was calculated from the 300 right anterior 
oblique ventriculogram by the area-length method. One of the participating 
centers did not routinely perform ventriculography. In 36 cases ejection fractions 
at angiographic follow-up were not available. In 15 of these data were retrieved 
and/or retrospectively assessed (M.B./F.W.A.V.); information from the medical chart 
and ejection fractions determined otherwise (echocardiography, nuclear imaging) 
were used in the case angiograms were not available and/or angiographic ejection 
fraction data were not reported. 
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Clinical follow-up
Ten-year survival data were collected from medical charts, municipal registries, or 
by telephone contact with the patient, relatives or the general practitioner. Cardiac 
mortality was defined based on the information of the treating physician, and only in 
the case of a confirmed cardiac diagnosis. An instantaneous death, for which the cause 
could not be determined with certainty, was scored as a death of cardiac origin. 
Confirmed vascular deaths (strokes, aneurysms, dissections, pulmonary embolisms) 
were not considered as cardiac death. If the cause was unknown/uncertain and 
death did not occur instantaneously it was classified as ‘cause undetermined’. 
Statistics
Statistical analysis was performed with SPSS 11.0 (SPSS Inc. 2001, Chicago, USA). 
Differences between continuous variables were compared using the Student’s t-
test and Mann-Whitney-U-test whenever appropriate. Comparisons of proportions 
between groups were performed with the χ2-test. Statistical significance was defined 
as a two-sided p-value < 0.05. 
Long-term survival analysis was performed according to Kaplan and Meier, using 
the log-rank test for a univariate comparison between patients with coronary 
patency at follow-up angiography and those with a reoccluded infarct artery. 
Multivariable Cox-regression analysis using forward logistic regression was used to 
determine the association between infarct artery patency at follow-up angiography 
and 10-year cardiac survival. Variables studied were baseline characteristics that 
were imbalanced between the study groups (p < 0.10, see Results) and variables 
with a univariate association with 10-year cardiac survival (p < 0.10, see Results). 
Infarct artery, left ventricular function and age were prospectively chosen to be 
included, irrespective of the corresponding p-value.
Table 1 European Cooperative Study Group classification
Stenosis grade
0 Normal
1 < 50% diameter stenosis
2 50% to 90% diameter stenosis
3 91% to 99% diameter stenosis, complete filling within 3 cycles
4 91% to 99% diameter stenosis, no complete filling within 3 cycles
5 Total occlusion with or without collateral filling
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Results
Of the 284 patients who had a patent infarct artery 24 ± 14 hours after fibrinolytic 
therapy, 248 (87%) underwent follow-up angiography performed 75 ± 31 days 
later. Refusal to undergo the second angiography was reported in 28 of 36 cases; 
two patients died and the other six patients had coronary bypass surgery. Patients 
without follow-up angiography were more often female (31% vs. 17%, p < 0.05), 
older (60 ± 7 vs. 56 ± 9 years, p < 0.01) and more often had a history of myocardial 
infarction (17% vs. 6%, p < 0.03). 
Reocclusion was observed in 29% of patients, dividing the present study population 
in 71 with reocclusion and 177 with sustained infarct artery patency at follow-up 
angiography. During follow-up a total number of 59 deaths was observed, 40 of 
which were cardiac, 18 were non-cardiac and 1 was unclassifiable (in the group 
with sustained patency). In all but one of the surviving patients more than 10-year 
follow-up was available (99.6%). In total, clinical follow-up was available for 9.0 
± 2.4 years, without a difference between groups. Baseline characteristics of both 
groups are presented in Table 2. 
Infarct artery patency and cardiac survival
Overall, 21 deaths were observed in the reocclusion group, and 38 in the group 
with sustained patency. All-cause 10-year survival did not differ significantly: 70% 
vs. 79% (p = 0.16). Cardiac 10-year survival rates were lower in patients with 
reocclusion: 73% versus 88%, respectively (Fig. 1, log-rank p < 0.01). Table 3 
shows the impact of reocclusion according to infarct location and left ventricular 
function. Also in the case of infarctions related to the right coronary artery, a marked 
difference in cardiac survival was observed: 77% vs. 91% (p=0.06). The negative 
prognostic impact of reocclusion was observed both in patients with and in those 
without an ejection fraction < 40%. Also in the case of an ejection fraction > 50% 
this adverse effect was apparent: 10-year cardiac survival was 76% in those with 
reocclusion (n=38) and 90% in patients with sustained patency (n=107; p < 0.05).
Of the 71 patients with reocclusion 33 (47%) were asymptomatic between 
angiograms (no reinfarction, unstable angina, or angina with positive stress 
testing). Their 10-year cardiac survival rate was 73% as compared to 85% for the 
asymptomatic patients with an open infarct artery (Fig. 2, log-rank p < 0.03). 
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Revascularizations
In 14 patients reocclusion was detected due to clinically driven angiography, before 
the scheduled 3-month angiography. In all angioplasty was performed, which was 
unsuccessful in two. One of these patients was successfully revascularized with a 
subsequent CABG. 
In 12 patients from the group with sustained patency angiography was performed 
earlier than scheduled. In all angioplasty was performed. Two procedures 
were unsuccessful, and one was followed by a CABG resulting in a successful 
revascularization.
If these patients were analyzed according to the status of the infarct artery after 
the revascularization (CABG = restored patency), the respective 10-year cardiac 
survival rates would have been 72% for the “reocclusion” group (n=59) and 87% 
for the group with “sustained/restored patency” (p = 0.01). 
Prognostic impact of infarct artery patency and left ventricular function
By univariate comparison age, previous myocardial infarction, multivessel disease 
and a left ventricular ejection fraction tended to be associated with lower 10-year 
cardiac survival (Table 4).
These variables were studied in a multivariable Cox-regression model including 
infarct artery patency and infarct artery at angiographic follow-up. Forward logistic 
regression analysis identified reocclusion as predictor of 10-year cardiac death (HR 
2.10; 95%CI 1.10 - 4.02), independent of left ventricular function, which turned 
out as the only other independent prognostic variable (Table 5). When including 
ejection fraction as dichotomous variable, the corresponding hazard ratios for 10-
year cardiac death were 2.18 (95%CI 1.14 - 4.17) for reocclusion and 2.10 (95%CI 
0.99 - 4.47) for an ejection fraction < 40%. 
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Table 2 Clinical and angiographic characteristics at 3-month angiography
Sustained Patency
n = 177
Reocclusion
n = 71
Men 138 (81%)   62 (87%)
Age (years) 56 ± 9 57 ± 9
History of MI* 11 (6%)    4 (6%)
Antithrombotic therapy:
  Aspirin   70 (40%)   23 (32%)
  Coumadin   57 (32%)   24 (34%)
  Placebo   50 (28%)   24 (34%)
Clinical status:
  Symptomatic   32 (18%)   38 (53%)
  Asymptomatic 145 (82%)   33 (47%)
Infarct-related artery:
  LAD   71 (40%)   34 (48%)
  LCX   28 (16%)   11 (15%)
  RCA   78 (44%)   26 (37%)
Single vessel disease 106 (60%)   36 (51%)
Ejection fraction% 55 ± 11 
(n=158)
51 ± 12 
(n=69) 
  ≤ 40%   17 (11%)   14 (20%)
  ≤ 50%   51 (32%)   31 (45%)
Data are presented as the number (%) of subjects for discrete variables, and as mean ± SD for 
continuous variables
* Not including the index infarction related to inclusion in APRICOT-trial
MI = myocardial infarction; LAD = left anterior descending artery; LCX = left circumflex coronary 
artery; RCA = right coronary artery
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Figure 1: Impact of reocclusion on 10-year cardiac survival after fibrinolysis for 
 ST-elevation myocardial infarction.
Table 3 Prognostic impact of late coronary patency for infarct site and 
 left ventricular function 
Coronary patency and 10-year cardiac survival in subgroups
Variable
Patency
(n = 177)
Reocclusion
(n=71) p Value Interaction-p
Infarct Artery
  LAD (n=105) 85% 68% 0.03
ns
  nonLAD (n=143) 89% 78% 0.09
  Left (n=144) 85% 71% 0.04
ns
  Right (n=104) 91% 77% 0.06
Ejection Fraction
  ≤ 40% (n=31) 82% 57% 0.08
ns
  > 40% (n=196) 88% 78% 0.08
Survival percentages as determined by Kaplan and Meier, compared by log-rank.
LAD = left anterior descending artery; Left= LAD and left circumflex coronary artery;
Right = right coronary artery 
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Figure 2: Impact of reocclusion on 10-year cardiac survival after fibrinolysis in patients 
 without ischemic symptoms at the time of angiographic follow-up.
Table 4 Univariate associations with 10-year cardiac death
Cardiac death
(n = 40)
No cardiac death
(n = 208) p Value
Age (years) 58 ± 9 56 ± 9 0.09
Previous MI 13%   5% 0.02
Multivessel disease 55% 40% 0.06
Infarct Artery
  LAD 53% 40% 0.13
  Left 68% 56% 0.16
Ejection Fraction (%) 50 ± 14 
(n = 37)
55 ± 11 
(n = 190)
0.05
  ≤ 40% 24% 
(n = 9)
12% 
(n = 22)
0.08
  ≤ 50% 49% 
(n = 18)
34% 
(n = 64)
0.10
LAD = left anterior descending artery; Left= LAD and left circumflex coronary artery 
MI = myocardial infarction
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Table 5  Independent predictors of 10-year cardiac death
 Hazard Ratio 95% CI p Value
Age per year 1.04 0.99 - 1.08 0.06
Ejection Fraction % (continuous) 0.97 0.94 - 0.99 0.03
Reocclusion 2.10 1.10 - 4.02 0.03
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Discussion
This 10-year clinical follow-up report on 248 ST-elevation myocardial infarction 
patients shows that reocclusion in the subsequent 3 months after fibrinolysis is an 
important predictor of long-term cardiac mortality, independent of left ventricular 
function, even in a rather low-risk population of patients.
Late infarct artery patency and long-term survival
Although the prognostic consequences of early infarct artery patency (5) and 
early reinfarction and reocclusion are undisputed (1-3), conflicting data have 
been reported regarding the independent impact of late coronary patency (13). 
Part of this may be related to the fact that single angiogram observations studied 
mixed populations of patients, with either persistently occluded or reoccluded 
arteries, with or without prior reperfusion therapy. When restricted to patients after 
reperfusion therapy, data corroborate well, supporting the concept of late patency 
(9,10,14-16). Importantly, these studies often had paired angiography (9,10,16) and 
reflected the impact of sustained patency versus reocclusion. 
The first study after fibrinolysis that showed an independent relationship between late 
reocclusion and long-term mortality described consecutive patients who underwent 
routine angioplasty about 10 days after fibrinolysis, with reocclusion detected at 6-
month angiographic follow-up (10). In the APRICOT study a rather conservative, 
ischemia-guided revascularization strategy was adopted, with an overall 3-month 
revascularization rate of only 11%. The present findings therefore merely reflect the 
‘natural course’ after fibrinolysis. Extension of our 3-year follow-up report shows 
that reocclusion is not only associated with increased rates of reinfarction and 
revascularization (9), but also with 10-year cardiac mortality. Also after primary 
angioplasty reocclusion has been reported to have independent prognostic impact 
(16), but observational evidence suggests that with the introduction of stenting 
reocclusion is a rather infrequent phenomenon (~6%) (17).
In all three studies, with different reperfusion and subsequent revascularization 
strategies, reocclusion increased mortality by factor 2, with the most pronounced 
effects in patients with anterior infarction and/or impaired left ventricular function 
(10,16). Its adverse impact has now been reconfirmed for patients with good 
ejection fractions (> 50%) after fibrinolysis (10) and extends to patients with right 
coronary artery infarctions in the present report. 
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Adverse consequences of reocclusion for left ventricular function have been noted 
in all studies (6,10,11,16). Although the deleterious impact of clinical reinfarction 
is well-established, our group demonstrated impaired left ventricular recovery even 
when reocclusion occurs in the absence of clinical reinfarction (11). Moreover, 
we demonstrated an increased risk for ventricular dilatation during 5-year 
echocardiographic follow-up (18). Interestingly, both observations after fibrinolysis 
show that at least half of reocclusions occur without ischemic symptoms (9,10), 
and the present analysis underscores the adverse impact of these clinically silent 
reocclusions. Even in patients without ischemic symptoms in the 3 months after 
fibrinolysis, and with reocclusion being merely detected as a result of the systematic 
angiographic follow-up, 10-year cardiac survival was adversely affected. 
As of to date, new treatment regimens have primarily aimed at a reduction in the 
incidence of reinfarction, but our findings underscore the need to expand our 
focus toward predictors of these ‘silent’ reocclusions and corresponding preventive 
strategies. 
Prevention of reinfarction and reocclusion: antithrombotic strategies
With the role of aspirin being undisputed after fibrinolytic therapy (19), several 
alternatives to unfractionated heparin have been tested, such as low-molecular 
weight heparins, the specific Xa inhibitor pentasaccharide and the direct thrombin 
inhibitor hirudin (20-24).
Although all randomized comparisons reported reduced reinfarction rates on 
the new agents (20,22,23), only hirudin was administered for a similar duration 
as unfractionated heparin (24). The other new antithrombotics were often given 
until discharge, reducing reinfarction rates during treatment, but with a catch up 
phenomenon after discontinuation (20,22).
The angiographic trials showed higher patency rates at discharge after prolonged 
anticoagulation with the new agents when compared to a regimen of 48-72 hours 
of unfractionated heparin (21,22,23). These clinical and angiographic observations 
suggest that to prevent reinfarction and to improve patency rates a prolonged 
antithrombotic regimen is mandatory.
The results of the APRICOT-2 trial support this hypothesis with a 40-50% reduction 
in 3-month reocclusion after a prolonged, combined antithrombotic regimen (8). 
Now that several clinical trials have demonstrated a benefit of the combination 
of aspirin with medium-high intensity oral anticoagulation (25), oral thrombin 
inhibitors (26) may become a practical alternative. 
 CHAPTER 10 187
As far as additional anti-platelet therapy to aspirin is concerned, the currently 
running CSS-2 trial and the CLARITY-TIMI 28 trial study the impact of the adjunctive 
use of clopidogrel on clinical outcome and predischarge coronary patency, 
respectively. 
Prevention of reinfarction and reocclusion: revascularization strategies
With stenosis severity being one of the few variables consistently reported to be 
associated with reocclusion (1,4,28), more aggressive revascularization strategies 
early after fibrinolysis have been tested. These studies primarily addressed the 
prevention of reinfarction, and did not assess reocclusion. Most trials were 
performed a decade ago, and a routine invasive strategy after successful fibrinolysis 
did not improve clinical outcome, mainly due to high peri-procedural event rates 
(29). These studies do not represent modern cardiology with improved angioplasty 
techniques, stenting and the protective effect of concomitant use of glycoprotein 
IIb/IIIa receptor blockers. The GRACIA-1 trial re-evaluated the safety and feasibility 
of a modern routine invasive strategy within 24 hours after fibrinolysis, though not 
restricted to patients with open infarct arteries, and reported higher patency rates 
and improved left ventricular function at one year (30). Larger trials and long-term 
follow-up are needed to substantiate conclusions regarding the clinical benefit.
Systematic angiography and subsequent elective intervention before discharge 
seems another promising revascularization regimen after ST-elevation MI. In stable 
patients with one vessel disease recurrent angina was reduced, and 5-year follow-
up suggested a positive effect on survival when compared to standard medical 
care (31). Reocclusion was not studied, but sustained infarct artery patency after 
angioplasty and stenting may hypothetically have contributed to the observed 
clinical outcomes.
Late opening of (re)occluded arteries
Although prevention of reocclusion is to be preferred, late recanalization has 
become a new challenge given the improvements in the field of interventional 
cardiology (13). Several potential mechanisms of benefit have been implicated, 
varying from better electrical stability, the possibility of collateral supply to another 
coronary territory and assumed beneficial effects on left ventricular function (32). 
When confronted with an occluded infarct artery at some time point after 
reperfusion therapy it is difficult to differentiate between a persistently occluded 
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and a reoccluded artery. In view of the adverse impact of coronary (re)occlusion, 
reopening might exert a positive effect. Notwithstanding the hypothetical advantages 
of prevention of reocclusion, and of recanalization after reocclusion, it should be 
realized that reocclusion could only be a marker of poor prognosis, and not have a 
direct causal relationship with outcome. 
The randomized trials on late recanalization have so far been underpowered for 
clinical endpoints. Unexpectedly, routine recanalization about 1 month after 
fibrinolysis resulted in a higher incidence of ventricular dilatation (33). In the 
prematurely discontinued DECOPI study (34), 6-month-patency after myocardial 
infarction was significantly better after the invasive strategy (83% vs. 40%), as was 
ejection fraction (43.5% vs. 40.0%). The currently running Occluded Artery Trial 
(OAT) will be the first properly sized randomized trial to address the clinical impact 
of late recanalization (13). 
Limitations
Although the present study population was well defined (all fibrinolysis, open infarct 
artery, participating in angiographic follow-up trial) they form a rather selected 
group of low-risk patients (7). The cardiovascular risk profile and medication were 
not routinely scored during follow-up, and thus, differences between groups can 
not be excluded. Finally, the low mortality rate and relatively modest sample size 
reduced the power of subgroup analyses. 
Conclusions and implications
The present report fuels the interest in the concept that late infarct artery patency 
is an important prognostic factor for long-term cardiac mortality after ST-elevation 
myocardial infarction, independent of left ventricular function. Whereas many 
of the previous trials addressed mixed populations of patients with persistently 
occluded and reoccluded infarct arteries, the APRICOT-trial describes the impact 
of sustained infarct artery patency in the 3 months after fibrinolytic therapy. In 
view of the profound clinical consequences, future strategies should focus on 
the prevention of not only symptomatic, but also asymptomatic reocclusion. A 
combination of more intensive antithrombotic regimens and a more aggressive 
revascularization strategy, with routine stenting and including late recanalizations, 
should become the platform for future research. 
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Epicrise
This thesis has covered various elements in the antithrombotic treatment of 
acute ST-elevation myocardial infarction. We tried to demonstrate the potential 
of angiographic follow-up studies and of trials with long-term clinical follow-up 
to gain further insights with regard to the treatment of ST-elevation myocardial 
infarction. 
The reported observations such as reocclusion in the absence of overt clinical 
symptoms, and its potential prognostic impact, emphasize the importance of 
mechanistic studies initiated by clinicians themselves. The presently more and more 
common routine seems to expeditiously conduct large scale trials, often industry-
initiated, comparing two agents or strategies and restricted to clinical endpoint 
comparisons at 4-5 weeks after infarction. Perhaps under pressure of competing 
firms, it has even occurred that angiographic pilot trials were published later than 
the subsequent clinical trial.
In contrast, the renowned GUSTO-1 trial has offered unique insights in our 
understanding of the treatment, risk-stratification and several pathophysiological 
concepts in ST-elevation myocardial infarction, as it incorporated both a comparison 
on clinical endpoints, including long-term follow-up, and an angiographic 
substudy. 
In the studies reported in this thesis, the university and clinicians initiated the 
projects, using antithrombotic regimens of which the potential consequences for 
the industry sharply contrast with the previously mentioned studies. However, both 
in the field of reperfusion therapy, and with regard to the prevention of recurrent 
thrombotic events, either with antithrombotic agents or by a more aggressive 
revascularization strategy, our observations have provided additional information 
that may affect future research and further improve clinical practice.
Improvements in the field of reperfusion therapy 
Chapter 2 and 3. With the demonstration that 90-minute TIMI grade 3 flow was 
strongly correlated with outcome, many new fibrinolytics have been developed, 
which have all been tested in a moderately sized angiographic trial before a clinical 
trial was undertaken. Unfortunately, the recent large scale clinical trials did not 
incorporate an angiographic substudy to validate the hypotheses based upon 
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the results of the pilot studies. Although various agents with higher angiographic 
patency were tested, mortality rates did not improve. The lack of systematically 
performed angiographic, electrocardiographic and laboratory substudies has 
precluded a thorough analysis for explanations of these findings. 
Perhaps blinded in search of newer, more potent pharmacological agents several 
basic guidelines have not been applied to practice to its full extent. Many patients 
that meet the criteria for reperfusion therapy (fibrinolysis/primary PCI) are not treated 
accordingly. In addition, in-hospital treatment delays are still often trivialized, and 
the potential impact of reducing treatment times is often underestimated. In analogy, 
it has taken over years for prehospital fibrinolysis programs to be implemented on 
a larger scale. 
The MITI trial is one of the best examples that even in the United States of America, 
with a rather strict system of law, these initiatives can be implemented successfully. 
It is often not realized that quantitative review of all randomized trials has 
demonstrated that about 16-18 lives can be saved per 1000 patients treated in the 
ambulance when compared to in-hospital initiation of treatment. These numbers 
are in the same order of magnitude as the benefit achieved by performing primary 
angioplasty in stead of in- hospital fibrinolysis. 
Head to head comparisons between prehospital fibrinolysis and primary 
angioplasty are scarce, and the single randomized trial, which was unfortunately 
prematurely discontinued, reported no difference in outcome. In this trial, a rather 
liberal policy of rescue angioplasty was adopted after fibrinolysis. These findings 
warrant further investigation, given the profound implications this might have for 
the currently existing logistic problems to meet the increasing need for primary 
angioplasty. With reocclusion and reinfarction being more frequent after a rather 
conservative revascularization strategy after pharmacological reperfusion therapy, 
future comparisons to a primary PCI should adopt a liberal intervention strategy 
after pharmacological reperfusion therapy.
Now that time to treatment has also been proven of importance for primary 
angioplasty, and outcome of the procedure has been shown to be dependent of 
preprocedural TIMI grade flow, the concept of facilitated percutaneous intervention 
has been introduced. Appreciating that prehospital fibrinolysis results in an hour 
time gain, and that door-to-balloon times of 60-90 minutes are common practice, a 
combination of prehospital fibrinolysis with subsequent intervention might be the 
optimal pact between pharmalogical and mechanical reperfusion therapy. Several 
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studies with different forms of pretreatment (fibrinolyis, glycoprotein IIb/IIIa receptor 
blockers or a combination of both) have been initiated to test this concept.
Based on these premises, the design of a randomized trial comparing two 
reperfusion strategies in the Nijmegen area is currently under investigation. 
In patients with large infarctions (cumulative ST-deviation of 15 mm or more) 
prehospital randomization is planned after administration of aspirin and heparin to 
either 1. primary angioplasty or 2. fibrinolysis with a subsequent clinically driven 
intervention. 
Need for better adjunctive antithrombotic strategies
Chapter 2, 4, 6,7 and 9. Although early realization of brisk, antegrade coronary 
flow forms a main priority in the acute phase, maintaining an open infarct artery 
afterwards is crucial: Early reinfarction and reocclusion increase the risk of 
mortality by factor 2. Until now, the efficacy of new antithrombotic regimens has 
always been expressed in terms of a reduction in death and reinfarction. With the 
improvements made over the years, the rate of this combined endpoint has been 
markedly reduced and large sample sizes are required to demonstrate significant 
improvements. Incorporation of reocclusion as an endpoint, and studying a 
restricted, but better defined population may tackle part of this problem. 
Notably, this requires paired angiography, and to study reocclusion randomization 
will have to take place after TIMI grade 3 flow in the infarct artery has been 
demonstrated. Given its incidence of 7-10% at the time of discharge and 20-30% 
in the 3 months after myocardial infarction, studies could be markedly reduced 
in sample size when considering 30-day reinfarction rates of 4-5%. Appreciating 
the adverse effects on left ventricular function, this could also be assessed as an 
‘indirect’ endpoint given its potential impact on late survival. For further validation, 
subsequent long-term clinical follow-up could be performed.
If follow-up angiography is considered practically difficult, a second possibility 
is to restrict comparisons of new antithrombotic regimens to patients in whom 
reinfarction is more likely to occur, for example those with electrocardiographic signs 
of reperfusion and demonstrated viability in the infarct area. In the recently performed 
studies large numbers of patients had to be included, because much of the potential 
reductions of new agents on recurrent thrombotic events is diluted either due to a 
considerable proportion of patients in whom reperfusion is not achieved, or to a lack 
of viable myocardium in the area supplied by the infarct artery. 
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These strategies may allow moderately sized studies to give a first impression as 
to the potential of new antithrombotic agents. Another aspect that deserves more 
thorough investigation as compared to recently introduced agents concerns the 
kinetics of the new agents, especially in the elderly and patients with impaired 
renal function. Subsequently, larger scaled clinical trials, with angiographic and 
laboratory substudies could be restricted to the agents that showed promising 
findings in the smaller, more conceptual studies. 
Another important aspect concerns the duration of the compared antithrombotic 
regimens, and the definition of the outcome measure used. As of to date, no 
convincing evidence has been published that low-molecular weight heparins are 
more potent than unfractionated heparin. The perception that these agents are 
superior is caused by two factors. First, the new agents were administered until 
discharge, as compared to 48-72 hours of unfractionated heparin. Second, the 
primary endpoint of the trials did not always incorporate reinfarctions occurring 
after discharge. If these are taken into account a catch-up phenomenon after 
discontinuation is observed for patients on the low-molecular-weight heparins. 
For the design and interpretation of future trials, these factors should be taken into 
account. Moreover, more laboratory substudies are warranted to further elucidate 
the complex interplay of the coagulation factors, platelet activation and their 
association with future events. 
In line with the observations from APRICOT that recurrent thrombotic events and 
reocclusion are still frequent after successful fibrinolysis, one of our future projects 
will address the issue of ‘aspirin resistance’. Despite a marked 20% relative risk 
reduction as result of the introduction of this agent after acute coronary syndromes, 
four out of five recurrent events are still not prevented. The prediction of which 
patients are at increased risk of subsequent events, and the insight into the 
underlying pathophysiological mechanism can still be futher improved. 
The Study on Asprin Resistance in major Antithrombotic (SARA) trials has been 
designed to further unravel pathophysiological, clinical and angiographic aspects, 
and to come to a more sound definition of this rather ill-defined phenomenon. 
Routine vs. ischemia-guided revascularizations 
Chapter 8. Although previous studies on a routine invasive strategy did not result in 
better outcomes than an ischemia-guided approach, a re-evaluation in the current 
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era of improved interventional techniques is awaited. Periprocedural events can 
now be reduced by as much as 50% with the concomitant use of glycoprotein 
IIb/IIIa receptor blockers, and equipment has improved. With the observations 
from ischemia guided angiographic follow-up studies that reinfarction may not 
be predicted by the severity of the residual lesion, a mere re-do of the previous 
trials seems too restricted. In these studies death and reinfarction were the primary 
endpoint(s), which are relatively infrequent after successful fibrinolysis. Moreover, 
angioplasty was often not performed in the case of intermediate residual lesions.
Angiographic patency at some time point, or, preferably, reocclusion should be 
incorporated as (part of the) endpoint, as well as left ventricular function. It remains 
to be determined whether the expected benefits of such a strategy of routine 
revascularization outweigh the also incorporated procedural risks. Irrespective 
of the outcome of the trials, they will provide insight into which patients are at 
increased risk for periprocedural events in the current era of improved interventional 
techniques. In the case a routine invasive strategy may not prove beneficial, these 
data may allow a risk-benefit stratification which could form the basis for a future, 
elective, risk stratified invasive approach. 
The APRICOT-3 trial will be a mechanistic, angiographic study addressing the 
impact of a routine invasive approach after successful fibrinolysis. Patients with 
an open infarct artery after fibrinolysis will be randomized to a routine invasive 
strategy or an ischemia-guided approach. Reocclusion and left ventricular function 
will be the primary outcome measures, and long-term clinical follow-up will be 
collected.
From angiography to clinical practice
Despite the abovementioned advantages of performing angiographic (sub)studies, it 
is important to realize that this type of research requires specialist knowledge and 
experience, not only because of the (small) chance of complications, but also with 
respect to the design and organization of such a study. 
The type of studyquestion also determines whether angiography is an appropriate 
method to get a first impression of a given intervention. As has been demonstrated 
in this thesis, studies regarding the influence of interventions on (sub)total coronary 
(re)occlusions after ST-elevation myocardial infarction and its impact on prognosis 
can be reliably performed provided the implementation of a sound methodology. 
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Studies describing the impact on the more subtle changes of coronary artery 
disease progression are more difficult to interpret, partly because of the limititations 
inherent to angiography to detect these changes.
In addition, the timing of the second angiography is crucial when recurrent 
coronary thrombosis is studied. If repeat angiography is performed at a standard 
time, valuable information could be lost in patients with a recurrent ischemic 
event before the scheduled angiography. In these patients, the second angiography 
should be performed at the time of the event, or as early as possible afterwards to 
detect a possible coronary (re)thrombosis. Unfortunately, only a few studies follow 
this policy. Various medical interventions (ACE-inhibitor, poly-unsaturated acids) 
that proved cardioprotective in clinical trials did not show a reduction in coronary 
thrombosis in the angiographic trials, probably partly caused by the timing of the 
follow-up angiography. Even prothrombotic agents such as hormone replacement 
therapies were not identified as such in the angiographic trials. It is therefore of 
the utmost importance to carefully consider the study population, the type of 
intervention tested, and the expected effects in the consideration to perform an 
angiographic (follow-up) study. Subsequently, hypothesis testing is required in large 
scale clinical trials. 
If the above mentioned elements are carefully considered, and the study is 
performed by an experienced research group, angiographic (sub)studies can 
certainly contribute to comparisons of interventions, improvement of our 
understanding of underlying pathophysiological mechanisms, and refinement 
of postinfarction risk stratification to come to a more individualized treatment of 
patients after myocardial infarction.
In view of the above, it can be concluded that with the development of three lines 
of research new opportunities have been created towards the further improvement 
of the treatment after myocardial infarction, based on the insights that will be 
obtained through conduction of these projects. Appreciating that not all treatments 
are as successful for everyone, and that both with respect to efficacy and safety 
different risk-benefit profiles should be distinguished for each patient individually, 
our search should be aimed at a more individualized approach. In anticipation, 
the design and protocol of future research will have to be designed accordingly, to 
start and provide a sound background to support and optimize such an approach 
in daily clinical practice.
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Summary
After a general introduction in Chapter 1 explaining some basic background 
information with respect to acute coronary syndromes and more specific terms used 
throughout the manuscript, the outline of the thesis forms a concise description of 
the study questions and briefly addresses their clinical and scientific impact.
Chapter 2 describes the current standard of care for the pharmacological treatment 
of acute ST-elevation myocardial infarction. Moreover, it forms a brief review of the 
history of developments in this field and provides insight into the pathophysiological 
rationale of these new treatment regimens. 
Reperfusion therapy. Despite a strong relationship between 90-minute TIMI-grade 
3 flow and 30-day mortality, new reperfusion regimens with higher patency rates 
did not result in improved survival. An example forms the combination of half-
dose lytic with full-dose glycoprotein IIb/IIIa receptor blocker therapy. Moreover, 
this regimen was expected to reduce bleeding rates, intracranial hemorrhage in 
particular, but resulted in increased intracranial bleeding in the elderly, whereas in 
the younger patients the expected reduction was observed.
Adjunctive antithrombotics. New anticoagulant therapies that were tested against 
unfractionated heparin after fibrinolysis seemed to do better in the prevention 
of reinfarction and recurrent ischemia, and were therefore often reported to be 
superior to unfractionated heparin. In fact, a strategy of prolonged anticoagulation 
until discharge with the new agents resulted in better outcomes when compared to 
48-72 hours of intravenous unfractionated heparin. With a ‘catch-up phenomenon’ 
after discontinuation of the new agents, 30-day and 1-year reinfarction rates were 
similar to those after unfractionated heparin. Only with hirudin, administered for 
a similar duration as unfractionated heparin, 30-day reinfarction rates have been 
reduced after fibrinolysis with streptokinase. Angiographic studies after fibrinolysis 
showed comparable 90-minute patency to unfractionated heparin, and often 
suggested higher patency and lower reocclusion rates at 5-7 day angiography after 
prolonged anticoagulation with the new agents. 
These findings suggest that ‘the ceiling’ of pharmacological reperfusion may 
be reached, and underscore the need of a prolonged combined antithrombotic 
regimen of both anti-platelet and anticoagulant therapy to prevent recurrent 
thrombotic events in the first weeks to months after myocardial infarction.
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Chapter 3 describes a randomized comparison of two antithrombotic treatment 
regimens for ST-elevation myocardial infarction: prehospital versus in-hospital 
fibrinolytic therapy. As part of the study protocol, with the prehospital care team 
screening the patient’s eligibility, the in-hospital treatment times were markedly 
reduced, which resulted in a smaller difference in time to treatment between the 
two strategies than was anticipated, i.e. 32 minutes in stead of the often reported 
50-60 minutes. 
Although early outcome was not improved according to the randomized comparison, 
patients treated within 70 minutes after symptom had lower mortality and infarct 
size, and a higher global ejection fraction when compared to those treated later. 
These differences were not explained by differences in other characteristics but 
time to treatment. In the present long-term follow-up report, 2-year survival rates 
were 89% for prehospital and 91% for in-hospital fibrinolysis. The initial survival 
benefit for patients treated within 70 minutes was clinically sustained up to 2 years 
(98% vs. 89%) but was not statistically significant in the longer term. Event-free 
survival (clinical course free of death, reinfarction, revascularization, admission for 
angina, congestive heart failure) did not differ either. Moreover, time to treatment 
was not found to be an independent predictor of long-term outcome, neither as 
a continuous variable, nor as a dichotomous variable. Other factors such as age, 
a history of congestive heart failure or bypass surgery, or the need for coronary 
surgery after inclusion were independent predictors of long-term outcome.
These findings show that in the long-term many other factors determine outcome 
after fibrinolytic therapy. In addition to the clinical variables mentioned above, 
maintenance of a patent infarct-related artery after fibrinolysis could also be a 
likely predictor of outcome. This is addressed in Chapter 4, being the first report 
after fibrinolysis to address the long-term implications of reocclusion occurring in 
patients who survived the first 24-48 hours after reperfusion therapy and had an 
open infarct artery. A previous report, describing early reocclusion in patients after 
90-minute angiography had demonstrated an increased risk of in-hospital mortality. 
In the APRICOT-trial no difference in 3-year survival was observed (> 90% in both 
groups), despite the fact that reocclusion, even in the absence of clinical reinfarction, 
was shown to have detrimental impact on the recovery of left ventricular function, 
the most important prognosticator after infarction. Patients in whom reocclusion 
was observed showed an increased risk for reinfarction (23% vs. 5% at one year) 
 CHAPTER 11 207
and ischemia-driven revascularizations. The difference in outcome occurred in the 
first months after myocardial infarction and was sustained in the long-term when 
compared to patients without reocclusion in the 3 months after fibrinolysis.
Although quantitative overviews have suggested that therapy with aspirin reduces 
reocclusion of the infarct artery, little is known with respect to the potential impact 
on coronary artery disease progression in the non infarct artery, which is postulated 
to be a more subtle process, which involves phasic, often subclinical, non-occlusive 
thrombus formation. In Chapter 5 a randomized placebo controlled 1-year 
angiographic follow-up study addressing the influence of anti-platelet therapy on 
coronary artery disease progression in the non infarct related arteries is presented 
in patients after ST-elevation myocardial infarction. At about one month after 
myocardial infarction, patients with an open infarct-related artery were randomized 
to either continue the combination of aspirin (50mg) and dipyridamole (400mg) or 
to matching placebo. A total of 1436 non infarct artery coronary segments were 
studied. The average change in QCA-parameters (MLD, diameter stenosis, mean 
luminal diameter) did not differ between groups. In a semi-quantitative analysis, 
the proportion of patients with progression was not affected by the combined 
anti-platelet regimen either (68% and 64%). Angiographic progression did not 
predict future clinical outcome. These findings underscore the previously suggested 
concept that anti-platelet therapy may not be effective in the often subclinical, 
subtle process of thrombusdeposition and organization of the plaque, as previously 
suggested in animal studies. It seems that the impact of anti-platelet therapy may be 
restricted to the prevention of acute events due to (sub)total occlusive thrombosis. 
The randomized angiographic follow-up trial APRICOT-2 is presented in Chapter 
6. The adverse clinical impact of reocclusion and its incidence of 25-30% in 
the first year after fibrinolysis calls for better preventive strategies, one of which 
is a more potent antithrombotic regimen. In 274 patients with TIMI-3 flow at 
inclusion angiography, performed within 48 hours after fibrinolysis, a prolonged, 
combined antithrombotic regimen of anti-platelet and anticoagulant therapy 
significantly reduced 3-month reocclusion, and improved recurrent ischemic 
events. Reocclusion was reduced from 28% to 15%. Reinfarction (8% vs. 2%) 
and ischemia-driven revascularizations (31% vs. 13%) were also significantly 
reduced on the combined regimen. The control antithrombotic regimen consisted 
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of 48 hours of intravenous heparin and the indefinite use of aspirin. The combined 
regimen consisted of the start of coumadin after the inclusion angiography, with 
heparinization until the target INR of 2-3. Consequently, heparinization lasted 66 
hours longer in the patients allocated to coumadin (110 vs. 44 hours). Bleeding 
rates were higher on the prolonged combined antithrombotic regimen (5% vs. 3%), 
but no intracranial hemorrhages were observed. This conceptual study provided a 
mechanistic rationale to further investigate the role of prolonged anticoagulation 
after fibrinolytic therapy. 
In Chapter 7 the collective evidence of all randomized trials assessing the impact 
of the addition of oral anticoagulation to aspirin is reviewed. Given the prolonged 
hypercoagulable state after an acute coronary event, and the association of both a 
first and a recurrent acute coronary syndrome with the level of factor VII, the use 
of oral anticoagulation therapy seemed a promising intervention to further improve 
prognosis. Moreover, the fact that the risk reductions of oral anticoagulation therapy 
in placebo controlled trials was of the same magnitude as the reductions observed 
by aspirin underscored the potential of this regimen, especially now that lower 
doses of aspirin are used and the international normalized ratio (INR) has been 
introduced. 
Importantly, regimens that merely focused on factor VII, and did not, or only slightly 
affected the INR, were not successful in improving outcome. A fixed, low-dose 
of vitamin K antagonists was used and monitoring was not necessary. CARS and 
LOWASA are examples of these trials. Although anticoagulant with respect to an 
effect on factor VII, these regimens did not have an antithrombotic effect: Bleeding 
increased, but thrombotic events were not reduced. 
Other trials investigated the effect of dose-adjusted anticoagulant strategies that 
aimed to effect the generation of thrombin. With a reached INR > 2.0 dose-adjusted 
administration of vitamin K antagonists reduced recurrent thrombotic events, albeit 
at the expense of an increased risk of, primarily, minor bleeding. Intracranial 
hemorrhage rates were not increased. These findings in the clinical trials are in line 
with the observations in APRICOT-2. The Dutch ASPECT-2 trial and the Swedish 
WARIS-2 study are the most important clinical trials studying this regimen. Dose-
adjusted anticoagulation with a reached INR < 2.0 did not result in better outcome 
either, as demonstrated in the CHAMP-trial.
Despite the evidence of a clinical benefit, the practical implementation of this 
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combined treatment strategy largely depends on a well organized infrastructure of 
INR monitoring. In view of the promising efficacy, the results of new anticoagulant 
agents such as the direct thrombin inhibitor ximelagatran with a more predictable 
effect, obviating the need for monitoring, are eagerly awaited. 
Another strategy that has been prosposed in the prevention of reocclusion is a more 
aggressive approach with respect to revascularizations after fibrinolysis. In Chapter 
8 we studied the relationship between a severe residual stenosis after fibrinolysis 
and the chances for reocclusion and reinfarction, respectively. In APRICOT-1 a 
rather conservative, ischemia-guided revascularization strategy was followed, with 
only 11% revascularizations at 3 months. This offered the unique opportunity to 
study the ‘natural course’ of reocclusion and recurrent thrombotic events after 
fibrinolysis. Rationale behind the randomized studies on the impact of a routine 
invasive strategy was that routine angioplasty in patients with a severe residual 
stenosis would reduce reocclusion, and with it, reinfarction. Yet, an angiographic 
follow-up study performed in the same era questioned the relationship between a 
severe stenosis and reinfarction. In view of these observations we also studied this 
relationship in APRICOT-1.
With reocclusion being a predictor of reinfarction and recurrent events, the 
studypopulation was dichotomized according to the residual stenosis severity that 
best predicted reocclusion, i.e. a QCA-stenosis of 62.7%. Patients with a severe 
residual lesion (> 62.7%) had a reocclusion rate of 40% (47/118), as compared to 
16% (20/122) for patients with a mild-moderate culprit stenosis. Notably, death 
and reinfarction rates did not differ between groups: 6% (7/118) vs. 9% (11/122). 
This is explained by the fact that in the case of reocclusion on a severe lesion this 
more often occurs without clinical reinfarction (15%; 7/47) when compared to 
reocclusion on a low-medium grade residual stenosis (55%; 11/20). 
Whereas ROC-analysis was able to detect an optimal predictive residual stenosis for 
reocclusion, this was not the case for reinfarction. This suggests that periprocedural 
events rates may not have been the only explanation for the lack of benefit of 
the randomized trials on a routine invasive strategy. The fact that many of these 
angioplasty trials primarily focused on dilatation of severe lesions may also have 
contributed. 
Our observations are in line with the only previous angiographic follow-up study 
showing an absence of association between stenosis severity and outcome after 
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successful thrombolysis, and extends these findings in the long-term. In the event 
of a future re-evaluation on the potential effect of a routine invasive strategy, these 
findings carry important implications for the design and protocol of such a study.
Chapter 9 is the first report on the impact of late reocclusion on long-term survival 
after fibrinolytic therapy in the setting of an ischemia-guided revascularization 
strategy. Whereas the prognostic consequences of early patency, reocclusion and 
reinfarction are undisputed, conflicting findings have been reported on the impact 
of late coronary patency. 
Of the 248 patients of the APRICOT-1 trial 71 had reocclusion at 3-month follow-
up angiography. Their 10-year cardiac survival rate was significantly lower when 
compared to 177 patients with sustained patency: 73% vs. 88%.
Interestingly, even in patients without ischemic symptoms until the time of the 
second angiography (no reinfarction,unstable angina or stable angina with positive 
stress testing) this difference was apparent: 73% vs. 85%. Thus, even in patients 
without recurrent ischemic symptoms, in whom reocclusion was merely detected 
as a result of systematic angiographic follow-up, reocclusion has adverse prognostic 
influence. The impact of reocclusion was independent of left ventricular function, 
which fuels the interest in the concept of late coronary patency. 
This extension of our previously published 3-year follow-up project (Chapter 4), 
underscores the need to prevent late reocclusion, not only to reduce recurrent 
ischemic events, but also to improve cardiac survival. In contrast to previous new 
interventions the focus should be both on reinfarction and on clinically silent 
reocclusions. A combination of more potent antithrombotic regimens, with a more 
aggressive revascularization strategy at some timepoint after fibrinolysis seem to 
be the key elements for future studies to optimize outcome after pharmacological 
reperfusion therapy.
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Epicrise
Dit manuscript heeft verschillende elementen van de antitrombotische behandeling 
van het acute ST-elevatie infarct bestreken. Daarnaast is geprobeerd inzicht te 
verschaffen in welke mate angiografische follow-up studies van belang kunnen 
zijn voor het verkrijgen van nieuwe inzichten omtrent de behandeling van het ST-
elevatie infarct, zeker wanneer dit gecombineerd wordt met het vervolgen van de 
kliniek op de lange termijn.
Beschreven observaties, zoals het optreden van reocclusie in de afwezigheid van 
een klinisch reinfarct, en de mogelijke prognostische consequenties, benadrukken 
het belang van mechanistische studies geinitieerd door clinici zelf. Het lijkt 
tegenwoordig steeds meer gangbaar om snel grootschalige, veelal door de industrie 
georganiseerde studies te verrichten, vaak beperkt tot een vergelijking op klinische 
eindpunten op 4-5 weken na het infarct. Wellicht onder druk van de concurrentie, 
komt het zelfs voor dat angiografische voorstudies later worden gepubliceerd dan 
de daarop volgende klinische trials.
In tegenstelling tot de voornamelijk op klinische eindpunten gerichte studies, 
was het vooral een trial als de alom bekende GUSTO-1 studie die daadwerkelijk 
heeft bijgedragen aan ons inzicht in de behandeling, risicostratificatie en 
pathofysiologische concepten op het gebied van het ST-elevatie infarct. Deze 
studie had alle bovengenoemde elementen geincorporeerd in het protocol: naast 
een grootschalige vergelijking op klinische eindpunten, met daarbij lange termijn 
follow-up, werd ook een belangrijke angiografische substudie ingebouwd. 
Bij de in dit proefschrift beschreven studies lag het initiatief bij de betrokken 
universiteit en clinici. De studievragen behelzen antitrombotische regimes 
waarvan de mogelijke consequenties voor de industrie in schril contrast staan 
met de hiervoor beschreven studies. Echter, zowel op het gebied van reperfusie 
therapie, als wat betreft de preventie van terugkerende trombotische events 
(intensievere antitrombotische therapie/aggressiever revascularisatiebeleid) leveren 
onze observaties aanvullende informatie voor toekomstig onderzoek en klinisch 
handelen.
Verbeteringen op het gebied van reperfusietherapie 
Hoofdstukken 2 en 3. Met het bekend worden van de sterke associatie tussen TIMI-
3 flow op 90 minuten na fibrinolyse en de overleving in de eerste maand na het 
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infarct, zijn er vele nieuwe middelen ontwikkeld die in een angiografische studie 
van bescheiden grootte werden uitgetest voordat een klinische studie werd verricht. 
Helaas is bij geen van de recentere grootschalige klinische reperfusie studies de 
moeite genomen een angiografische substudie in te plannen ter verificatie van de 
hypotheses gevormd op basis van angiografische pilotstudies. Hoewel verschillende 
middelen met angiografisch veelbelovende uitkomsten zijn getest, werd klinisch 
geen mortaliteitswinst waargenomen. Het gebrek aan systematisch verrichte 
angiografische, electrocardiografische en/of laboratorium substudies heeft er mede 
toe bijgedragen dat een diepgaande analyse naar een verklaring van het uitblijven 
van klinische winst met de nieuwe middelen niet mogelijk is. 
Wellicht verblind in de zoektocht naar een nieuwer, potenter farmacologisch 
reperfusieregime, werden bepaalde basale richtlijnen in de praktijk niet optimaal 
gevolgd. Een nog immer belangrijk deel van de patiënten dat volgens de richtlijnen 
in aanmerking komt voor reperfusietherapie (fibrinolyse/primaire PCI) wordt niet 
als zodanig behandeld. Ook de vertragingen in het ziekenhuis voordat behandeling 
wordt geinitieerd worden vaak nog gebagatelliseerd, terwijl de potentiele impact 
van het reduceren van deze vertragingen vaak wordt onderschat. Analoog hieraan 
heeft het de nodige jaren gekost voordat prehospitale fibrinolyse programma’s op 
grotere schaal werden geimplementeerd.
De MITI trial is één van de beste voorbeelden dat zelfs in de Verenigde Staten, met 
een straf en gecompliceerd juridisch stelsel, dit soort initiatieven met succes kunnen 
worden geimplementeerd. De te behalen winst is niet gering: uit kwantitatieve 
analyse van gerandomiseerde studies is gebleken dat per 1000 in de ambulance 
behandelde patiënten zo’n 16-18 levens kunnen worden gered in vergelijking met 
in het ziekenhuis geinitieerde fibrinolyse. De winst bereikt met prehospitale in 
plaats van in-hospitale initiatie van fibrinolyse is in dezelfde orde van grootte als 
bereikt met een primare PCI in plaats van in-hospitale fibrinolyse.
Directe vergelijkingen tussen prehospitale fibrinolyse en een primaire PTCA 
zijn schaars, en de enige gerandomiseerde studie tot dusver, helaas prematuur 
beeindigd, liet geen verschil in uitkomst zien. In deze studie werd een liberaal 
rescue beleid gevoerd na fibrinolyse. Deze bevindingen vereisen nader onderzoek, 
mede gezien de consequenties die de uitkomst van een dergelijke trial op de huidige 
logistieke problemen zou kunnen hebben ivm de toenemende vraag naar primaire 
PCI’s. Aangezien de eindpunten reinfarct en reocclusie nu eenmaal frequenter zijn 
in geval van een relatief conservatief revascularisatiebeleid na farmacologische 
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reperfusie therapie, zullen toekomstige gerandomiseerde vergelijkingen met een 
primaire PCI een liberaal beleid wat betreft het verrichten van interventies na 
fibrinolyse moeten voorschrijven.
Nu ook voor de prognose na een primaire PCI is aangetoond dat de tijd tot 
behandeling van belang is, net als de flow in het infarctvat bij aanvang van de 
procedure, is het concept van de gefaciliteerde PCI geintroduceerd. Met het uur 
tijdswinst geboekt met prehospitale fibrinolyse, en het feit dat de ‘door-to-balloon’ tijd 
vaak nog 60-100 minuten bedraagt, zou de combinatie van prehospitale fibrinolyse 
met een daarop volgende interventie de optimale pact tussen farmacologische en 
mechanische reperfusie therapie kunnen betekenen. Verscheidende studies met 
varierende vormen van voorbehandeling (fibrinolyse, glycoproteine IIb/IIIa receptor 
blokkade of een combinatie van beide) zijn geinitieerd om dit concept te testen. 
Voortvloeiend uit bovenstaande ontwikkelingen, wordt in onze regio momenteel 
gewerkt aan een protocol gericht op patiënten met grote ST-elevatie infarcten (> 
15 mm ST deviatie) die zich vroeg presenteren. Hierbij wordt gestreefd patiënten 
na toediening van aspirine en heparine prehospitaal te randomiseren naar ofwel 1. 
primare PCI danwel 2. fibrinolyse in de ambulance met daarna een interventie. 
Noodzaak tot betere adjuvante antitrombotische therapie
Hoofdstukken 2, 4, 6, 7 en 9. Hoewel het vroegtijdig realiseren van goede antegrade 
coronaire flow van groot belang is, vormt het openhouden van het infarctvat een 
minstens even grote uitdaging: het optreden van een reinfarct en vroege reocclusie 
verdubbelen het risico op vroegtijdig overlijden. Tot dusver is de effectiviteit van 
antitrombotische regimes altijd uitgedrukt in de mate waarin het eindpunt dood/
reinfarct gereduceerd werd. Met de vooruitgang geboekt in de behandeling van 
het infarct, is de frequentie hiervan dusdanig gereduceerd dat grote aantallen 
patiënten nodig zijn om significante verbeteringen aan te tonen. Wanneer ook 
reocclusie als eindpunt zou worden meegenomen, en als een scherper omschreven 
studiepopulatie zou worden bestudeerd, is het mogelijk met studies van beperktere 
omvang uit te komen. 
Een methodologische vereiste voor onderzoek naar reocclusie is het verrichten van 
twee angiogrammen, waarbij randomisatie plaatsvindt nadat er TIMI-3 flow in het 
infarct vat is aangetoond. Met een incidentie van 7-10% ten tijde van ontslag, en 
van 20-30% in de eerste 3 maanden na het infarct, is het aantonen van een effect 
op reocclusie minder bewerkelijk dan op het eindpunt reinfarct dat in 4-5% van de 
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patiënten wordt gezien in de eerste maand na het infarct. Mede gezien de negatieve 
effecten op de kamerfunctie, zou ook dit als eindpunt gebruikt kunnen worden als 
indirecte maat voor overleving op de lange termijn. Via lange termijn klinische 
follow-up zou dit vervolgens kunnen worden gestaafd. 
Indien follow-up angiografie op praktische bezwaren stuit, is het ook een 
mogelijkheid om vergelijkingen tussen antitrombotische strategieën te beperken tot 
patiënten bij wie het optreden van een klinisch reinfarct waarschijnlijker is. Hierbij 
valt te denken aan patiënten met electrocardiografische tekenen van reperfusie, en 
aangetoonde viabiliteit in het infarct gebied. In de huidige studies wordt veel van 
het potentiele effect van nieuwe middelen op terugkerende trombotische events 
verdund als gevolg van een behoorlijk aantal patiënten zonder reperfusie, of door 
een gebrek aan viabel myocard.
Deze manier van aanpak maakt studies van beperktere grootte mogelijk om een 
eerste indruk te krijgen van de potentiele effecten van nieuwe antitrombotische 
strategieën. In tegenstelling tot onderzoek bij vorige nieuwe medicijnen, zou meer 
aandacht kunnen worden besteed aan de kinetiek van deze middelen bij bepaalde 
patiëntengroepen, zeker omdat ze vaak kort na toediening van fibrinolyse worden 
toegediend. Hierbij zou gedacht kunnen worden aan ouderen en patiënten met een 
verminderde nierfunctie. Ook experimenteel dieronderzoek, een traject dat steeds 
minder uitgebreid wordt bewandeld, zou van toegevoegde waarde kunnen zijn in 
de verdere ontrafeling van het atherosclerotisch en trombotisch proces. Vervolgens 
zouden er grootschalige onderzoeken met angiografische en laboratorium 
substudies verricht kunnen worden met de middelen die in de meer conceptuele, 
mechanistische studies veelbelovend lijken. 
Een ander belangrijk aspect met betrekking tot vergelijking van antitrombotische 
regimes betreft de duur van toediening en het eindpunt waarop de effectiviteit werd 
bepaald. Tot op heden is er geen overtuigend klinisch bewijs dat laag moleculaire 
heparines potenter zijn dan ongefractioneerde heparine. De veronderstelling dat 
deze middelen effectiever lijken wordt veroorzaakt door 2 factoren. Ten eerste is 
dit het gevolg van het feit dat de nieuwe middelen tot ontslag werden toegediend, 
in vergelijking met 48-72 uur ongefractioneerde heparine. Ten tweede werden 
reinfarcten die na ontslag optraden niet altijd meegeteld in het primaire eindpunt. 
Wanneer deze hierin wel betrokken worden, is er geen verschil in reinfarct 
waarneembaar. 
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Voor het ontwerp en de interpretatie van toekomstige studies kunnen dit soort 
factoren mee worden genomen. Bovendien zou door het verrichten van meer basaal 
laboratorium onderzoek in de grotere trials meer inzicht kunnen worden verkregen 
in het complexe proces van interactie tussen stollingsfactoren, plaatjesactiviteit en 
de associatie met terugkerende events. 
Gezien de observaties uit APRICOT, waarin terugkerende trombotische events 
en reocclusie frequent voorkomen na successvolle fibrinolyse, zal één van onze 
toekomstige projecten gericht zijn op het fenomeen ‘aspirine resistentie’. Ondanks 
een 20% relatieve risicoreductie sinds de invoering van aspirine na het infarct, 
kunnen vier van de vijf toekomstige events niet voorkomen worden. Het inschatten 
van welke (groep) patiënten hierop een verhoogde kans hebben kan nog worden 
verbeterd. De Study on Aspirin Resistance in major Antithrombotic (SARA) trials 
is ontworpen om dit proces pathofysiologisch nader te doorgronden en tot een 
gedegener definitie van dit fenomeen te komen op basis van klinisch, angiografisch 
en laboratorium onderzoek.
Routinematig versus een op ischemie gebaseerd interventiebeleid 
Hoofdstuk 8. Hoewel voorgaande gerandomiseerde studies naar het effect van een 
routinematig invasief beleid geen winst ten opzichte van een ‘ischemia-guided’ 
strategie lieten zien, is een re-evaluatie noodzakelijk in het huidige tijdperk van 
verbeterde interventietechnieken. Periprocedurele events kunnen tegenwoordig 
worden gereduceerd met ongeveer 50% met gebruik glycoproteine IIb/IIIa receptor 
blokkade en bovendien is het materiaal verbeterd. Gezien de observaties uit 
‘ischemia-guided’ studies met systematische angiografisch follow-up waarbij de 
kans op een reinfarct niet geassocieerd leek met de ernst van de reststenose, lijkt 
het simpelweg opnieuw uitvoeren van de gerandomiseerde studies van vroeger 
niet bijdragend genoeg. In deze studies werd het eindpunt gevormd door dood en 
reinfarct, terwijl dit na succesvolle fibrinolyse niet frequent voorkomt. Bovendien 
werden intermediaire leasies in de voorgaande onderzoeken vaak ongemoeid 
gelaten.
In analogie aan de studies naar het effect van nieuwe antitrombotische strategieën, 
lijkt ook hier het meenemen van een angiografisch eindpunt (doorgankelijkheid 
van het infarctvat op 6 maanden, reocclusie, kamerfunctie) een aanpassing die niet 
alleen tot een reductie van het benodigde aantal patiënten zal leiden, maar ook 
meer mechanistisch onderzoek mogelijk maakt. 
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Het onderzoek zal moeten uitwijzen of de verwachte voordelen van een 
routinematig revascularisatiebeleid zullen opwegen tegen de ook aanwezige 
procedurele risico’s. 
Onafhankelijk van de uitkomst van de studies, zal er inzicht worden verkregen 
welke patiënten(groepen) een grotere kans hebben op periprocedurele 
complicaties in het huidige tijdperk van verbeterde interventietechnieken. Mocht 
een routinematige invasieve strategie niet succesvol zijn, dan zouden deze data 
een meer op het individu toegespitste risicostratificatie mogelijk kunnen maken, die 
de basis zou kunnen vormen voor een electieve, risico-gestratificeerde, invasieve 
interventiestrategie.
Naar aanleiding van het bovengenoemde, is de gerandomiseerde APRICOT-3 studie 
ontworpen, waarin de waarde van een routinematige invasieve strategie zal worden 
onderzocht bij patiënten met een open infarctvat na fibrinolyse. Reocclusie en 
linkerventrikel functie zullen de primaire eindpunten zijn, en er zal lange termijn 
klinische follow-up plaatsvinden.
Van angiografie naar kliniek
Ondanks de bovenstaande voordelen en meerwaarde van het verrichten van 
angiografische (sub)studies is het belangrijk te realiseren dat dit specialistisch 
onderzoek betreft, niet alleen gezien de (geringe) kans op complicaties, maar 
vooral ook qua ontwerp en organisatie van de studie. 
Ook het type studievraag bepaalt in hoeverre angiografie een geschikte methode 
is om een eerste indruk te krijgen van een bepaalde interventie. Zoals uit dit 
proefschrift blijkt, zijn studies naar (sub)totale afsluitingen in de coronairen na een 
ST-elevatie infarct goed te verrichten op voorwaarde dat een gedegen methodologie 
wordt gehanteerd. Echter, onderzoek naar minder uitgesproken veranderingen van 
de coronaire leasies is moelijker te interpreteren, deels vanwege de beperkingen 
die angiografie met zich meebrengt wat betreft de mogelijkheid tot detectie van de 
vaak geringe veranderingen. 
Daarnaast spelen aspecten met betrekking tot de timing van het tweede angiogram 
een belangrijke rol: het niet op het moment van hernieuwde klachten, maar op een 
vast tijdstip verrichten van het follow-up angiogram doet waardevolle informatie 
verloren gaan bij patiënten die tussentijds opnieuw worden opgenomen voor 
een reinfarct of onstabiele angina. Slechts een aantal onderzoeksgroepen houdt 
rekening met deze klinisch geindiceerde, en daardoor vroeger dan geplande 
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follow-up angiografieën. Waarschijnlijk ondermeer hiermee samenhangend, is bij 
verscheidende therapieën die klinisch cardioprotectief bleken, maar zelfs ook bij 
middelen die in de kliniek protrombotisch bleken te zijn lieten, op angiografisch 
niveau geen duidelijke verandering waargenomen in het risico op coronaire 
trombose. Het is daarom van groot belang het type studiepopulatie, het soort 
medicatie en de te verwachten effecten mee te wegen in de afweging tot het al dan 
niet verrichten van angiografisch (follow-up) onderzoek. 
Wanneer echter bovenstaande elementen goed worden overdacht, en het onderzoek 
door een ervaren groep wordt verricht, kunnen angiografische (sub)studies zeker 
bijdragen aan vergelijkingen van behandelingsstrategieën en het verfijnen van 
de risicostraficatie na het infarct om zo tot een meer op het individu toegespitste 
behandeling te komen. 
Concluderend kan gesteld worden dat met de ontwikkeling van de 3 beschreven 
onderzoekslijnen er nieuwe mogelijkheden liggen om in de komende jaren middels 
de verkregen inzichten opnieuw vooruitgang te gaan boeken in de behandeling 
van patiënten na het acute infarct. Met het besef dat niet elke behandeling 
even succesvol is voor iedereen, en dat zowel qua effectiviteit en veiligheid 
verschillende risicoprofielen per patiënt bestaan, zal een verdere verfijning van 
een op het individu gerichte behandeling het streven moeten worden. Toekomstige 
onderzoeken zullen hier qua ontwerp en protocol op moeten inspringen, om zo 
een gedegen basis te leveren om deze vorm van klinisch handelen te ondersteunen 
en te perfectioneren.
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Samenvatting
In de algemene introductie in Hoofdstuk 1 wordt basale achtergrond informatie 
met betrekking tot acute coronaire syndromen beschreven en worden meer 
specifieke specialistische begrippen toegelicht die regelmatig in het manuscript 
terugkeren. In de uiteenzetting van het proefschrift worden beknopt de 
studievragen weergegeven, alsmede een korte beschrijving van de klinische en 
wetenschappelijke importantie. 
Hoofdstuk 2 beschrijft de huidige standaard met betrekking tot de farmacologische 
behandeling van het ST-elevatie myocardinfarct. Daarnaast vormt het een kort 
historisch overzicht omtrent de ontwikkelingen op dit gebied en geeft het inzicht in 
de pathofysiologische rationale achter de productie en ontwikkeling van de nieuwe 
middelen. 
Reperfusietherapie. Ondanks een sterke associatie tussen de TIMI flow in het 
infarctvat op 90 minuten na fibrinolyse en de kans op overlijden binnen 30 
dagen, hebben nieuwe reperfusie regimes met hogere percentages TIMI-3 flow 
niet tot een reductie in mortaliteit geleid. Een voorbeeld betreft het gebruik van 
een halve dosis fibrinolyse gecombineerd met een glycoproteine IIb/IIIa receptor 
blokker. Bovendien was verwacht dat dit tot een reductie in het aantal bloedingen 
zou leiden, m.n. intracraniële bloedingen. Echter, bij patiënten boven de 57 jaar 
werd een verhoogd risico waargenomen, terwijl bij jongere patiënten minder 
hersenbloedingen voorkwamen op dit gecombineerde regime.
Adjuvante antitrombotica. Nieuw ontwikkelde producten op het gebied van 
antistolling leken superieur aan ongefractioneerde heparine wat betreft de 
preventie van reinfarcten en terugkerende ischemische events. In feite betrof het 
in de meerderheid van de gevallen een vergelijking van twee strategieën van 
antistolling, waarbij het nieuwe middel tot ontslag werd gecontinueerd terwijl de 
ongefractioneerde heparine voor 48-72 uur werd toegediend. Hoewel vaak het 
voordeel in reinfarcten tot ontslag wordt benadrukt, blijkt dat er na het stoppen van 
de nieuwe medicatie een “inhaalfenomeen” optreedt, zich uitend in vergelijkbare 
reinfarctpercentages op 30 dagen tot 1 jaar. Alleen de directe trombineremmer 
hirudine, in studies evenlang toegediend als ongefractioneerde heparine, lijkt 
daadwerkelijk een sterker antitrombotisch effect te sorteren, zich uitend in een 
lager reinfarctpercentage na fibrinolyse met streptokinase. Angiografische studies 
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met nieuwe antitrombotica rapporteerden vergelijkbare reperfusiepercentages op 
90 minuten na fibrinolyse als ongefractioneerde heparine. Bovendien werd er 
een groter aantal open vaten en minder reocclusie bij angiografie voor ontslag 
beschreven na een strategie van langduriger antistolling met de nieuwe middelen. 
Deze bevindingen suggereren dat ‘het plafond’ van farmacologische reperfusie 
wellicht is bereikt, en ondersteunen het concept dat een langere periode van 
antistolling naast het gebruik van aspirine succesvol zou kunnen zijn in het verder 
reduceren van terugkerende trombotische events in de eerste weken tot maanden 
na een infarct.
In Hoofdstuk 3 worden twee antitrombotische strategieën voor de behandeling van 
het ST-elevatie infarct gerandomiseerd vergeleken: prehospitale versus in-hospitale 
fibrinolyse. In het kader van het onderzoek inventariseerde het ambulance personeel 
al of de patiënt in aanmerking kwam voor reperfusietherapie, met als gevolg dat 
voor patiënten die gerandomiseerd werden naar behandeling in het ziekenhuis de 
tijdsduur tot initiatie van fibrinolyse sterk afnam. Deze afname van de vertraging 
in het ziekenhuis zorgde ervoor dat de tijdswinst ten opzichte van het starten in de 
ambulance minder uitgesproken was dan initieel verwacht: 32 minuten in plaats 
van de ongeveer 50-60 minuten in de meeste studies. Hoewel de prognose op korte 
termijn niet verschillend was in de gerandomiseerde vergelijking, hadden patiënten 
die binnen 70 minuten werden behandeld (ofwel pre- dan wel in-hospitaal) een 
lagere mortaliteit, een beperktere infarctgrootte, en een betere globale kamerfunctie 
in vergelijking met later behandelde patiënten. Deze verschillen werden niet 
verklaard door andere karakteristieken dan de tijd tot de start van behandeling. In de 
huidige lange termijn analyse, waren de overlevingspercentages op 2 jaar 89% voor 
prehospitale en 91% voor in het ziekenhuis gestarte fibrinolyse. Het initiele voordeel 
in overleving voor patiënten behandeld binnen 70 minuten bleef behouden tot op 2 
jaar (98% vs. 89%), maar bleef niet significant hoger op de langere termijn. Event-
vrije overleving (een klinisch beloop zonder overlijden, reinfarct, revascularisatie, 
heropname voor angina en hartfalen) was ook niet verschillend. Bovendien bleek 
de tijd tot behandeling geen onafhankelijke voorspeller van de uitkomst op lange 
termijn te zijn, noch als continue, noch als dichotome variabele. Andere factoren, 
zoals leeftijd, een voorgeschiedenis van hartfalen of bypass chirurgie, dan wel de 
noodzaak tot bypass chirurgie na inclusie bleken wel onafhankelijke voorspellers. 
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Deze bevindingen geven aan dat op de lange termijn vele andere factoren van 
belang zijn voor de prognose na fibrinolyse. Naast de bovengenoemde klinische 
variabelen, is het behouden van de doorgankelijkheid van het aan het infarct 
gerelateerde coronairvat mogelijk ook van prognostisch belang. Hoofdstuk 4 is het 
eerste onderzoek na fibrinolyse dat de lange termijn gevolgen van reocclusie heeft 
beschreven in patiënten die de eerste 24-48 uur na reperfusietherapie overleefden, 
en een open infarctvat hadden. Een voorgaande publicatie, die het effect van 
vroege reocclusie bestudeerde bij patiënten met een angiografisch bewezen 
open infarctvat op 90 minuten na reperfusietherapie had een verhoogd risico op 
overlijden voor ontslag gerapporteerd.
In de APRICOT-studie werd geen verschil gevonden in de overleving op 3 jaar 
(>90% in beide groepen). Dit, ondanks het negatieve effect dat reocclusie heeft op 
de linkerkamerfunctie, zelfs wanneer dit optreedt in afwezigheid van een klinisch 
reinfarct. Patiënten bij wie reocclusie werd geobserveerd hadden een verhoogd 
risico op reinfarcten (23% vs. 5% op 1 jaar) en interventies, verricht ten gevolge van 
terugkerende ischemie in rust of bij inspanning. Het verschil in klinische uitkomst 
ten opzichte van patiënten bij wie geen reocclusie was opgetreden ontstond in de 
eerste maanden na het infarct en bleef over een periode van 3 jaar aanwezig.
Hoewel kwantitatieve overzichten het aannemelijk maken dat behandeling met 
aspirine de kans op reocclusie in de eerste twee weken na het infarct vermindert, 
is er weinig bekend over de mogelijke invloed op het meer sluipende proces van 
progressie van coronaire atherosclerose. Dit wordt verondersteld in fasen op te 
treden, meestal subklinisch, waarbij het met name om een meer subtiel proces 
van murale niet-occlusieve trombusvorming zou gaan. In Hoofdstuk 5 wordt een 
gerandomiseerde, placebo-gecontroleerde studie met angiografische follow-up 1 
jaar na een ST-elevatie infarct beschreven. Hierin wordt het effect bestudeerd van 
antiplaatjestherapie op het proces van atherosclerose in de kransslagaderen die 
niet tot het infarct hebben geleid. Dit werd mede onderzocht, omdat het starten 
van aspirine twee tot zes maanden na het infarct ook van prognostisch belang is 
gebleken, en de dan optredende events minder vaak aan het infarctvat gerelateerd 
zijn dan in de acute fase.
Op ongeveer een maand na fibrinolyse werden 154 patiënten met een open infarct 
arterie gerandomiseerd naar het continueren van antiplaatjestherapie (aspirine 
50 mg en dipyridamol 400 mg) of placebo. In totaal werden 1436 coronaire 
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segmenten van de niet aan het infarct gerelateerde vaten bestudeerd op toename 
dan wel afname van de op het eerste angiogram waargenomen leasies, c.q. 
vernauwingen. De gemiddelde verandering in de middels kwantitatieve coronair 
angiografie geanalyseerde variabelen (diameter stenose, gemiddelde lumen 
diameter, minimale luminale diameter) verschilde niet tussen beide groepen. In 
een semi-kwantitatieve vergelijking, bleek de proportie patiënten met tekenen van 
angiografische progressie niet beinvloed (68% en 64%). Angiografische progressie 
was geen voorspeller van toekomstige klinische gebeurtenissen. Deze bevindingen 
ondersteunen de veronderstelling dat antiplaatjes- therapie geen effect sorteert op 
het vaak subklinische, subtiele proces van murale trombusdepositie en daarop 
volgende (re)organisatie van de plaque, zoals reeds eerder gesuggereerd via 
observaties in dierexperimenteel onderzoek. De werking van antiplaatjestherapie 
zou derhalve grotendeels berusten op de preventie van voornamelijk acute 
klinische events, veroorzaakt door (sub)totale occlusieve trombose. 
De gerandomiseerde APRICOT-2 studie wordt gepresenteerd in Hoofdstuk 6. 
Gezien de negatieve gevolgen van reocclusie, en de incidentie van 25-30% 
in het eerste jaar na fibrinolyse, is betere preventie vereist. Dit zou ondermeer 
bereikt kunnen worden middels meer intensieve antitrombotische regimes. Bij 
274 patiënten met TIMI-3 flow in het infarctvat tijdens de inclusieangiografie, 
verricht binnen 48 uur na fibrinolyse, bleek een gecombineerd antitrombotisch 
regime van antiplaatjestherapie met antistollingstherapie gecontinueerd voor 3 
maanden de incidentie van reocclusie op 3 maanden significant te verminderen: 
28% vs. 15%. Het aantal reinfarcten (8% vs. 2%) en op basis van ischemie verrichte 
revascularisaties (31% vs. 13%) was ook significant lager op het gecombineerde 
antitrombotische regime. De controlearm werd behandeld met de gebruikelijke 48 
uur intraveneuze heparine en het gebruik van aspirine voor onbepaalde tijd. Het 
te testen antitrombotische beleid bestond uit het starten met coumarinederivaten 
nadat bij inclusieangiografie een open infarctvat was aangetoond, terwijl de 
heparine werd gecontinueerd totdat de streefwaarde van de INR was bereikt 
(2-3). Als gevolg hiervan was de totale duur van hepariniseren 66 uur langer in 
de patiënten gerandomiseerd naar het gebruik van coumarine (110 vs. 44 uur). 
Het bloedingsrisico op het nieuwe regime verdubbelde, maar bleef acceptabel: 
intracraniele bloedingen werden niet waargenomen. Deze conceptuele studie 
geeft een mechanistische verklaring voor het potentiele effect van de toevoeging 
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van langdurige antistollingstherapie aan aspirine, en vereist confirmatie in grote 
klinische studies.
Hoofdstuk 7 betreft een review van alle gerandomiseerde studies naar het effect van 
het toevoegen van orale antistolling aan aspirine na een acuut coronair syndroom. 
Met het bestaan van een verhoogde stollingsactiviteit tot op 6 maanden na een 
acuut coronair syndroom, en de associatie tussen factor VII en zowel een eerste 
infarct als een recidief infarct, lijkt het gebruik van orale antistollingstherapie een 
veelbelovende interventie om de prognose gunstig te beinvloeden. Zeker nu er 
heden ten dage lagere doseringen aspirine worden voorgeschreven, en het effect 
van antistollingstherapie beter kan worden gecontroleerd na de introductie van de 
INR is de hernieuwde interesse voor deze behandelingsoptie te begrijpen.
De onderzoeken verschilden qua pathofysiologische rationale en dientengevolge 
in de intensiteit van antistolling. Een deel van de studies was erop gericht de 
concentratie van factor VII te beinvloeden met een lage gefixeerde dosis orale 
antistolling, zonder wezenlijk effect op de INR. Voorbeelden zijn studies als CARS 
en LOWASA: ondanks additie van een anticoagulans met effect op factor VII, en 
een verhoogd bloedingsrisico, bleek er geen antitrombotisch effect in de zin van 
een verminderde kans op terugkerende trombotische events.
In andere onderzoeken werd via hogere doseringen orale antistollingstherapie, 
getitreerd middels herhaaldelijke INR controle, ook een effect op trombine 
nagestreefd, zich vertalend in een duidelijke verlenging van de INR. Wanneer een 
INR > 2.0 werd bereikt, zoals in de WARIS-2 en ASPECT-2 studies, werd wel een 
verbetering in klinische uitkomsten waargenomen, voornamelijk bepaald door een 
reductie in terugkerende trombotische events, met een verhoogd risico op bloeden 
als keerzijde. De kans op intracraniele bloedingen werd echter niet verhoogd. De 
observaties in deze klinische studies liggen in lijn met die van de angiografische 
APRICOT-2 studie. In het geval dat een INR < 2.0 werd bereikt, zoals in de CHAMP-
studie, bleef het gewenste klinische effect uit.
Ondanks een bewezen klinisch effect, heeft het gebruik van vitamine K antagonisten 
geen algemene ingang gevonden, wat deels samenhangt met het feit dat het succes 
afhankelijk is van een goede infrastructuur wat betreft INR controle. Gezien het 
bewezen effect van langdurige, intensieve orale antistollingstherapie, waarbij ook 
trombine wordt beinvloed, worden de resultaten van nieuwe middelen als de 
directe trombineremmer ximelagatran met spanning afgewacht, omdat regelmatige 
monitoring dan niet noodzakelijk is.
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Een andere strategie die geopperd is om reocclusie succesvoller te voorkomen is 
een aggressiever revascularisatiebeleid na fibrinolyse. In Hoofdstuk 8 bestudeerden 
wij de relatie tussen een ernstige reststenose na fibrinolyse en de kans op het 
optreden van reocclusie enerzijds, en de kans op een reinfarct anderzijds. In de 
APRICOT-1 studie werd een redelijk conservatief interventiebeleid gevoerd, op 
geleide van ischemie, met slechts 11% revascularisaties op 3 maanden. Dit maakte 
het mogelijk het “natuurlijke proces” van reocclusie en terugkerende trombotische 
events na fibrinolyse te bestuderen. De rationale achter de gerandomiseerde 
studies die het effect van een routinematig revascularisatiebeleid onderzochten 
was de volgende: door systematisch patiënten met een ernstige stenose te dotteren, 
onafhankelijk van klachten, zou het risico op reocclusie afnemen, en daarmee de 
kans op een reinfarct. Een angiografische follow-up studie uit dezelfde periode 
deed echter vermoeden dat de kans op een reinfarct niet samenhangt met de ernst 
van de reststenose na fibrinolyse. 
Vandaar dat in APRICOT-1 deze relatie eveneens is onderzocht. Aangezien 
reocclusie een belangrijke voorspeller is van reinfarcten en terugkerende 
ischemische events, werd de studiepopulatie verdeeld op basis van de reststenose 
die de kans op reocclusie optimaal voorspelde: een stenose van 62.7% bepaald 
middels kwantitatieve coronairangiografische analyse. Patiënten met een ernstige 
reststenose hadden een kans van 40% (47/118) op reocclusie, vergeleken met 16% 
(20/122) bij patiënten met een minder ernstige reststenose. Opvallend was dat de 
reinfarctpercentages niet significant verschilden tussen de beide groepen: 6% (7/
118) vs. 9% (11/122). 
Dit wordt verklaard door het feit dat in geval van reocclusie op een reeds ernstige 
restleasie een klinisch reinfarct minder vaak optrad (15%; 7/47) dan bij reocclusie 
op een minder uitgesproken vernauwing (55%; 11/20).
Hoewel middels ROC-analyse wel een optimaal predictieve reststenose voor 
reocclusie kon worden gevonden, was dit voor het reinfarct niet het geval. Met 
andere woorden: op basis van de ernst van de reststenose viel het optreden van 
een reinfarct na succesvolle trombolyse niet te voorspellen. Dit suggereert dat het 
verhoogde aantal periprocedurele events wellicht niet de enige verklaring vormt 
voor het ontbreken van een klinisch voordeel van een routinematige revasculari
satiestrategie. Deze observaties, gekoppeld aan het feit dat in voorgaande studies 
vaak alleen de ernstiger leasies werden gedotterd, kunnen van belang zijn voor het 
ontwerp van een toekomstige herevaluatie van deze strategie. In de loop der jaren 
226 Epicrise en Samenvatting
zijn de interventietechnieken immers sterk verbeterd, worden periprocedureel 
glycoproteineblokkers gebruikt, en is het bovendien gebruikelijker geworden ook 
minder ernstige leasies te dotteren. 
Hoofdstuk 9 is de eerste beschrijvende studie waaruit blijkt dat ook bij patiënten 
die de eerste 24-48 uur na fibrinolyse voor een infarct overleven, en behandeld 
werden volgens een “ischemia-guided” revascularisatie strategie, het optreden van 
reocclusie in de maanden daarna van prognostische betekenis is. 
Van de 248 patiënten in de APRICOT-1 studie werd bij 71 patiënten reocclusie 
geconstateerd (29%). De cardiale 10-jaars overleving was significant slechter in 
het geval van reocclusie: 73% vs. 88%. Zelfs bij patiënten zonder aperte tekenen 
van terugkerende ischemie tot follow-up angiografie (reinfarct, onstabiele angina, 
stabiele angina met positieve stress test) was dit effect aanwezig: 73% vs. 85%.
Kortom, zelfs bij patiënten zonder klinisch geobjectiveerde terugkerende ischemische 
klachten, bij wie reocclusie puur als gevolg van systematische angiografie werd 
ontdekt, lijkt reocclusie een negatief effect op de prognose te sorteren. De 
prognostische consequenties bleken onafhankelijk van linkerventrikelfunctie, de 
enige andere onafhankelijke voorspeller van 10-jaars overleving. 
Deze extensie van ons eerder gepubliceerde 3-jaar follow-up project (hoofdstuk 
4), benadrukt de noodzaak tot verder onderzoek naar preventieve strategieën, ook 
gericht op na ontslag optredende reocclusies. Niet alleen in de hoop het aantal 
ischemische events te reduceren, maar ook om wellicht de cardiale overleving te 
verbeteren. In tegenstelling tot voorgaande preventieve strategieën, zal de focus 
niet alleen op reinfarcten gericht moeten zijn, maar ook op stille reocclusies. 
Een combinatie van krachtiger antitrombotische regimes en een aggressiever 
revascularisatiebeleid na fibrinolyse vormen de belangrijkste elementen voor 
toekomstige studies ter optimalisatie van de prognose na fibrinolyse. 
 CHAPTER 12 227

PART 4 Addenum

 Dankwoord 231
Dankwoord
232 Dankwoord
 Dankwoord 233
De weg naar een proefschrift is lang, en op die weg kom je vele mensen tegen 
die allemaal, ieder op zijn/haar eigen manier, hebben bijgedragen aan de 
totstandkoming ervan. In het geval van multicentrum studies is de lijst met mensen 
aan wie ik dank verschuldigd ben uitgebreid, helemaal wanneer één van die studies 
in het buitenland heeft gelopen zoals het geval was bij de MITI studie uit Seattle, 
USA. Vandaar dat ik mij tot de meerderheid zou willen richten met algemene 
dankzeggingen, om vervolgens een aantal mensen in het bijzonder te bedanken.
Hoewel vaak als vanzelfsprekend beschouwd, begint de mogelijkheid tot 
onderzoek met instemmende patienten, in dit geval meer dan 600 die bereid waren 
twee coronair angiografie onderzoeken te ondergaan. Daarnaast is in verschillende 
ziekenhuizen moeite gedaan om een speciale infrastructuur te ontwikkelen om 
angiografisch follow-up onderzoek tot een succes te maken. Alle betrokken artsen, 
arts-assistenten, verpleegkundigen en secretaresses van de betreffende centra 
verdienen hiervoor een groot compliment.
Wat betreft de spilfiguren op het gebied van studie en werk zijn Professor Verheugt, 
Dr. Weaver en Jan Böhncke de grondleggers van de in mij ontstane ‘drang’ tot het 
onderzoeksbestaan.
De spilfiguren
Prof. Dr. F.W.A. Verheugt, beste Freek: 
Grenzeloos enthousiasme en een bewonderenswaardige punctualiteit wat betreft 
afspraken zijn twee zaken die mij altijd zullen bijblijven als ik terugdenk aan de meer 
dan dertien jaar samen onderzoek doen. De grote vrijheid en verantwoordelijkheid 
die ik van u kreeg, niet alleen voor mijn eigen werk, maar ook om ‘in de kelder’ 
een onderzoekstoko op te zetten, waardeer ik enorm. Een dergelijke samenwerking 
op basis van wederzijds vertrouwen, waarin openheid centraal staat, maak je maar 
zelden mee. Ik hoop dat we daar nog lang de vruchten van mogen plukken!
Dr. W. D. Weaver, dear Doug:
My experience as a research student at the MITI office in 1994 undoubtedly fuelled 
my interest in future projects. I specifically remember the combination of a very 
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professional, efficiently organized center and a nice, lively atmosphere. Your sense 
of humour will certainly have contributed to it. Unlike many doctors in the field of 
research, you also emphasized to take enough time to personally study the acquired 
data thoroughly (linear, curvilinear, U-shaped relationship), and stimulated me to 
gain more in-depth knowledge with regard to statistical analyses.
Drs. J. Böhncke, beste Jan:
Zonder jouw assertieve houding had ik nooit aan zo’n vruchtbare wetenschappelijke 
stage gekomen als de lange termijn follow-up van APRICOT! Zeker wat betreft 
het leren organiseren van zaken, net binnen of net buiten de regels om, en het 
krijgen van inzicht in politieke spelletjes heb ik als 19-jarig mannetje veel van je 
meegekregen. En bovenal, dat als je ECHT iets wil, je er (bijna) altijd komt…Grote 
bewondering voor wat je allemaal zelf hebt klaargespeeld!
Bovengenoemden vormden de basis voor een prachtige onderzoeksperiode, maar 
zonder opslag en verwerking van data zou er weinig van terecht zijn gekomen. 
In dat kader wil ik met name Johan Karreman, Gérard Uijen en Truus Peijnenburg 
bedanken. 
De data-managers
VUmc, Amsterdam:
Beste Johan, het duurde even voordat ik doorhad hoe het moest, dat communiceren 
in databasecodes, maar inmiddels hebben we elkaars taal toch zeer goed leren 
spreken! 
UMC Nijmegen:
Allereerst natuurlijk onze ‘nestor’. Beste Gérard, ik heb minstens net zo veel geleerd 
van je verhalen over de geschiedenis van de cardiologie in het Radboud, en niet te 
vergeten “Het Bureau” van Voskuil, als van je gedegen statistiek onderwijs. Verder 
was je op belangrijke momenten een waar vaderfiguur, waarvoor dank.
Voor Truus een aparte passage…los van je werk aan de APRICOT-database en je 
moed om te doen wat goed was voor het slagen van het project… We hebben 
veel meegemaakt, en ik heb je leren kennen als iemand die erop ‘gebrand’ is 
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‘volle bak’ te geven, en kwaliteit na te streven. Weinig mensen weten hoezeer de 
onderbezetting tot 2001 zijn tol heeft geeist met Gérard, jij en ik als kampioenhouders 
vakantiedagen. Ik hoop van harte dat je er binnenkort weer vol vuur en vlam tegen 
aan kunt gaan, mááár…wel met een beetje meer de handrem erop!
Resten nog Rudi, Noor en Gabe. Weliswaar niet direct betrokken bij het project, 
maar toch. De laatste twee hebben er voor gezorgd dat er weer ademruimte is op 
de experimentele, wat zich direct heeft vertaald in een meer ontspannen sfeer, 
van groot belang om optimaal te kunnen functioneren. Rudi zal ik onthouden in 
een dubbelrol, eerst als promovendus en nu als vervanger van Gérard. Dubbelrol 
is eigenlijk een understatement, je lijkt wel een octopus, met een ongekend 
improvisatievermogen. Heel veel succes, en dat je na een hectische start de 
ingeslagen weg tot een gestructureerde, stabiele ondersteuningsafdeling maar mag 
perfectioneren! 
Naast technische ondersteuning is ook controle van het werk en de data van groot 
belang. Hierbij hebben mijn co-promotoren een belangrijke rol gespeeld, zeker 
gezien het feit dat er meer dan 300 paar ‘films’ moest worden beoordeeld.
De co-promotoren
Dr. G. Veen, beste Gerrit:
Initieel als auteur in jouw proefschrift contact gekregen, en inmiddels als mijn 
begeleider een vaste rots in de branding. Vooral je systematische aanpak van 
zaken, of het nu een film, een casus of een artikel is, heeft ook mijn eigen manier 
van handelen positief beinvloed. Daarnaast was het altijd fijn om een nuchtere blik 
van ‘buiten’ te hebben, op momenten dat men in Nijmegen te kort door de bocht 
dreigde te gaan.
Dr. W.R.M. Aengevaeren, beste Wim:
Prachtig om te zien hoe iemand van zijn vak kan genieten, hoe vol je kon zijn van 
een prachtige film! Je enorm hoge tempo, je discipline, toewijding en perfectionisme 
zijn een voorbeeld voor een ieder. Ik ervaar het als een groot compliment dat ik 
je presentaties mag controleren, en het protocol voor interventiecardiologie 
heb mogen screenen. Leuk om zoveel angiografische kennis van je te hebben 
meegekregen! En nu op naar APRICOT-3!
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Zeker omdat de APRICOT-studies voor een groot deel draaien om de organisatie in 
en rond het cathlab wil ik het personeel aldaar nogmaals extra bedanken voor hun 
medewerking en de daardoor onstane band, ook voor het verrichten van nieuwe 
studies. In het bijzonder wil ik dit keer iemand bedanken die het strijdtoneel gaat 
verlaten: Ingrid Steinmann. Zowel op het persoonlijke vlak als op het werk was het 
een waar genot je te hebben leren kennen: een representatieve, goede secretaresse 
als jij is met recht een visitekaartje, en van groot belang voor de eerste indruk die 
men krijgt over een afdeling. In het Canisius Wilhelmina Ziekenhuis verdienen 
Astrid Schut en Tineke Tiemes een speciale vermelding voor hun soepele, goede 
en gezellige samenwerking. Uit mijn studententijd wil ik graag twee secretaresses 
bedanken: één uit Nederland en één uit Amerika. Allereerst Tineke Welle, die ik me 
vooral herinner om haar enorme gevoel voor humor. From Seattle, Washingtion, 
USA, Miss Mona J Ries should be mentioned for her hospitality and the training she 
gave me to learn how to type faster than lightning. Thank you so much!
Resten nog de ‘jongens uit de kelder’, een begrip geintroduceerd door Janneke 
Timmermans. 
De jongens uit de kelder
Ralf ‘Overmars’ Vromans, beste Ralf:
Redenen te over om jou te bedanken. Als één van de grondleggers van de nieuwe 
aanpak en sfeer rondom het APRICOT-project verdien jij alle credit: tot in Groningen 
toe (lift Mercure, TCC) heb je jezelf onsterfelijk gemaakt! Je baan opgegeven om 
als student er volop met mij tegenaan te gaan. Onze haast maniakale manier van 
samenwerken kon maar op één voorwaarde goed gaan: de ultieme klik! En die was 
er… Altijd vonden we wel weer een manier om ‘must’ met ‘lust’ te combineren! 
Eén en al prachtige herinneringen en verhalen…En eh…dat week-endje Papendal, 
dat heb je nog te goed! Ralf, je bent uit mijn leven niet meer weg te denken. For 
better and for worse…dat weet je..
Peter ‘Middle Initial’ Kievit, beste Peter:
Zonder jouw hulp was het nooit gelukt om na APRICOT-2 de doorstart op 
de experimentele te realiseren. Toegegeven, het kostte wat bekeerwerk, maar 
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uiteindelijk bracht jij onder woorden wat ik je bedoelde te zeggen: het draait 
om onafhankelijkheid van geest. Hoezo te oud voor onderzoek? Dacht het 
niet!! Persoonlijke ontwikkeling, in plaats van snel mijlpalen op CV’s scoren. 
Een verhelderende nachtje in Curaçao gaf de doorslag….. En zo werden we een 
bevlogen, keihard werkend, superkritisch, en bij vlagen flamboyant duo (briefje 
Astra, podium New Orleans). Statler en Waldorf! Dank voor al je hulp en de mooie 
momenten. Nog meer dan de werkrelatie, koester ik de herinneringen aan de uren 
die we daarbuiten doorbrengen. Weten dat het goed zit. Voor elkaar door het vuur. 
Er zijn… Elkaar kennen van A tot Z: blindelings aanvoelen en aanvullen. Mooi…
Jaap ‘De Bison’ Remmen, beste Jaap:
Een visitekaartje voor ons vak, dat ben je! Je liefde voor mensen, je goede hart, je 
drive om te knallen, en juist ook je sigaretten…Heeerrrrrrrrrrrrrrrrrlijk! En vooral ook 
onze telepathische momenten, prachtig! De enthousiaste telefoongesprekken als je 
weer een mooie bevinding had gedaan, je ondeugende analytische vermogens (van 
wie zou je die nou hebben?), en de gezellige avondjes doorhalen in de kroeg of 
op de experimentele (ja…op de experimentele!). Een gouden gooser ben je, seeker 
weten! Samen met Peter altijd de meest kritische lezer van mijn stukken, waarvoor 
dank. Grote bewondering hoe je er vol in bent gegaan, promotie én opleiding, als 
echtgenoot en vader van twee kinderen. Japie, nog even volhouden, mijn steun heb 
je!
Etienne ‘The Philospher’ Cramer, beste Etienne: 
Troponine Billy, The Artist, The Genius het had allemaal gekund…Maar 
eigenlijk ook juist weer niet, natuurlijk….De man van de vele opties en de vele 
invalshoeken.. Etienne, het is me een waar genoegen dat onze paden zijn gekruist! 
Blind vertrouwen vanaf dag één, het allergrootste goed… Mooie, diepe gesprekken, 
openheid, en wederzijds begrip. Vriendschap met een hoofdletter V. Turijn, Milaan, 
Riccione, Florence…..Marathonacties…door kunnen zetten, af kunnen maken…
Na het vertrek van Peter was jij het die mij scherp hield, zowel met je immer 
doordachte op- en aanmerkingen op mijn artikelen, APRICOT-3 en SARA, als met 
je eigen, vaak originele onderzoeksvoorstellen. Mijn ‘van Persie’! En dat voor een 
Ajax-fan! Leuk dat ik je heb mogen enthousiasmeren…ontluikende bevlogenheid! 
Cramertje, it’s all mental, dus jij haalt zeker ook jouw doel! 
238 Dankwoord
Hendrik-Jan ‘Excuus’ Dieker, beste Hendrik-Jan:
Siamo nati bucati per non morire crepati! Als één van de weinigen van ‘the young 
generation’ nog écht beseffend dat keihard werken één van de voorwaarden van 
succes is… HIS ging dan mis, maar Nieuw Zeeland was toch een mooi alternatief! 
Hoop wel dat je bij toekomstig onderzoek minder last zult hebben van grillen van 
bazen en een beter georganiseerde financiële- en infrastructuur zult treffen. Grote 
klasse hoor, met welke toewijding jij jezelf probeert te ‘trainen’, en vooral dingen 
die je moeilijk of lastig vindt niet uit de weg gaat! Op weg om de ‘Encyclope-
Dieker’ van het ST-elevatie infarct te worden! Maar amico, vergeet niet hoe 
belangrijk de ‘cooling down’ is (minstens net zo belangrijk als stretchen?!), ook 
voor de ‘tensione’: Een avondje relaxen met een lekkere Merlot, of wordt het toch 
een Rosso di Montalcino??? 
Nick ‘Interesting’ Clappers, beste Nick:
Menigeen zal denken dat jij als waar neerlandicus al wat fouten in mijn Nederlands 
hebt ontdekt, maar gelukkig weet ik dat jij andere dingen ‘far more interesting’ 
vindt. Als je je daar niet te veel door laat afleiden, en er wellicht zelfs een beetje 
‘resistent’ voor wordt (tijdelijk dan), dan weet ik zeker dat het met SARA en jou wel 
goed komt. Erg leuk om samen al zo veel gedaan te hebben, zowel qua ‘stukken’ 
(schrijfwerk wel te verstaan) als de uitjes Amerika en Italië. Vergeet nooit hoe je 
ooit student Nick ‘met het vingertje’ was: dat is de Nick voor wie ik me hard heb 
gemaakt op de experimentele. Nicky Nick, jongen, zorg dat opa trots op je zou 
zijn! 
Wessel ‘The Resuscitation Kid’ Keuper, beste Wessel:
Na heel veel geduld eindelijk je verdiende plek gekregen: en zo hebben we nu drie 
oud wetenschappelijke stage lopers als opvolgers. Knap hoe je hebt volgehouden, 
één van de belangrijkste eigenschappen om een promotie af te ronden, overigens. 
Als student bleek al dat je er een hoop naast kunt doen (Hippocrates) en hebben: 
privé was je voor je familie een rots in de branding. Voor zo’n jong menneke als jij, 
al een volwassen instelling. Uit het goede hout gesneden! Zorg wel dat er gevoetbald 
blijft worden, hè! En laat Gomes en Camaro dan ook maar eens rennen! Tips voor 
een avondje relaxen, zoals genieten van een lekker muziekje of bijvoorbeeld lekker 
uit eten met een goed glas wijn, tja…die hoef ik jou niet te geven!
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Part-time ‘experimentelen’ die zeker niet vergeten mogen worden zijn Paul van den 
Bergh en Aline Huizenga. Aline, denk terug aan mijn speech tijdens je feest en je 
weet wat ik je wil zeggen. Paul, onvoorstelbaar wat jij aan werk weet te verzetten. 
Veel geleerd van je ‘verleg-het-initiatief’ strategie, risico stratificatie en financiële 
trucs. Wat betreft het onderzoek: degene met de langste adem komt er altijd, dus 
blijf ademenen, ha,ha! 
Hoewel het dus voornamelijk jongens in de kelder zijn, moeten ook Suzanne Jacobs 
en Irene Joziasse vermeld worden, dames die altijd voor een extra tintje qua sfeer 
wisten te zorgen. Suzanne, dank voor je luisterend oor, de gezellige momenten 
met wat druiven, kaas en wijn op de flat, je heerlijke improvisatievermogen en 
onvoorwaardelijke vriendschap. Verder wil ik Joke de Lange expliciet bedanken 
voor alle mooie werk- en privémomenten, en natuurlijk de goede en vooral ook 
altijd gezellige samenwerking. Tot slot, Diana Wuijster, hartstikke bedankt voor 
het altijd attente meeleven, en de vaak perfecte hulpacties bij surpriseparties, mijn 
ceremoniemeesteractiviteiten en speuracties naar Boss broeken. Blijven gáán hè!?!
De allerbelangrijksten
Zonder twijfel zijn dat mijn ouders… Mede dankzij de door hun meegegeven 
levensinstelling, en de geboden kansen en vrijheid, heb ik me kunnen ontwikkelen 
tot wie ik nu ben. Lieve mam, grote bewondering voor je hoe ‘het leven na pappa’ 
hebt opgepikt, dank voor je onvoorwaardelijke steun, en je hulp in de week-enden 
als ik weer eens ouderwets verwend werd en niet hoefde te koken. Daarnaast 
natuurlijk mijn zussen, die in allerlei privésituaties te hulp zijn geschoten. Naast 
Maarten en Jeroen, verdient vooral Wim een extra bedankje: wat rijdt mijn auto 
toch heerlijk!! 
In de roes richting de finish hoop ik dat ik niemand vergeten ben…
Onderzoek doe je met zijn allen, en ik hoop van harte dat die sfeer zich alleen nog 
maar sterker zal doorvertalen binnen onze afdeling. Dank aan allen die hier tot nu 
toe aan hebben bijgedragen!
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De ‘brouwer’ van dit proefschrift werd geboren op 24 maart 1971 te Bussum. Een 
van jongs af aan aanwezige, spelenderwijs ontstane interesse in ‘het waarom’ 
zou wel eens de voedingsbodem kunnen hebben gevormd voor een niet aflatend 
enthousiasme voor onderzoek, wellicht in lijn met de door Einstein gebezigde 
woorden: “Play is the highest form of research”. Hoewel door sommigen 
omschreven als ‘homo ludens’ (spelende mens), heeft het opnieuw moeten leren 
lezen en rekenen na een hardnekkige meningitis zeker ook bijgedragen aan 
de tevens bij onderzoek vereiste serieuze houding en het ontwikkelen van een 
systematische methodiek van werken en onthouden. 
In 1989 werd gestart met de opleiding geneeskunde aan de Vrije Universiteit 
in Amsterdam. Samen met Jan Böhncke begon reeds in 1991 een periode van 
wetenschappelijk onderzoek, op de afdeling cardiologie, onder begeleiding 
van Prof. Dr. F.W.A. Verheugt: een project dat resulteerde in een beloning van 
de Hartstichting, met de mogelijkheid tot nieuw onderzoek in Seattle, USA. Dit 
gebeurde onder leiding van een onderzoeker pur sang, Dr. W. Douglas Weaver, 
organisatorisch brein achter het superprofessioneel gerunde onderzoeksinstituut 
van o.a. de MITI studie.
Na het cum laude afsluiten van de doctoraalfase in 1994, werd het doen van 
co-schappen initieel ervaren als een bijkomstigheid, samenhangend met het 
plotseling overlijden van één van zijn grote voorbeelden, vader Martin Brouwer. 
Niet in de laatste plaats zal deze periode hebben bijgedragen tot een onomstotelijk 
geloof in het eigen improvisatievermogen, maar vooral ook tot het geloof in het 
‘on(be)grijpbare hogere’, het wetenschappelijk onverklaarbare.
Tijdens het keuze co-schap cardiologie, werd door Prof. Verheugt, inmiddels 
hoogleraar te Nijmegen, de opleiding in het verschiet gesteld op twee voorwaarden: 
promoveren en de eerste aanzet geven tot het opzetten van een onderzoeksafdeling. 
Na het cum laude behalen van de artsentitel in 1997, werd met de in het westen 
opgedane ervaring afgereisd om op onderzoek uit te gaan in het oosten. 
Initieel beschouwd als de wat vreemde eend in de bijt, de eerste assistent full-
time vrijgepland voor onderzoek, is geleidelijk een cultuur ontstaan waarin het 
onderzoek groeide en bloeide. In 2000 werden alle inspanningen, afdelingsbreed, 
bekroond met een uitnodiging tot een Hotline-presentatie over de APRICOT-
2 studie en wel op het hoogste internationale platform in Europa, tijdens het 
Europese cardiologie congres in de RAI te Amsterdam. Daarna volgde een periode 
waarin het met name het enthousiasmeren en begeleiden van andere assistenten 
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centraal stond, evenals het opzetten van een internationale samenwerking met een 
gerenommeerde onderzoeksgroep uit Nieuw Zeeland. Na lang volhouden kwam er 
ook geld voor vervolgonderzoek, zowel via de industrie (Eli-Lilly, 2000) als via de 
Hartstichting, middels twee gehonoreerde subsidieaanvragen (2004). 
Daar waar door velen promoveren als ‘goede hit’ op het CV wordt beschouwd, 
met een boekje als einddoel, kan het voor sommigen een “way of life” worden, iets 
waaraan je verknocht raakt, waarin je anderen wilt meekrijgen, een periode van 
persoonlijke ontwikkeling op vele terreinen…Na vele jaren ‘onderzoek op gebied 
van het hart’, zal zowel in het privéleven als op het werk een meer gesettelde 
levensweg worden nagestreefd en aan de klinische opleiding worden begonnen. Al 
blijft het bloed kruipen waar het niet gaan kan…
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name: Marc A. Brouwer
date of birth: March 24th 1971, Bussum
address: St. Annastraat 37, 6524 EE  Nijmegen
Education
1977 Elementary School: Rehobothschool, Naarden-Vesting.
1983 College at A-levels: Willem de Zwijger College, Bussum.
1989 Medicine, Free University, Amsterdam.
1994 University degree, preclinical program medicine, cum laude.
1997 M.D. degree, cum laude.
Research activities
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